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Abstract
Contrast-enhanced ultrasound and/or colour duplex
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Clare Robertson,1 Michal Shimonovich,1 Graeme MacLennan,1
Cynthia Fraser,1 Russell Jamieson3 and Srinivasa Rao Vallabhaneni4
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*Corresponding author m.brazzelli@abdn.ac.uk
Background: Endovascular abdominal aortic aneurysm repair (EVAR) of abdominal aortic aneurysm (AAA)
is less invasive than open surgery, but may be associated with important complications. Patients receiving
EVAR require long-term surveillance to detect abnormalities and direct treatments. Computed tomography
angiography (CTA) has been the most common imaging modality adopted for EVAR surveillance, but it is
associated with repeated radiation exposure and the risk of contrast-related nephropathy. Colour duplex
ultrasound (CDU) and, more recently, contrast-enhanced ultrasound (CEU) have been suggested as
possible, safer, alternatives to CTA.
Objectives: To assess the clinical effectiveness and cost-effectiveness of imaging strategies, using either
CDU or CEU alone or in conjunction with plain radiography, compared with CTA for EVAR surveillance.
Data sources: Major electronic databases were searched, including MEDLINE, EMBASE, Science Citation
Index, Scopus’ Articles-in-Press, Cochrane Central Register of Controlled Trials (CENTRAL), Database of
Abstracts of Reviews of Effects (DARE) and NHS Economic Evaluation Database from 1996 onwards.
We also searched for relevant ongoing studies and conference proceedings. The final searches were
undertaken in September 2016.
Methods: We conducted a systematic review of randomised controlled trials and cohort studies of patients
with AAAs who were receiving surveillance using CTA, CDU and CEU with or without plain radiography.
Three reviewers were involved in the study selection, data extraction and risk-of-bias assessment.
We developed a Markov model based on five surveillance strategies: (1) annual CTA; (2) annual CDU;
(3) annual CEU; (4) CDU together with CTA at 1 year, followed by CDU on an annual basis; and (5) CEU
together with CTA at 1 year, followed by CEU on an annual basis. All of these strategies also considered
plain radiography on an annual basis.
Results: We identified two non-randomised comparative studies and 25 cohort studies of interventions, and
nine systematic reviews of diagnostic accuracy. Overall, the proportion of patients who required reintervention
ranged from 1.1% (mean follow-up of 24 months) to 23.8% (mean follow-up of 32 months). Reintervention
was mainly required for patients with thrombosis and types I–III endoleaks. All-cause mortality ranged from
2.7% (mean follow-up of 24 months) to 42% (mean follow-up of 54.8 months). Aneurysm-related mortality
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occurred in < 1% of the participants. Strategies based on early and mid-term CTA and/or CDU and
long-term CDU surveillance were broadly comparable with those based on a combination of CTA and
CDU throughout the follow-up period in terms of clinical complications, reinterventions and mortality.
The economic evaluation showed that a CDU-based strategy generated lower expected costs and higher
quality-adjusted life-year (QALYs) than a CTA-based strategy and has a 63% probability of being
cost-effective at a £30,000 willingness-to-pay-per-QALY threshold. A CEU-based strategy generated
more QALYs, but at higher costs, and became cost-effective only for high-risk patient groups.
Limitations: Most studies were rated as being at a high or moderate risk of bias. No studies compared
CDU with CEU. Substantial clinical heterogeneity precluded a formal synthesis of results. The economic
model was hindered by a lack of suitable data.
Conclusions: Current surveillance practice is very heterogeneous. CDU may be a safe and cost-effective
alternative to CTA, with CTA being reserved for abnormal/inconclusive CDU cases.
Future work: Research is needed to validate the safety of modified, more-targeted surveillance protocols
based on the use of CDU and CEU. The role of radiography for surveillance after EVAR requires clarification.
Study registration: This study is registered as PROSPERO CRD42016036475.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Plain English summary
An abdominal aortic aneurysm is a swelling of the lower part of the major blood vessel that suppliesblood to the body. A type of keyhole surgery (called endovascular abdominal aortic aneurysm repair)
can be used to repair the aneurysm, but it can cause some complications to the patient. People are,
therefore, followed up (surveillance) for a very long time after surgery so that complications can be
identified and treated appropriately. Follow-up includes taking images of the abdomen with technologies
like computed tomography angiography (CTA) or ultrasound – either colour duplex ultrasound (CDU) or
contrast-enhanced ultrasound (CEU) – or a combination of these techniques. CTA is considered to be
accurate, but it carries the risk of repeated exposure to radiation and a potentially unpleasant contrast
agent. Ultrasound has been suggested as a possible, safer, alternative, but it is currently not used in all
hospitals. It is therefore unclear which type of imaging technique is best. How frequently imaging tests
should be carried out is also unclear. We assessed the current evidence on the use and costs of the two
types of ultrasound (CDU and CEU) compared with CTA. We identified 27 studies, mainly of poor or
moderate quality, that reported different types of follow-up after aneurysm surgery. Because the studies
were very different, we could not combine data or draw firm conclusions. The economic evaluation
showed that CDU was the best value for money for the NHS for people at a normal level of risk of
developing complications. CTA was the next-best value and CEU was the least-best value for money.
CDU might therefore be an appropriate alternative to CTA for the long-term follow-up of some patients
after aneurysm surgery, but there is a need to identify how often imaging should occur, taking a person’s
individual risk of developing complications into consideration.
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Scientific summary
Background
Endovascular abdominal aortic aneurysm repair (EVAR) consists of placing a stent–graft within the
aneurysm via the femoral arteries. The purpose of the stent–graft is to reduce the risk of rupture by
excluding the aneurysm from the influences of blood flow and blood pressure. Failure to obtain, or
maintain, aneurysm exclusion, such that blood leaks into the aneurysm sac, is seen as a failure of the
technique and is called ‘endoleak’. Although less invasive than open surgery, with a lower perioperative
mortality rate, EVAR is associated with important complications, such as different types of endoleaks,
stent–graft migration, distortion or kinking of the stent–graft, structural disintegration of the stent–graft
and stent–graft thrombosis. Any complication leading to a loss of aneurysm exclusion risks the failure of
treatment in the form of aneurysm rupture, whereas any complication leading to stent–graft thrombosis
risks the failure of supplying blood to the patient’s legs. Post-EVAR surveillance is performed to detect
complications and direct treatments with adequate surveillance relying on appropriate imaging strategies.
Since the development of EVAR, computed tomography angiography (CTA) has been the most common
modality adopted for surveillance; however, its use is associated with repeated radiation exposure and with
the risk of contrast nephropathy. Modified surveillance protocols have recently been proposed as a way to
minimise radiation exposure by eliminating unnecessary CTA examinations. Colour duplex ultrasound
(CDU) and, more recently, contrast-enhanced ultrasound (CEU) have been suggested as possible, safer,
alternatives to CTA.
Objective
To assess the current evidence for the clinical effectiveness and cost-effectiveness of strategies using either
CDU or CEU alone or in conjunction with plain radiography compared with CTA for surveillance after
EVAR.
Methods
Clinical effectiveness
Ovid MEDLINE Epub Ahead of Print, MEDLINE In-Process & Other Non-Indexed Citations, Daily and
Ovid MEDLINE, EMBASE, Science Citation Index, Scopus’ Articles-In-Press, Cochrane Central Register of
Controlled Trials (CENTRAL), Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews
of Effects and the Health Technology Assessment (HTA) database were searched from 1996 onwards to
identify reports of studies of interventions and systematic reviews of diagnostic studies.
The World Health Organization’s International Clinical Trials Registry Platform, Current Controlled Trials,
and Clinical Trials.gov were also searched for ongoing studies, clinical experts and relevant websites were
consulted and reference lists were perused.
Clinical effectiveness evidence was considered from randomised controlled trials, non-randomised
comparative studies and/or prospective and retrospective cohort studies of different imaging modalities
and follow-up strategies. In particular, we assessed the relative effectiveness of CEU or CDU, used alone or
in conjunction with plain radiography, for the long-term surveillance following EVAR. The comparator
modality was CTA. The population considered were adults undergoing surveillance following EVAR for
abdominal aortic aneurysm (AAA).
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Two reviewers independently selected studies for inclusion. One reviewer completed data extraction and
assessed the risk of bias of included studies, and two reviewers independently cross-checked the details
extracted by the first reviewer. A formal meta-analysis and metaregression of outcome data proved to
be unfeasible, owing to the dearth of relevant comparative studies. Outcome data are summarised
descriptively.
Cost-effectiveness
The evidence on cost-effectiveness was explored using a two-step approach: (1) a systematic review of
economic evaluations, followed by (2) a de novo decision-analytic model.
The NHS Economic Evaluations Database, the HTA database, MEDLINE In-Process & Other Non-Indexed
Citations, Epub Ahead of Print, EMBASE and Research Papers in Economics were searched from 1996
onwards for relevant economic evaluations. Clinical experts and relevant websites were consulted and
reference lists were scanned. The titles and abstracts of all of the identified citations were screened by one
reviewer. The full-text papers of potentially relevant studies were retrieved and assessed for inclusion.
A Markov model was developed to include five surveillance strategies:
1. annual CTA plus plain radiography
2. annual CDU plus plain radiography
3. annual CEU plus plain radiography
4. colour duplex ultrasound together with CTA and plain radiography at 1 year, followed by CDU and
plain radiography on an annual basis
5. contrast-enhanced ultrasound together with CTA and plain radiography at 1 year, followed by CEU and
plain radiography on an annual basis.
The parameter estimates were derived from the systematic review of clinical effectiveness, expert opinions
and other UK-based sources. The model considered a cohort of 74-year-old men, a lifetime time horizon,
a 6-month cycle length, a 3.5% discount rate and a NHS and Personal Social Services perspective. The costs
were expressed in 2015–16 Great British pounds and the effectiveness was expressed in quality-adjusted
life-years (QALYs) and incremental cost per QALY.
Adverse events and complications during surveillance were generically named as ‘abnormalities’. These were
divided into those conditions that would trigger an elective intervention (abnormal I) and those that, on
clinical assessment, would require a closer follow-up (abnormal II – e.g. type II endoleaks with sac expansion
of < 5 mm in 6 months or with limbs with kinking or partial thrombosis). The first category was further
subdivided into two: abnormal Ia includes non-endoleak-triggered interventions (e.g. limb occlusions, graft
infections) and abnormal Ib accounts for the endoleak-prompted interventions (e.g. types I, III and IV, type II
or endotension with sac expansion of > 5 mm).
Results
Clinical effectiveness
The evidence for this assessment is derived from two non-randomised comparative studies (including
750 participants, 694 participants in one study and 56 participants in the other), 25 cohort studies (including
7196 participants) and nine systematic reviews of diagnostic test accuracy (including 174 primary studies).
Surveillance protocols based on a combination of CTA and CDU or CEU were assessed.
The study duration ranged from 3 years to 16 years. The mean duration of follow-up ranged from 14 months
(interquartile range 7–27 months; range 1–46 months) to 54.8 months (standard deviation 35.9 months).
Patient characteristics and the type of aneurysm varied between studies.
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The two non-randomised comparative studies compared a surveillance protocol based on a combination
of CTA and CDU, with a simplified protocol based on CDU for long-term surveillance. In the largest
comparative study (694 participants), no significant differences between the two surveillance strategies
were observed during the 3-year follow-up in terms of reinterventions, clinical complications, mortality and
adverse effects, including renal impairment.
All studies included CDU as part of their surveillance protocols, apart from one study that followed up
patients using CEU and/or CTA. Studies that used CDU for annual long-term surveillance were published
more recently than those that used a combination of CTA and CDU for long-term surveillance. In the majority
of the included cohort studies (n = 10), surveillance was based on a combination of CTA and CDU throughout
follow-up. Eight studies used CTA and/or CDU for early and mid-term assessments and CDU for long-term
surveillance. Two studies used CTA for long-term surveillance (i.e. CTA at discharge, CDU at 6 months and
then CTA at 12 months and annually thereafter). Three studies adopted a protocol based exclusively on CDU
after EVAR and two studies included CEU together with CTA as part of their surveillance strategy.
Overall, the proportion of participants requiring reintervention after EVAR ranged from 1.1% during a mean
follow-up of 24 months to 23.8% in a cohort that included high-risk patients with hostile neck anatomy
who underwent a secondary procedure after a mean follow-up period of 32 months. Reintervention was
required mainly for the treatment of limb occlusion (< 1% to 7.2% of participants), thrombosis/stenosis
(< 1% to 5.6% of participants), type I endoleaks (<1% to 8.3% of participants), type II endoleaks (< 1% to
3.6% of participants) and type III endoleaks (< 1% to 1.6%). Across the studies, all-cause mortality ranged
from 2.7% (mean follow-up period of 24 months) to 42% among a cohort that included a proportion of
high-risk patients with hostile neck anatomy (mean follow-up period of 54.8 months). In the four cohort
studies that reported it, aneurysm-related mortality occurred in < 1% of the participants.
The studies that used a combination of CTA and CDU throughout follow-up reported the highest all-cause
mortality (42%) and the highest proportion of participants who required reinterventions for complications
after EVAR (23.8%). However, it is worth noting that the study that reported the highest all-cause mortality
(42% of patients) and the highest proportion of patients requiring reinterventions (23.8%) focused on
high-risk patients, some of whom presented with features of hostile neck anatomy. Apart from this study,
the remaining studies based on early and mid-term CTA and/or CDU and long-term CDU surveillance were
broadly comparable with those based on a combination of CTA and CDU throughout follow-up in terms of
clinical complications, reinterventions and mortality.
The findings of the nine systematic reviews of diagnostic accuracy show that for CDU the pooled sensitivity
for detection of all types of endoleaks ranged from 65% to 96% and the pooled specificity ranged from
90% to 97%, whereas for CEU the pooled sensitivity ranged from 81% to 98% and the pooled specificity
ranged from 78% to 88%. CEU accuracy improved when only studies that utilised the second generation
of contrast agents were considered.
Cost-effectiveness
Five economic studies were identified. All of the studies were cohort studies and they compared a
surveillance strategy based on the use of CDU or CEU with a strategy based on CTA and assessed the
reduction in costs as a result of fewer CTA scans in accordance with a modified surveillance protocol.
Although all of the studies fairly agree on the clinical outcomes of interest (i.e. endoleaks, AAA size and
the need for secondary interventions), the reporting of costs and cost methods was disparate. None of
the studies used a preference-based measure of effectiveness and the time horizon chosen was not
long enough to allow for all relevant costs and consequences. Consequently, as a result of insufficient
information for decision-making, a decision-analytic model was developed.
The Markov model base-case analysis results shows that annual follow-up with CDU only is the strategy with
the lowest expected cost (£3791), followed by CTA only (£3828) and CEU only (£4709). The strategies with
higher expected costs are those that use CDU (£4732) or CEU (£5644) in conjunction with CTA at the start
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of follow-up. A CTA-only strategy produces the lowest expected QALYs (6.552) and is dominated by CDU
only (6.553). Moreover, adding CTA to CDU or CEU at the start of follow-up results in more QALYs than
using only one imaging modality, but these strategies are either dominated or the incremental cost for
an additional QALY is well above the accepted cost-effectiveness threshold (i.e. £30,000). CEU-based
strategies result in higher expected QALYs (i.e. 6.559 and 6.560) than all of the other strategies, although
the incremental cost-effectiveness ratios to adopt any of these are well above the £30,000 threshold.
The probabilistic analyses show that, for willingness-to-pay (for an extra QALY) values of up to £50,000,
annual follow-up with CDU only has a > 58% probability of being cost-effective, with CTA having a
probability of between only 32% and 42% and CEU having a probability of between only 0.1% and
4.1%. CTA added to CDU or CEU has zero probability of being cost-effective.
The sensitivity analyses showed that a CEU-only strategy became cost-effective at very high rates of test
sensitivity and specificity (e.g. when it was assumed to produce perfect information – sensitivity and specificity
of 100% and no indeterminate results) and for a cost difference between CDU and CEU of < £55. A further
sensitivity analysis explored the effect of surveillance in a very high-risk group. At an annual incidence rate of
7% for the abnormal Ib group (e.g. type I and III endoleaks, together with type II endoleaks with a > 5-mm
sac expansion and other conditions commonly detected by non-X-ray modalities), CEU-based surveillance
becomes cost-effective. Although in clinical practice it is unlikely to observe an incidence of 7% for type I or
type III endoleaks, an incidence of 7% for type II endoleaks with sac expansion is, perhaps, possible.
Limitations
The majority of the studies were rated as being at a high or moderate risk of bias.
There was considerable heterogeneity in terms of imaging modality and the frequency of imaging, the
duration of follow-up, outcome measures, definition of the outcomes (e.g. the definition of decreased
aneurysm size) and the time points at which the outcomes were assessed. Owing to the observed clinical
heterogeneity, a statistical synthesis of the relevant outcomes was considered to be inappropriate.
Studies comparing protocols based on CDU with those based on CEU were not found. The majority of
surveillance protocols were based on a combination of CTA and CDU. Data from studies that exclusively
used a CDU-based surveillance (three studies) and from studies that used CEU as part of their imaging
protocol (two studies) were scarce.
The economic model was hindered by a lack of suitable data. The identification and selection of input data
were particularly challenging, with key model parameter values being based on expert opinions.
Conclusions
The current evidence assessing the effects of surveillance after EVAR is very heterogeneous, with protocols
being based on different imaging modalities, frequency of imaging and length of follow-up. No firm
conclusion can be drawn with regard to the optimal surveillance strategy after EVAR. There is a need
to improve current protocols to reduce radiation exposure, the risk of contrast nephropathy and costs,
while ensuring that patients are adequately followed up to minimise their risk of secondary complications,
especially aneurysm rupture. CDU may be a safe alternative to CTA, with CTA being reserved for abnormal
or inconclusive CDU cases that require further investigation. Further research is required, however, to validate
the safety of modified protocols based on the use of CDU and/or CEU. Access to modern equipment and
highly experienced operators remains a crucial requirement for the adoption of CDU surveillance. The
economic evaluation shows that CDU is the most cost-effective option, with a 63% probability of being
cost-effective at a £30,000 willingness-to-pay-per-QALY threshold. Strategies based on CEU produce more
QALYs, but are also more expensive and might be cost-effective for only higher-risk patients.
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Suggested research priorities
l Further research is needed to assess the value of targeted surveillance (i.e. patients with a greater risk
of complications may receive more frequent surveillance, whereas those with uncomplicated EVAR may
undergo less-frequent assessments or be discharged from surveillance).
l If surveillance is to be targeted, is CDU and/or CEU surveillance satisfactory for all patient groups or are
there groups for which CTA is required to avoid excessive risk?
l The criteria used for identifying patients at high risk of complications (e.g. use of validated score
systems, risk prediction models) require further investigation.
l The role of plain radiography as part of EVAR surveillance needs to be clarified. If CTA is to be
performed less frequently or avoided, should plain radiography be mandatory or reserved for patients
with abnormalities on ultrasound imaging?
l Future research should explore the effects of the information generated by the imaging modalities used
for surveillance and incorporate this within economic analyses.
Study registration
This study is registered as PROSPERO CRD42016036475.
Funding
Funding for this study was provided by the HTA programme of the National Institute for Health Research.
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Chapter 1 Background
Description of the health problems
Brief statement describing the health problem
Endovascular abdominal aortic aneurysm repair (EVAR) was undertaken for the first time by a Ukrainian
surgeon, Nicholas Volodos, in 19871 and introduced into wider clinical practice by Juan Parodi in 1991.2
Since then, EVAR has become the preferred treatment option for abdominal aortic aneurysm (AAA).3
A typical EVAR device consists of a stent covered with graft material to prevent the leakage of blood out
of the device.4 Although it is less invasive than open surgery, and has a lower perioperative mortality rate,
EVAR is associated with complications in the follow-up period, such as different types of endoleaks,
stent–graft migration, distortion or kinking of the stent–graft, structural disintegration of the stent–graft
and aneurysm expansion, all of which could potentially lead to failure of treatment in the form of an
aneurysm rupture.5–8 Therefore, all patients receiving EVAR are placed on surveillance with a view to
identifying complications in time to allow for remedial secondary interventions.
Data from The EUROpean collaborators on Stent–graft Techniques for abdominal aortic Aneurysm Repair
(EUROSTAR) registry of 2846 patients treated with EVAR from December 1999 to December 2004 showed
a cumulative incidence of secondary interventions of 6.0%, 8.7%, 12% and 14% at 1, 2, 3 and 4 years,
respectively.9,10 It is therefore necessary that patients receive lifelong surveillance following EVAR. The main
purpose of surveillance is to detect clinically significant complications, which are often asymptomatic, and to
prevent aneurysm rupture.11 Endoleaks are the most common complications that occur after EVAR.12–14
Classification of endoleaks
An endoleak, which can be defined as a persistent blood flow within the aneurysm but outside the
stent–graft, is the most frequent complication after EVAR, and is noted in approximately 20% of patients at
some point during follow-up. Endoleaks vary in size, direction and the rate of blood flow, and they have
variable origins.15 Five categories of endoleaks have been described in the literature in accordance with the
source of blood flow (Table 1).
Treatment and prognosis depends on the type of endoleak. Type I endoleaks, which have been reported to
occur in as many as 10% of patients after EVAR,17 have blood flow from the stent–graft attachment site as
a result of sealing failure and are associated with increased pressure in the aneurysm sac. Type I endoleaks
are usually treated at the time of the index operation and require urgent treatment if they present later.
The risk of intraoperative as well as a secondary late type I endoleak is higher in anatomically difficult
situation.17,18 Type II endoleaks, which are characterised by retrograde blood flow into the aneurysm, are
the most common type of endoleaks after abdominal EVAR and could be noted in as many as 20–30% of
patients at 30 days, 18.9% of patients at 1 year and 10% of patients after 1 year.17 Most of the type II
endoleaks run a benign course and hence are dealt with a ‘wait and see’ follow-up approach. In some
patients, surveillance monitoring may be increased. Treatment is required if the aneurysm increases in size;
often a > 5 mm increase is deemed to be clinically significant.15,18 Type III endoleaks result from structural
defects arising in the stent–graft or modular disconnection, and always require immediate treatment.
Structural failure of the device is more likely to happen over time as arterial pulsations and other factors
cause repetitive stress on the device. Tears or holes in the fabric of the graft can be hard to detect, but
modular disconnections are usually well seen with computed tomography angiography (CTA) and on plain
radiography (stent–grafts have radio-opaque markers to allow for the diagnosis of modular distraction or
dissociation on radiological examinations). The incidence of type III endoleaks is usually low (with an
estimated incidence of 4% beyond 1 year).17 Type IV endoleaks occur perioperatively or in the early
postoperative phase (defined as being within 30 days) as a result of graft fabric porosity. However, with the
advent of low-porosity graft fabrics, this type of endoleak is now observed less frequently. An endoleak
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detected on follow-up imaging should not be considered a type IV endoleak. Type IV endoleaks usually
resolve once the coagulation profile returns to normal after the EVAR procedure. Treatment of type IV
endoleaks is not usually required, but care should be taken to exclude other types of endoleaks at the point
of diagnosis.15,18–20 Type V endoleaks are a diagnosis of exclusion when no endoleak is actually demonstrable.
This refers to the phenomenon of endotension, defined as the persistent or recurrent pressurisation of an
aneurysm, which is identified by the continued expansion of the aneurysm sac. Although the exact cause of
endotension is not always elucidated, possible causes include slow blood flow that is not visible on current
imaging techniques, ultrafiltration of blood through the stent–graft, seroma, infection and the transmission
of pressure through the thrombus in seal zones. Type V endoleaks are managed on an individual basis.15,18
Epidemiology of abdominal aortic aneurysm
Abdominal aortic aneurysm represents a significant health risk in the older population. Studies conducted
in the 1990s in Europe and the USA indicated an overall prevalence of 2–4% for men and 1–2% for
women.10,21,22 A prospective population-based study conducted in Oxfordshire, UK, between 2002 and
2014 showed an annual incidence rate per 100,000 population of 55 in men aged 65–74 years; the
incidence increased to 112 in men aged 75–84 years and to 298 in those aged ≥ 85 years.23 Similarly,
a systematic literature review published in 2014, which estimated the global and regional incidence and
prevalence of AAA in 21 world regions, reported that in 2010 the age-specific annual incidence rate per
100,000 population ranged from 0.83 [95% confidence interval (CI) 0.61 to 1.11] in the 40–44 years
age group to 165 (95% CI 152.20 to 178.78) in the 75–79 years age group.24
In the USA, even though the total number of AAAs remains stable at 45,000 cases per year, the overall
use of EVAR has risen sharply in the past 10 years (from 5.2% to 74% of the total number of AAA repairs).25
In the UK, the 2016 report of the National Vascular Registry (NVR), which was based on information on
AAA repairs from 98 NHS organisations (82 in England, five in Wales, nine in Scotland and two in Northern
Ireland), showed an increasing trend in the proportion of EVAR procedures, growing from 54% in 2009 to
TABLE 1 Classification of endoleaks8,16
Endoleak Origin of blood flow
Type I Attachment site leaks
A Proximal
B Distal
C Iliac occluder
Type II Branch leaks
A Simple (one patent branch)
B Complex (two or more patent branches)
Type III Graft defect
A Junctional leak or modular defect
B Fabric disruption (midgraft hole)
Type IV Fabric porosity (within 30 days of procedure)
Type V Endotension
A With no endoleak
B With sealed endoleak
C With type I or III endoleak discovered at the time of open redo surgery
D With type II endoleak discovered at the time of open redo surgery
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66% in 2013. This trend appears to have stabilised over the last few years, with EVAR procedures accounting
for 69% of the elective AAA repairs in 2015. The total number of elective EVAR repairs submitted to the NVR
in 2015 was 2882. The majority of the EVAR procedures performed were in men (89%) and in people aged
> 65 years (86%). Similarly, the UK 2015–16 record of the Hospital Episode Statistics indicates that there
were 2975 hospital admissions for endovascular insertion of a stent–graft for AAA in England. Of these,
2650 were admissions of male patients and 382 were emergency admissions. The mean age of admitted
patients was 76 years.
Current post-endovascular abdominal aortic aneurysm repair surveillance: variation
in services and uncertainty about best practice
Surveillance following EVAR is now universally accepted and recommended, even though there are currently
no standard regimens.26 Post-EVAR surveillance should include a measurement of the aortic aneurysm, the
identification and classification of endoleaks and the detection of stent–graft deformation and thrombus
build-up within the graft.27,28 The ideal frequency of surveillance is not defined and heterogeneous strategies
exist between centres.8,15,29 A web-based survey of UK surveillance practice conducted among the members
of the British Society of Interventional Radiologists (BSIR) in 2011 indicated that imaging protocols comprise
routine CTA imaging at 1 month, 6 months, 12 months and annually thereafter.29 CTA is still considered
to be the current reference standard for monitoring aneurysm size and migration and for the detection
of endoleaks.26 CTA scanning, however, does not provide information on the direction of blood flow
associated with an endoleak and its frequent use has the disadvantage of exposing the patient to cumulative
doses of ionising radiation with a potential lifetime cancer risk, as well as exposing the patient to contrast
medium-induced nephrotoxicity.30–32 The risks associated with the repeated use of CTA have led some
investigators to consider revising the current surveillance protocols in order to minimise the radiation dose
and to eliminate unnecessary CTA examinations.12,33–35 The results of the 5-year follow-up of the US Zenith
(Cook Inc., Bloomington, IN, USA) trial suggest, for example, that, in patients without an early endoleak, the
6-month surveillance can be safely omitted from the surveillance schedule.36 Moreover, it has been observed
that only 1.4–9% of patients require reintervention as a result of surveillance-detected abnormalities,
whereas the majority of reinterventions occur in symptomatic patients with previously normal surveillance
assessments.11,26,37–39 Colour duplex ultrasound (CDU) and, more recently, contrast-enhanced ultrasound
(CEU) have been proposed as possible safer alternatives to CTA.40–43 Some investigators have suggested
that CDU/CEU might have a role in situations when CTA is equivocal or when endotension is suspected.44
It has also been suggested that CDU/CEU could replace CTA for annual surveillance for patients who have
not experienced endoleaks or an increase in aneurysmal sac size in the first year after EVAR.19,36,45,46 It is
debatable whether or not CDU or CEU can currently replace CTA in the immediate post-EVAR surveillance
period, as complications are more likely in the early postoperative period and CTA provides more precise
evaluation of aneurysm morphologic changes, sac diameter, graft anchorage and integrity.18 A significant
increase in aneurysm size, the detection of a new endoleak or cases in which CDU is non-diagnostic
because of obesity, gas or the lack of a suitable window, may also prompt further imaging with CTA
for clarification.3,12,36
A survey conducted in 2010 among the 41 clinical centres enrolled in the UK EVAR trial 147 showed that
12 out of 41 centres used CTA as the primary surveillance modality, 14 out of 41 centres used CDU as the
primary surveillance modality and 15 out of 41 centres used a combination of CTA and CDU. Similarly,
the recently published 15-year follow-up of the UK EVAR trial 148 demonstrated a shift in contemporary
practice towards CDU.
Although the original EVAR trial 1 protocol was for annual follow-up using CTA, which was used in the
early stages of the trial, in the later stages, many EVAR patients were followed up with CDU.48 The change
from CTA to CDU was partly influenced by the growing concern about the risks associated with radiation
exposure.49
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Relevant clinical guidelines
Although there is currently no consensus on the best place for CDU/CEU in the care pathway of surveillance
after EVAR, some clinical guidelines allude to a possible role of CDU/CEU within the existing imaging care
pathway. In the USA, the Society for Vascular Surgery practice guidelines, published in 2009,19 recommend
contrast-enhanced computerised tomography (CT) imaging at 1 month and 12 months during the first year after
EVAR. If at 1 month the CT imaging identifies an endoleak or other abnormalities of concern, postoperative
imaging at 6 months should be considered to further evaluate the proper exclusion of an aneurysm. If
neither an endoleak nor an aneurysm enlargement is detected during the first year of surveillance after
EVAR, colour duplex ultrasound may be regarded as a reasonable alternative to CT imaging for postoperative
surveillance. The presence of a type II endoleak should initially prompt continued CT surveillance to ascertain
whether or not the aneurysm is increasing in size. However, if the aneurysm is shrinking in size or is stable,
follow-up with CDU may be an option.
Despite some existing algorithms and guidelines,19,29 there is currently no consensus on the optimal surveillance
strategy after EVAR. Current surveillance paradigms in the UK are considerably heterogeneous, with each
centre performing its own protocol, which varies in both the timing and the modality of imaging.
Description of technology under assessment
Summary of interventions
Computed tomography angiography
Computed tomography angiography is widely used as an imaging modality for surveillance after EVAR
and is considered to be the reference standard imaging test.11 Multiple-phase CTA is recommended initially,
because of the variable flow rates of endoleaks after contrast injection. With multiple-phase CTA, imaging is
conducted before the administration of an intravenous iodinated contrast medium, after administration in
the arterial phase of contrast circulation as determined by bolus chasing, and in a delayed phase, usually in
the portal venous phase of contrast circulation.15 CTA is quick, widely available and less operator dependent.
CTA offers clear vascular and non-vascular imaging, and enables differentiation between true endoleaks and
areas of calcification or high attenuation that may mimic an endoleak.
The disadvantages of CTA include the cost of follow-up imaging, radiation exposure (15–31 mSv per
study11 compared with 0.014 mSv for a chest radiography),50 the nephrotoxic properties of the contrast
medium and occasional allergic reactions to the contrast material. The incidence of contrast-induced
nephropathy is estimated to range from 7% to 12%.32,45,47,51 CTA imaging is therefore unsuitable for use
in patients with, or at risk of, significant renal impairment.
Plain radiography
Despite the availability of advanced imaging modalities, plain radiography is still used in many centres in
Europe and North America for a general assessment of stent–graft position and integrity,12,52 as well as for
evaluating device migration, wire frame fracture, kinking or distortion.53,54 The European Society for Vascular
Surgery recommends using plain radiography in conjunction with CTA for the first 12 months of surveillance
and, if no endoleaks are detected, in conjunction with CDU or CEU thereafter.31 The BSIR survey showed
that 20 out of 37 respondents (54%) performed plain films in addition to CTA at the 1-year postoperative
follow-up.29 Contrary to CTA, CDU and CEU, plain radiography has little to no role in surveillance for
sac enlargement and the detection of endoleaks.12 For this reason, plain radiography must be used in
conjunction with other imaging modalities and cannot be used as the sole surveillance modality after EVAR.11
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Colour duplex ultrasound
Colour duplex ultrasound offers high levels of endoleak characterisation by delivering information
regarding the direction of endoleaks and velocity of blood flow, which is not provided by CTA. CDU can
also be used to guide the endovascular treatment of endoleaks, is inexpensive and portable, and avoids
exposing the patient to radiation and potentially nephrotoxic contrast agents. The imaging quality of CDU
is, however, operator-dependent, and scanning and reporting protocols can vary considerably between
institutions.55 CDU imaging is also affected by patient body habitus and bowel gas and is less able to
detect stent–graft defects or migration than CTA.
Contrast-enhanced ultrasound
Contrast-enhanced ultrasound is an evolving imaging modality that provides dynamic examination through
the administration of an intravenous contrast agent, which can be followed in real time as it appears within
the graft, with endoleaks appearing as a contrast outside the stent–graft, but within the aneurysm.11
During the last decade, the technique of CEU has changed and the developments include more stable
microbubble contrast material, as well as the introduction of a fundamentally different method of
generating ultrasound images utilising harmonics, compared with the earlier version of Doppler imaging
with contrast material.56 The contrast agents used in contemporary CEU are stabilised microspheres
consisting of sulphur hexafluoride or perfluorocarbon encapsulated by a phospholipid shell.20,57
Unlike CTA, CEU is safe to use in patients with renal impairment. Like CDU, CEU imaging is operator
dependent and, because of its technical requirements and the need to administer a contrast agent, should
be conducted by specialist sonographers trained in EVAR surveillance, rather than general sonographers.
Obesity and bowel gas can interfere with ultrasound scanning.29,56 Ultrasound equipment needs to be of
adequate standard and equipped with the relevant capabilities, which is often missing in dated equipment.
Purpose of this assessment
The purpose of this appraisal is to assess the current evidence for the clinical effectiveness and cost-effectiveness
of imaging strategies using either CDU or CEU alone or in conjunction with plain radiography compared with
CTA for the surveillance of EVAR.
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Chapter 2 Clinical effectiveness and diagnostic
accuracy of endovascular abdominal aortic aneurysm
repair surveillance imaging modalities
This chapter reports the assessment of the clinical effectiveness and diagnostic accuracy of imagingstrategies using either CDU or CEU alone or in conjunction with plain radiography compared with CTA
for the surveillance of EVAR. The methods were prespecified in a research protocol (PROSPERO database
CRD42016036475).
Clinical effectiveness
Methods for assessing the outcomes arising from the use of the intervention
We conducted an objective synthesis of the evidence for the clinical effectiveness of imaging strategies
using either CDU or CEU alone or in conjunction with plain film X-ray compared with CTA for the
surveillance of EVAR. The evidence synthesis was carried out in accordance with the general principles of
the Centre for Reviews and Dissemination (CRD)’s guidance for undertaking reviews in health care,58 the
recommendations of the Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0.59 and
the National Institute for Health and Care Excellence (NICE)’s guidance on the methods of technology
appraisal,60 and it is reported in accordance with the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA).61
Identification of studies
Comprehensive electronic searches were conducted to identify reports of published randomised trials
and cohort studies. Highly sensitive search strategies were designed, including appropriate subject
headings and text-word terms, to combine the search facets for endovascular aneurysm repair, the
imaging modalities under consideration and the study design. The searches were initially undertaken on
25 January 2015 and updated on 5 September 2016, and these included studies published from 1996
in order to reflect the introduction of CEU into clinical practice. There were no language restrictions,
but non-English-language reports were excluded because the evidence base containing English-language
reports was sufficiently large. Full details of the search strategies are reported in Appendix 1. The databases
searched were Ovid MEDLINE Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily and Ovid
MEDLINE (1946 to 5 September 2016), EMBASE (1996 to week 36 2016), Science Citation Index (1997 to
5 September 2016), Scopus’ Articles-in-Press (inception to 5 September 2016), Cochrane Central Register of
Controlled Trials [(CENTRAL) issue 3 2016], Cochrane Database of Systematic Reviews [(CDSR) issue 3 2016],
Database of Abstracts of Reviews of Effects [(DARE) inception to 25 January 2016] and the Health Technology
Assessment (HTA) database (inception to 25 January 2016). The reference lists of all of the included studies
were perused for further evidence. Members of the advisory group were contacted for details of additional
reports.
Identification of other relevant information, including unpublished data
The World Health Organization’s International Clinical Trials Registry Platform (ICTRP), Current Controlled
Trials and Clinical Trials.gov were searched on 27 January 2016 for evidence of ongoing studies.
Eligibility criteria
Studies fulfilling the following criteria were included in this assessment.
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Population
Adults undergoing surveillance following EVAR for AAAs.
Setting
Secondary or tertiary care settings.
Interventions
Contrast-enhanced ultrasound or CDU, used either alone or in conjunction with plain radiography for
long-term surveillance following EVAR.
Colour duplex ultrasound
Colour duplex ultrasound is inexpensive, portable and avoids exposing the patient to radiation and
potentially nephrotoxic contrast agents; however, the imaging quality of CDU is dependent on the quality
of the machine and the thoroughness of the examination. Similarly, CDU image reporting is operator
dependent and scanning protocols can vary considerably between institutions.55 CDU imaging is also
affected by patient habitus and bowel gas and is less able to detect graft defects or migration than CTA.
Contrast-enhanced ultrasound
There is evidence that the use of contrast enhancement increases the sensitivity of ultrasound surveillance.62
The main advantage of CEU is better classification of endoleaks as a result of dynamic visualisation of the
direction of blood into the aneurysm sac.43,52 As with CDU, CEU is operator dependent, with scan quality
and scanning protocols varying considerably between centres. Unlike CTA, CEU is safe to use in patients
with renal impairment. The use of an intravenous contrast agent and the presence of a clinician for its
administration make CEU more expensive than CDU. At present in the UK, CEU is not as widely available
as CDU.29
Plain radiography
The European Society for Vascular Surgery recommends using plain radiography in conjunction with CTA
for the first 12 months of surveillance, and, if no endoleaks are detected, in conjunction with CDU or CEU
thereafter.29,31 In contrast to CTA, CDU and CEU, plain radiography has little to no role in surveillance for
sac enlargement and the detection of endoleaks.12
Comparator
Computed tomography angiography
Computed tomography angiography is the most widely used imaging modality for surveillance after EVAR
and is considered to be the reference standard imaging test.11 CTA is quick, widely available and less
operator dependent, and it is not affected by body habitus. CTA offers clear vascular and non-vascular
imaging and enables differentiation between true endoleaks and areas of calcification or high attenuation
that may mimic an endoleak. Disadvantages include the cost of CTA follow-up, radiation exposure11 and
nephrotoxic properties of the contrast medium.32,45,47,51
Outcomes
Studies providing data on any of the following outcomes (using any measure) were considered to be
suitable for inclusion:
l Clinical and surgical outcomes –
¢ incidence and type of complications (e.g. all types of endoleaks, migration, kinking and fracture),
as defined by the authors of the relevant selected studies
¢ reintervention rate
¢ incidence and type of secondary interventions.
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Adverse effects and harms associated with a specific mode of surveillance (imaging modality) were also
taken into consideration (e.g. contrast-induced nephropathy).
Study design
We considered randomised controlled trials (RCTs), non-randomised comparative studies and/or
prospective and retrospective cohort studies of different surveillance imaging modalities, regimens and
follow-up strategies.
Exclusion criteria
Studies not fulfilling the prespecified criteria and the following types of reports were excluded:
l preclinical and biological studies
l case reports
l reports investigating technical aspects of the imaging modalities used for surveillance after EVAR
l editorials and opinions.
Data extraction and management
Two reviewers (PS and MS or CR and MS) independently screened the titles and abstracts of all citations
identified by the search strategies. Full-text copies of all of the potentially relevant studies were retrieved
and assessed independently by the two reviewers for eligibility using a screening form developed ad hoc
for the purpose of this assessment (see Appendix 2). Any disagreements during study selection were
resolved by discussion or in consultation with a third reviewer (MB).
A data extraction form was specifically designed and piloted for the purpose of this assessment (see
Appendix 2). Detailed information on study design, characteristics of the participants, settings, characteristics
of the interventions and outcome measures was extracted. Data extraction was carried out by three reviewers
(PS, CR and MS). One reviewer completed the data extraction and a second reviewer cross-checked the
extracted data for errors or inaccuracies. There were no disagreements between reviewers.
Quality assessment strategy
The methodological quality of the included studies was independently assessed by two reviewers (PS, CR
or MS). Disagreements were resolved by consensus or arbitration with a third reviewer (MB). Studies were
not excluded on the basis of their methodological quality. We assessed the risk of bias of non-randomised
studies using a 17-item checklist that we developed for NICE through the Review Body for Interventional
Procedures [(ReBIP) see Appendix 3]. The ReBIP checklist was adapted from several sources, including the
NHS CRD guidance for conducting or commissioning systematic reviews,58 Verhagen et al.,63 Downs and
Black64 and the Generic Appraisal Tool for Epidemiology (GATE).65 The four italicised questions of the
checklist used to evaluate the risk of bias of comparative studies were disregarded for all but the two
included comparative studies.66,67 Individual items within the checklist were rated as ‘yes’, ‘no’ or ‘unclear’
so that a rating of ‘yes’ denoted the optimal rating for methodological quality. We did not assess the
quality of abstracts, as the word limit for abstracts is usually insufficient to make informed judgements
about the potential risk of bias of the reported study.
Method of analysis/synthesis
The summary results and baseline characteristics from eligible studies have been described, tabulated and
demonstrated by graphs using methods that are appropriate for the types of measurements reported by
the included studies. We had planned a formal meta-analysis and metaregression of outcome data from
the included studies; however, this was not possible, owing to the lack of comparative studies. The
outcome data have been summarised descriptively.
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Results of the evidence synthesis
Quantity and source of the evidence
The original primary searches and subsequent updates retrieved a total of 3249 records after deduplication.
After reviewing the titles and abstracts, 456 records were subsequently excluded. Full-text copies of 483
potentially relevant reports were obtained and screened for inclusion, of which 27 were deemed to be
eligible for inclusion. This comprised 24 full-text papers (two non-randomised comparative studies and
22 cohort studies) and three abstracts (all cohort studies). Figure 1 shows the flow diagram of the study
selection process. Appendix 4 lists all of the studies included in this assessment, and Appendix 5 lists the
studies excluded after full-text scrutiny together with the reasons for their exclusion. Studies were excluded
if they failed to meet one or more of the specified inclusion criteria with regard to study design, participants,
intervention or outcomes.
Quality assessment of included studies
Non-randomised comparative cohort studies
The results of the methodological quality assessment for the two non-randomised comparative cohort
studies66,67 indicated that the Chisci et al.66 study was of moderate methodological quality, whereas the
Nyheim et al.67 study was of poor methodological quality, mainly because over half of the ReBIP checklist
items were rated as having an ‘unclear’ risk of bias.67 In particular, it was unclear if the patients were taken
from a representative sample – at a similar point in their disease progression – or selected consecutively,
and if the study groups were comparable.67 The study groups in the Chisci et al.66 study were comparable,
but we noted that the length of the follow-up period was not similar between the study groups. In both
studies, it was unclear whether or not the outcomes were assessed blindly or if the authors had adjusted
for confounding factors. Figure 2 summarises the results of the methodological assessment of the two
non-randomised comparative studies.
Cohort studies
The 22 cohort studies published in full were of mixed quality (Figure 3).40,41,68–87 The individual study-level
results are detailed in Appendix 6. For the majority of studies, over half or more of the ReBIP criteria were
not met, or the information provided in the studies was insufficient to determine if the criteria were met,
and were, therefore, judged as being of low or moderate quality. Three cohort studies were deemed to be
Selected from screening
(n = 483)
Total after deduplication 
(n = 3249)
Included studies
(n = 27)
reported in 28 papers
Excluded studies
(n = 456)
• Retained for summary of diagnostic
   test accuracy reviews, n = 9
• Ineligible imaging modalities, n = 179
• Ineligible participants, n = 23
• Insufficient participants, n = 22
• Ineligible study design, n = 131
• Unclear or irrelevant surveillance
   protocol, n = 70
• Ineligible outcomes, n = 11
• Duplicate or unable to obtain, n = 11
Databases searched
• MEDLINE/EMBASE deduplicated search, n = 2970
• Science Citation Index, n = 1556
• CENTRAL, n = 43
• Scopus’ Articles-in-Press, n = 24
FIGURE 1 Flow diagram of the study selection process.
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FIGURE 3 Quality assessment for non-comparative cohort studies. N/A, not applicable.
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of higher quality as they met all the ReBIP criteria.76,84,87 Three of the included cohort studies were
published only as abstracts88–90 and therefore were not quality assessed.
Participants were selected consecutively and were a representative sample in just over one-third of the
22 cohort studies. Similarly, the majority of studies undertook prospective data collection (see Appendix 6),
clearly defined the intervention and clinical setting and considered long-term outcomes. The majority of
the cohort studies (85%) were not clear in their reporting of participant dropouts and withdrawals and
over one-third did not clearly report their inclusion/exclusion criteria.
Study characteristics of all included studies
Details of all of the included studies, including baseline characteristics of participants, description of the
adopted surveillance strategy (imaging modality and frequency) and clinical outcomes, are described in the
subsequent text and Table 2, and are presented in Appendix 8.
TABLE 2 Participant characteristics in the included studies
Participants’ characteristics Total
Studies
Comparative Cohort
Total enrolled, n 9596 1282 8314
Total analysed, n 7946 750 7196
Number lost to follow-up, n (%)a 1650 (17.2) 532 (41.5) 1118 (13.4)
Number of men, n (%)b 5399 (67.9) 663 (88.4) 4856 (86.0)
Range of mean age (years) 68.7–77.5 74–77.5 68.7–76.6
Range of aneurysm diameter (mm)c 51.6–64 61–64 51.6–59
Comorbidities, n (%)d N = 5918 N = 1613 N = 4225
Hypertension 1602 (27.4) 523 (32.4) 1079 (25.5)
Cardiovascular diseasee 1468 (25.1) 449 (27.8) 1019 (24.1)
Cerebrovascular disease 181 (3.1) NR 181 (4.3)
Hyperlipidaemia 988 (16.9) 417 (25.9) 571 (13.5)
Respiratory diseasef 169 (2.9) NR 169 (4.0)
Diabetes 649 (11.1) 224 (13.9) 425 (10.1)
Smoking 773 (13.2) NR 773 (18.3)
Other 8 (0.1) NR 8 (0.2)
Type/terminology of AAA, n (%)
AAA (no additional description supplied) 6770 (85.2) 514 (68.5) 6256 (86.9)
Infrarenal AAA 842 (11.3) 0 (0) 842 (11.7)
Iliac artery aneurysmg 295 (3.7) 236 (31.5) 59 (0.8)
Ruptured AAA 39 (0.5) 0 (0) 39 (0.5)
NR, not reported.
a Per cent of total studies that provided data. Information was not available from six studies.69,71,78,81,82,89
b Per cent of total studies that provided data. Seven studies did not provide data.69–71,73,81,87,89
c Information not available from 15 trials.41,67,69,71–74,79,80,82,84,88–90
d Per cent of total studies that provided data. Information was not available from 14 studies.41,67,69,71–73,78,81–83,86,88–90
e Includes congestive heart failure, myocardial infarction, heart disease, coronary heart disease, hypercholesterolaemia,
coronary artery bypass.
f Includes chronic obstructive pulmonary disease.
g Includes iliac artery aneurysms and bilateral iliac aneurysms.
DOI: 10.3310/hta22720 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 72
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Brazzelli et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
13
Country
Nine of the included studies were conducted in the USA,40,69–71,73,80,81,87,88 six studies were conducted in
Italy,66,75,76,83,86,89 three studies were conducted in Germany,68,77,84 three studies were conducted in the
UK,41,78,82 two studies were conducted in France,72,85 one study was conducted in the Czech Republic,79
one study was conducted in Norway67 and one study was conducted throughout Europe.74 The location
was not reported in one study.90
Setting
Surveillance following EVAR took place largely at hospitals, vascular centres and tertiary referral centres.
Two studies were conducted in two centres each,68,74 one study involved 33 centres81 and the remaining
24 studies were conducted in a single centre.
Length of follow-up
The study duration ranged from 340,68,76,84,86 to 16 years.89 The longest median length of follow-up was
68 months (range 1–144 months),90 whereas the shortest median length of follow-up was 23.4 months.72
Mean follow-up ranged between 14 months [interquartile range (IQR) 7–27 months; range 1–46 months]83
and 55 months [standard deviation (SD) 36 months].85 Seven studies had mean or median follow-up
assessment periods that were > 36 months.41,66–68,78,85,90
Participants
A total of 7946 participants were assessed among the 27 included studies. The characteristics of the patients’
aneurysm type varied. The majority of studies (17/27 studies with a total of 6770 participants) did not specify
the type of AAA or reported only that participants had ‘abdominal aortic aneurysm’.40,41,67,69,72–74,76–82,86–90
In four studies, participants (total of 898) were reported to have infrarenal AAAs;70,71,84,85 in two studies
participants (total of 295) were reported to have iliac artery aneurysms;66,83 in two other studies, participants
(total of 195) were reported to have asymptomatic aneurysms;77,79 in three studies, participants (total of 45)
were reported to have symptomatic aneurysms;75,77,79 and, in two studies, participants (total of 39) were
reported to have ruptured AAAs.68,75
Surveillance imaging and frequency
We did not identify any studies that compared a surveillance protocol based on CEU with one based on CDU.
Non-randomised comparative cohort studies
Of the two included non-randomised comparative studies, the study by Chisci et al.66 compared a surveillance
strategy based on CDU and CTA 1 month after EVAR and every 6 months thereafter, with a strategy based
on CDU and CTA 1 month after EVAR and CDU and radiography every 6 months thereafter. The study by
Nyheim et al.67 compared a conventional surveillance protocol consisting of CTA, CDU and plain radiography
at 1, 6 and 12 months and annually thereafter with a simplified surveillance protocol based on CDU and plain
radiography at 6–8 weeks, CTA/CDU/plain radiography at 1 year and CDU and plain radiography annually
thereafter.
Cohort studies
Among the included 25 cohort studies, the majority (22/25 studies) reported surveillance protocols based
on mixed CDU and CTA imaging. Only three studies included CEU with or without CDU as a part of their
surveillance strategy.75,76,86 Of these, one study included CEU used alone at 6 months and in combination
with CTA annually thereafter,75 one study used CEU along with CTA and CDU at 1, 3, 6 and 12 months
and annually thereafter86 and, in the remaining study, the use of CEU instead of CDU was restricted to
selective cases only.76 Two of the three studies did not report the technique,76,86 and one reported the use
of SonoVue [sulphur hexafluoride microbubbles (Bracco UK, High Wycombe, UK)].75
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There was significant heterogeneity with regard to the modality of imaging, the timing of imaging and
the duration of surveillance among the included cohort studies (Table 3). Depending on the type and
frequency of imaging, the included cohort studies were broadly categorised into the following six
surveillance protocols:
1. Early and mid-term CTA and/or CDU and long-term CDU surveillance – eight studies (CTA and/or CDU
then CDU).
i. The eight studies varied in their early and medium-term surveillance; however, all studies used CDU
for the annual long-term surveillance after EVAR. Six studies used a combination of CTA and CDU
for early surveillance after EVAR (1-month or 3-month follow-up).41,77,80,82,89,90 Four studies assessed
patients at 6 months.76,80,89,90 Two of these studies used CDU for the 6-month follow-up,76,89 whereas
two studies used both CTA and CDU.79,90 Of the two studies that used CDU at 6 months, one study
reported the use of CEU alongside CDU for selective cases only.76 One study assessed patients using
CTA at 1 and 12 months and CDU annually thereafter.40
ii. Computed tomography angiography scans were performed in case of abnormalities in three
studies40,41,82 and plain abdominal radiography was used as a part of the surveillance protocols in
two studies.41,82
2. Early CTA, mid-term CDU and long-term CTA surveillance – two studies (CTA then CDU then CTA).
i. In two studies, CTA was used immediately after EVAR (at discharge), CDU was used at 6 months
and CTA was used for long-term surveillance (12 months and annually thereafter).68,74
3. Combination of CTA and CDU throughout surveillance – 10 studies (CTA and CDU).
i. Ten studies used CTA and/or CDU for both short- and long-term surveillance after EVAR. The frequency
of imaging was broadly similar between the surveillance protocols, with most of the studies using
imaging at 1 month, 6 months, 12 months and annually thereafter (see Table 3).70–72,79,81,83–85,87,88
Six of these studies included the use of radiography alongside CTA and CDU for the surveillance
examinations following EVAR.70,72,81,83,85,87
4. Colour duplex ultrasound-based surveillance – three studies.
i. Two studies used CDU exclusively as the imaging modality for surveillance after EVAR.69,78 Another
study used CDU at 1 month, 6 months and thereafter, and CTA was used only in selective cases.73
5. Combination of CTA and CEU/CDU throughout surveillance – one study (CTA and CDU and CEU).
i. In one study, participants underwent CTA, CEU and CDU surveillance at 1, 3, 6 and 12 months after
EVAR and annually thereafter.86
6. Early CTA, mid-term CEU and long-term CTA or CEU surveillance – one study (CTA then CEU then CTA
or CEU).
i. In one study, the surveillance protocol after EVAR included CTA at 1 month, CEU at 6 months and
yearly examinations with either CTA or CEU thereafter.75
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TABLE 3 The imaging modality and frequency of imaging in included cohort studies
Study, first author
(year of publication)
Surveillance frequency
< 1 month 1 month 3 months 6 months Every 6 months 12 months
Annually
thereafter 18 months 24 months
Annually
thereafter
Early and mid-term CTA and/or CDU and long-term CDU surveillance
Chaer (2009)40 CTA CTA CDU
(CTA selectively)
Fargion (2016)89 CTA and CDU CDU
Freyrie (2014)76 CDU CTA CDU
(CEU selectively)
CTA CDU
Ghotbi (2010)77 CDU CTA and CDU CTA and CDU CDU
Harrison (2011)41 CTA and CDU CDU and AXR
(CTA selectively)
CDU and AXR
(CTA selectively)
Kray (2015)80 CTA and CDU CTA and CDU CTA and duplex
ultrasound
CDU
Mazzaccaro (2011)90 CTA and CDU CTA and CDU CDU CDU
Oshin (2010)82 CTA and CDU
and AXR
CDU and AXR
(CTA selectively)
Early CTA, mid-term CDU and long-term CTA surveillance
Bisdas (2014)68 CTA CDU CTA CTA
Donas (2016)74 CTA CDU CTA CTA
Combination of CTA and CDU throughout surveillance
Bush (2001)70 CTA CTA and CDU
and radiography
CTA and CDU
and radiography
CTA and CDU
and radiography
Carroccio (2002)71 CTA and CDU CTA and CDU CTA and CDU CTA and CDU CTA and CDU
Cochennec (2007)72 CTA and CDU
and radiography
CTA and CDU
and radiography
CTA and CDU
and radiography
CTA and CDU
and radiography
Dominguez (2010)88 CTA and CDU CTA and CDU CTA and CDU
Köcher (2004)79 CTA and CDU CTA and CDU CTA and CDU CTA and CDU
Meier (2001)81 CTA and CDU
and radiography
CTA and CDU
and radiography
CTA and CDU
and radiography
CTA and CDU
and radiography
Parlani (2002)83 CTA and CDU
and AXR
CDU and AXR CDU and AXR CDU and AXR CTA
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Study, first author
(year of publication)
Surveillance frequency
< 1 month 1 month 3 months 6 months Every 6 months 12 months
Annually
thereafter 18 months 24 months
Annually
thereafter
Schunn (2000)84 CTA and/or CDU
(every 6 to 12 months)
Soler (2015)85 CTA and CDU
and AXR
CTA and CDU
and AXR
CTA and CDU
and AXR
CTA and CDU
and AXR
CTA and CDU
and AXR
Wolf (2002)87 CTA and CDU
and AXR
CTA and CDU
and AXR
CTA and CDU
and AXR
CDU-only surveillance
Blom (2012)69 CDU CDU CDU
Collins (2007)73 CDU CDU (CTA
selectively)
CDU (CTA selectively)
Karthikesalingam (2012)78 CDU CDU CDU CDU (at 9 months) CDU CDU annually
thereafter
Combination of CTA and CEU/CDU throughout surveillance
Stella (2009)86 CTA and CDU
and CEU
CTA and CDU
and CEU
CTA and CDU
and CEU
CTA and CDU
and CEU
CTA and CDU
and CEU
Early CTA, midterm CEU and long term CTA or CEU surveillance
Fossaceca (2013)75 CTA CEU CTA/CEU
AXR, abdominal radiography.
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Assessment of outcomes and follow-up
Of the 27 included studies, > 90% reported data on reinterventions and on the incidence and type of clinical
complications, 85% reported mortality data and 37% reported changes in aneurysm diameter. In total,
20 studies reported the incidence of type I endoleaks,40,41,66–68,73–77,79,82–85,87–91 18 studies reported the incidence of
type II endoleaks,40,41,66–68,73,75–77,79,80,82–85,88–90 10 studies reported the incidence of type III endoleaks,66–68,74–76,79,83,85,86
10 studies reported the incidence of limb occlusion40,41,66,69,72,74,78,82,84,85 and 12 studies reported the rate of
aneurysm rupture41,66,74,76,77,80,82,83,85–87,90 (see Appendix 9). Other complications reported in the included studies
were thrombosis (seven studies68,71,75,76,79,86,90), infection (seven studies66–68,70,74,79,85), stenosis (five studies41,74–76,79),
migration (six studies66,67,72,76,77,79), ischaemia (five studies66,68,72,88,92) and kinking (three studies41,72,78). All of
the outcomes were measured at different time points after EVAR and during surveillance using various
imaging modalities. When reported, the definitions of complications varied among the included studies.
Results of individual studies
The results of the included studies in terms of type and rate of EVAR-related clinical complications,
reintervention rates and types of secondary procedure performed, changes in aneurysm diameter and
mortality rates are presented in Appendices 10–13.
Results of non-randomised comparative cohort studies
The two non-randomised comparative studies included a total of 750 participants. Both studies used
CTA along with CDU, but the timing of imaging varied between the two studies. The results from two
comparative studies are shown in Table 4 and described in the text below.
The study by Chisci et al.66 compared CTA and CDU surveillance at 1 month after EVAR and every 6 months
thereafter (protocol I; 376 participants) with CTA and CDU at 1 month after EVAR and CDU and radiography
every 6 months thereafter (protocol II; 341 participants) and reported outcomes on reintervention rates,
clinical complications, mortality and aneurysm diameter. The proportion of participants who required
reintervention was similar between the two protocols (18.1% vs. 16.4%; p = 0.625). There was no evidence
of a difference between the two protocols with regard to early reintervention and late reintervention rates.
Similarly, the incidence of type Ia and Ib endoleak, type II endoleak, type III endoleak, graft migration, limb
occlusion, limb ischaemia, aneurysm rupture, graft infection and bowel ischaemia was similar between the
two protocols (Table 5). A higher proportion of graft kinking was picked up by protocol II compared with
protocol I (3.0% vs. 1.3%; p = 0.050). Mortality was similar between the two protocols (2.1% vs. 1.8%;
p = 0.932) and there was no evidence of a difference in the proportion of participants with permanent
(> 30% over baseline) renal impairment (8.8% vs. 8.5%; p = 0.997).
The study by Nyheim et al.67 compared a conventional surveillance protocol consisting of CTA, CDU and
plain radiography at 1, 6 and 12 months and annually thereafter (participant numbers not reported), with
a simplified surveillance protocol of CDU and plain radiography at 6–8 weeks, CTA/CDU/plain radiography
at 1 year and CDU and plain radiography annually thereafter (56 participants), but failed to provide
suitable comparative data. Data on reintervention rates, mortality rates and aneurysm diameter were
available for the simplified protocol only. The number of participants who died (16%) or required
reintervention (25%) was fairly high. In general, the rate of complications picked up by a surveillance
protocol based on CDU soon after EVAR, CTA/CDU at 1 year and CDU annually thereafter was higher
than that in the study by Chisci et al.66
Results of cohort studies
Reintervention and complication rates
Eighteen studies reported the number of participants requiring reintervention for various complications
(see Appendix 11).40,41,68,70,72,74–80,83,85–88,90 The proportion of participants who required reintervention ranged
from 1.1% during a mean follow-up of 24 months40 to 23.8% in a cohort that included high-risk patients
with hostile neck anatomy during a mean follow-up of 32 months.85 Five studies did not provide a breakdown
of the type of reintervention or the type of complication that required reintervention.69,80,83,88,90 Six studies
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TABLE 4 Results from the two non-randomised comparative studies
Outcomes
Study, first author (year of publication)
Chisci (2012)66 Nyheim (2013)67
Time point
Protocol
p-value Time point
Protocol
p-value
I: CTA, CDU at 1 month
and every 6 months
thereafter (N= 376)
II: CTA, CDU at 1 month
and CDU every 6 months
thereafter (N= 341)
I: CTA, CDU at 1,
6 and 12 months and
annually thereafter
(N=NR)
II: CDU at 6–8
weeks, CT/CDU
at 1 year and
CDU yearly
thereafter
(N= 56)
Reintervention
Number (%) of secondary
interventions
During
3 years
68 (18.1) 56 (16.4) 0.625 – – – –
< 30 days 17 (4.5) (two asymptomatic
and 15 symptomatic)
11 (3.2) (one asymptomatic
and 10 symptomatic)
0.602 – – – –
> 30 days 51 (13.6) (31 asymptomatic
and 20 symptomatic)
45 (13.2) (24 asymptomatic
and 21 symptomatic)
0.621 > 30 days NR 14 (25) –
Secondary intervention
free survival (%)
At 3 years 82 83.5 0.876 – – – –
Conversion to open
repair, n (%)
Not specified 3 (0.8) 1 (0.3) 0.626 – – – –
Mortality
Number (%) of
participants who died
(all cause)
During
3 years
8 (2.1) 6 (1.8) 0.932 < 30 days NR 0 –
– – – – > 30 days NR 9 (16)
Number of participants
who died (AAA related)
– – – – > 30 days NR 0
Overall survival rate (%) At 3 years 83 84 0.764 – – –
Freedom from AAA-
related mortality (%)
At 3 years 94.9 95.6 0.814 – – – –
continued
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TABLE 4 Results from the two non-randomised comparative studies (continued )
Outcomes
Study, first author (year of publication)
Chisci (2012)66 Nyheim (2013)67
Time point
Protocol
p-value Time point
Protocol
p-value
I: CTA, CDU at 1 month
and every 6 months
thereafter (N= 376)
II: CTA, CDU at 1 month
and CDU every 6 months
thereafter (N= 341)
I: CTA, CDU at 1,
6 and 12 months and
annually thereafter
(N=NR)
II: CDU at 6–8
weeks, CT/CDU
at 1 year and
CDU yearly
thereafter
(N= 56)
EVAR-related adverse events (only symptomatic data for Chisci et al.66), n (%)
Type I endoleak During
3 years
7 (1.9) 5 (1.5) NR – – – –
A (proximal) < 30 days 2 (0.5) 1 (0.3) 1.000 < 30 days NR 2 (3.6) –
> 30 days 4 (1.1) 4 (1.2) 1.000 – – – –
B (distal) During
3 years
1 (0.3) 0 1.00 – – – –
Type II endoleak 57 (15.2) 45 (13.2) 0.519 < 30 days NR 9 (16) –
– – – – At
6 months
NR 1 (1.8) –
Type III endoleak During
3 years
3 (0.8) 3 (0.9) 1.000 – – – –
< 30 days 0 1 (0.3) 1.000 < 30 days NR 1 (1.8) –
> 30 days 3 (0.8) 2 (0.6) 1.000 – – – –
Graft migration > 1 cm;
during
3 years
2 (0.5) 1 (0.3) 0.565 > 10mm;
> 30 days
NR 4 (7.1) –
Graft kinking > 30 days 5 (1.3) 10 (3.0) 0.050 – – – –
Limb occlusion During
3 years
10 (2.6) 8 (2.3) 0.977 < 30 days NR 2 (3.6) –
– – – – > 30 days NR 0 –
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Outcomes
Study, first author (year of publication)
Chisci (2012)66 Nyheim (2013)67
Time point
Protocol
p-value Time point
Protocol
p-value
I: CTA, CDU at 1 month
and every 6 months
thereafter (N= 376)
II: CTA, CDU at 1 month
and CDU every 6 months
thereafter (N= 341)
I: CTA, CDU at 1,
6 and 12 months and
annually thereafter
(N=NR)
II: CDU at 6–8
weeks, CT/CDU
at 1 year and
CDU yearly
thereafter
(N= 56)
Limb ischaemia During
3 years
5 (2.7) 2 (0.6) NR – – – –
< 30 days 2 (0.5) 0 0.501 – – – –
> 30 days 3 (0.8) 2 (0.6) 1.000 – – – –
Aneurysm rupture > 30 days 2 (0.5) 1 (0.3) 1.00 – – – –
Graft infection During
3 years
0 0 – < 30 days NR 2 (3.6) –
Bowel ischaemia During
3 years
2 (0.5) 0 0.501 – – – –
< 30 days 1 (0.3) 0 1.000 – – – –
> 30 days 1 (0.3) 0 1.000 – – – –
Aneurysm diameter/sac
size
> 5-mm
increase
during
3 years
54 (14.4) 43 (12.6) 0.565 > 5-mm
increase
within
> 30 days
NR 6 (10.8) –
Reduction in mean
aneurysm diameter
– – – – During
3 years
9 mm –
NR, not reported.
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TABLE 5 Results of the cohort studies according to the type of surveillance protocol
Study information
Surveillance protocols
Early and mid-term
CTA and/or CDU and
long-term CDU
surveillance
Early CTA, mid-term
CDU and long-term
CTA surveillance
Early CTA and CDU,
mid-term CDU and
long-term CTA
surveillance CDU-based surveillance
Combination
of CTA and
CEU and CDU
throughout
surveillance
Early CTA,
mid-term CEU
and long-term
CTA or CEU
surveillance
Number of studies 8 2 10 3 1 1
Total enrolled, n 2701 405 4000 886 100 222
Total analysed, n 1821 401 3766 886 100 222
Follow-up (months) Mean 20 Mean 24.6 Mean 14.6 Mean 22.3 Mean 23.2 Mean 29.6
Outcomes, % (number of studies reporting each outcome)
All-cause mortality Early: 0–1.2 (3)
Late: 0–19.7 (3)
17.2–28.6 (2)
Early: 0.8 (1)
Early: 0.5–7.7 (4)
Late: 3.9–42 (8)
4.4 (1) 6 6.8
Aneurysm-related mortality 0.5–0.8 (2) 0.2 (1) 0.4 (1) NR NR 0
Reintervention 1.1–11.5 (6) (NC = 2)a 9.5–15.6 (2) 2.9–23.8 (9); NC (1)a 10.1 (1) 6 10.8
Clinical complications
Type I endoleak 0–7.9 (5) 1.8–3.1 (2) Early: 0.8–8.3 (3)
Late: 1.8–7.7 (4)
NC (1)a 2 1.8
Type II endoleak 0.5–13 (6) 1.5–24.8 (2) 1–24.8 (5) NC (1)a 26 24.8
Type III endoleak 0 (1) 0.4–1.6 (2) 0–0.8 (4) NR 0 0.45
Thrombosis 0.6–5.6 (2) NR 2.5–4.5 (3) NR 4 4.5
Aneurysm rupture 0–1.3 (5) 0.8 (1) 0–0.6 (3) NR 0/100 NR
Limb occlusion 0–1.1 (3) 3.1–3.7 (2) 5.3–7.2 (2); NC (1)a 0–0.4 (2) NR NR
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Study information
Surveillance protocols
Early and mid-term
CTA and/or CDU and
long-term CDU
surveillance
Early CTA, mid-term
CDU and long-term
CTA surveillance
Early CTA and CDU,
mid-term CDU and
long-term CTA
surveillance CDU-based surveillance
Combination
of CTA and
CEU and CDU
throughout
surveillance
Early CTA,
mid-term CEU
and long-term
CTA or CEU
surveillance
Kinking 0.5 (1) NR NR 7.5 (1) NR NR
Migration 1 (1) NR NR NR NR NR
Infection NR 0.4–0.8 (2) 0–2 (2) NR NR NR
Ischaemia NR 0.4 (1) 0.2 (1) NR NR NR
Stenosis NR 4.7 (1) 0.5 (1) NR NR 0.4
NC, not calculable; NR, not reported.
a Fargion et al.89 (N= 966) and Oshin et al.82 (N= 295) who used CDU and a combination of CTA and CDU for surveillance, Carroccio et al.71 (N = 351) who used a combination of CTA
and CDU and both Blom et al.69 (N = 248) and Collins et al.73 (N= 160) who used CDU only, reported the number of events per total procedures and did not provide the number of
participants experiencing those events. Therefore, reintervention or complication rates could not be calculated.
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reported the total number of reintervention procedures performed during surveillance and are described
below in accordance with the type of surveillance protocol.69,71,73,82,85,89 In particular, three of these studies
reported the total number of graft limbs that required an intervention.69,71,82
Reintervention after EVAR was mainly indicated for a type I endoleak in < 1%75 to 8.3% of participants,79
for a type II endoleak in < 1%41,79 to 13.1% of participants,89 for a type III endoleak in < 1%68,79,85 and 1.6%
of participants,74 for limb occlusion in < 1%72,78,79 to 7.2% of participants and for thrombosis/stenosis in
< 1%41 to 10.7% of participants.85 In ≤ 1% of the participants for each report, reintervention was needed
for aneurysm rupture, infection, graft angulation, ischaemia, haematoma, false aneurysm, endotension,
migration and kinking.41,68,70,74–76,85,86 In one study, a high proportion of the participants (8.3%) who were
detected with primary endoleaks were treated during the early postoperative follow-up.79 Another study
reported that reintervention was required in 13.6% of participants for the repair of any endoleaks during a
mean follow-up of 15.8 months (range 1–48 months).87
Overall aneurysm diameter
Eleven of the studies reported various data on aneurysm shrinkage/expansion (see Appendix 12).40,41,68,74,76,
79,81,83,85–87 The observed average aneurysm size decrease was 4.3 mm83 to 15 mm.40 In studies assessing
aneurysm shrinkage, > 50% of participants were reported to have aneurysm shrinkage during
follow-up.68,74,76,79,83,85 It is worth noting that the definitions of decreased aneurysm size and the axis
of diameter measured varied among the included studies.
Overall mortality
Overall, 19 cohort studies reported the number of deaths during surveillance after EVAR (see Appendix 13).40,41,68,
70,72–77,79,80,83–88,90 The all-cause mortality rate ranged from 0% during a 12-month follow-up80 to 42% during
a mean follow-up of 54.8 months.85 It is worth noting that the study that reported the highest all-cause
mortality (42%) focused on high-risk patients, some of whom presented with features of hostile neck
anatomy. Two studies reported that no deaths occurred during follow-up.77,80 Early mortality rate
(< 30 postoperative days) ranged from 0.5%74 to 7.6%.75 With regard to the study that reported the
highest postoperative mortality rate (7.6%; 17 patients), it is worth noting that 13 out of the 17 patients
underwent EVAR as an urgent procedure, whereas 4 out of the 17 patients underwent EVAR as an elective
procedure.75 Aneurysm-related deaths occurred in < 1% of the participants in four studies.40,41,68,83 Three
studies reported no aneurysm-related deaths.70,75,87
Results in accordance with the type of surveillance protocols
The 25 included cohort studies (22 published in full40,41,68–87 and three abstracts88–90) assessed a total of 7196
participants. There was considerable heterogeneity among the included cohort studies in terms of imaging
modalities, frequency of imaging, length of follow-up and outcome measures.
The outcomes from the included cohort studies are presented according to the six broad surveillance
protocols we described before (see Study characteristics of all included studies). Table 5 presents a summary
of the results of the included cohort studies in terms of mortality, reintervention and complication rates.
1. Early and mid-term computed tomography angiography and/or colour duplex
ultrasound and long-term colour duplex ultrasound surveillance = eight studies
(computed tomography angiography and/or colour duplex ultrasound then colour
duplex ultrasound)
Table 6 details the results of the eight cohort studies, with a total of 1821 patients, that used CTA and
CDU for the short- and mid-term surveillance and CDU for the long-term surveillance following EVAR.
Reintervention Among studies that used CDU and/or CTA for the short- and mid-term surveillance and
CDU for the long-term surveillance after EVAR, reintervention was initiated in 1.1% of participants at a mean
follow-up length of 24 months40 to ≈11% of participants at a median follow-up length of 68 months.76,90 Only
four studies provided a breakdown of the type of reintervention or reported the proportion of participants
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TABLE 6 Results of studies that used early and mid-term CTA and/or CDU and long-term CDU surveillance (CTA and/or CDU then CDU)
Characteristic
Study, first author (year of publication)
aChaer
(2009)40 Fargion (2016)89 Freyrie (2014)76 Ghotbi (2010)77 Harrison (2011)41 Kray (2015)80 Mazzaccaro (2011)90 Oshin (2010)82
Follow-up, months
(range)
Mean 24
(1–48)
Median 30 (1–168) Mean 32.9± 23.3
(1–77)
Mean 20 (NR) Median 36 (12–57) Up to 12 months’
follow-up
Median 68 (1–144) Median 24 (NR)
All-cause mortality,
n/N (%)
5/184 (2.7) NR 2/177 (1.1) at
30 days
0/100 (0) at 30 days 25/219 (11.7) at
12 months
AAA related: 1/194
(0.5)
0/191 (0) at 12 months 6/488 (1.2) at 30 days
77/391 (19.7) at
> 30 days
AAA related: 3/391
(0.8)
NR
Reintervention rate,
n/N (%)
2/184 (1.1) 47/289 (16.3)
procedures
20/177 (11.3) at
45 months
6/100 (6) 9/194 (4.6) at
12 months
13/191 (6.8) at
> 6 months
45/391 (11.5) 11/583 (1.8) limbs
Clinical complications n/N (%)
Type I endoleak 2/184 (1.1) 9/289 (3.1)
procedures
2/177 (1.1) 0/100 (0) at 3 months
0/100 (0) at 12 months
1/194 (0.5) NR 31/391 (7.9) NR
Type II endoleak 1/184 (0.5) 38/289 (13.1)
procedures
23/177 (13.0) 15/100 (15) at
3 months
7/100 (7) at
12 months
4/194 (2.1) 17/191 (8.9) at 1 month
18/191 (9.4) at 6 months
3/391 (0.8) NR
Type III endoleak NR NR 0/177 (0) NR NR NR NR NR
Thrombosis NR NR 10/177 (5.6) NR NR NR 3/488 (0.6) at 30 days
8/391 (2.0)
NR
Limb occlusion 0/184b (0) NR 2/177c (1.1) NR 2/194 (1.0) NR NR 11/583 (1.8)
procedures
Kinking NR NR NR NR 1/194 (0.5) NR NR NR
continued
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TABLE 6 Results of studies that used early and mid-term CTA and/or CDU and long-term CDU surveillance (CTA and/or CDU then CDU) (continued )
Characteristic
Study, first author (year of publication)
aChaer
(2009)40 Fargion (2016)89 Freyrie (2014)76 Ghotbi (2010)77 Harrison (2011)41 Kray (2015)80 Mazzaccaro (2011)90 Oshin (2010)82
Aneurysm rupture 0/184 (0) NR 2/177 (1.1) NR 1/194 (0.5) 0/191 (0) at 6 months 5/391 (1.3) NR
Migration NR NR 0/177 (0) 1/100 (1.0) at
24 months
NR NR NR NR
Stenosis NR NR 1/177 (0.6) NR 1/194 (0.5) NR NR NR
NR, not reported.
a This study utilised CTA at 1 and 12 months and CDU annually thereafter.
b Graft occlusion.
c Renal artery occlusion.
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with complications who required reintervention. Reinterventions were performed for type Ia endoleaks in
0.6%76 to 1% of participants,77 for type Ib endoleaks in ≈2% of participants,40,76 for type II endoleaks in 1.1%
of participants,41,76 for thrombosis in 5.6% of participants,76 for stenosis, haematoma and kinking in 0.5%
of participants,41,76 for aortic rupture in 1.1% of participants,76 for occlusion in 1% of participants77 and
for migration in 1.5% of participants.41 Two studies82,89 provided information on the total number of
reinterventions. In one study, among 289 participants who were followed up for a median of 30 months, a
total of 47 reinterventions were required for the treatment of nine type I endoleaks and 38 type II endoleaks.89
In another study, among a total of 583 limbs at risk in 295 patients treated with EVAR, 11 stent–graft limb
occlusions (1.8%) were identified over a median follow-up length of 24 months, and eight of these required
secondary intervention.82
Clinical incidence/complications The proportion of participants with type I endoleaks ranged from 0%77
to 7.9%90 in five studies that reported this information,40,41,76,77,90 although the proportion of participants
with type II endoleaks ranged from 0.5%40 to 13%76 in six studies.40,41,76,77,80,90 No incidence of type III
endoleaks was reported. Two studies76,90 reported the proportion of participants with thrombosis and the
rate was fairly high in one study (5.6% at a median follow-up length of 32 months)76 compared with
the other study (2.0% at a median follow-up length of 68 months).90 Data from five studies showed
that aneurysm rupture occurred in up to 1.3% of participants.40,41,76,80,90 Less than 1% of participants
experienced limb occlusion (≈1%),41,76 kinking (0.5%),41 stenosis (0.5–0.6%)41,76 and migration (1%).77
Aneurysm diameter Three of the studies that used CDU for the long-term surveillance after EVAR
reported data on aneurysm shrinkage/expansion.40,41,76 Two studies observed an average decrease in
aneurysm size of 10 mm76 and 15 mm,40 respectively. One study reported that around 73% of participants
showed an aneurysm shrinkage of > 5 mm.76 Another study reported an aneurysm expansion of ≈1%.41
Mortality Of the eight studies that used CDU and CTA short- and mid-term surveillance after EVAR and
then CDU for the following examinations, six studies reported data on mortality. Of these, three studies
reported data on early mortality (< 30 days)76,77,90 and three studies reported data on late mortality
(> 30 days).40,41,80 With regard to early mortality, no deaths occurred in one study77 and the proportions of
participants who died were similar in the other two studies (1.1%76 and 1.2%,90 respectively). Mortality
rates of > 30 days ranged from 0% at 1 year80 to 19.7% during a median follow-up length of 68 months.90
Data from two studies indicate that < 1% of participants died as a result of aneurysm-related complications.41,90
The overall survival rate was 86.2% at 3 years in one study76 and 32% at 12 years in another study.90
2. Early computed tomography angiography, mid-term colour duplex ultrasound and
long-term computed tomography angiography surveillance – two studies (computed
tomography angiography then colour duplex ultrasound then computed
tomography angiography)
The results from the two studies that used CTA immediately after EVAR, CDU at 6 months and CTA at
12 months and annually thereafter are presented in Table 7. The studies included a total of 401 patients.
Reintervention The proportion of participants who required reintervention was 9.5% in one study
(median follow-up length of 42 months)68 and 15.6% in the other study (mean follow-up length of
24.6 months).74 In both studies, secondary procedures were undertaken mainly for treating limb occlusion
(≈4% of participants),68,74 stenosis (4.7% of participants)74 and type I endoleak (1.8% of participants).68
Clinical complications Data from the two studies indicate that the presence of a type I endoleak was
observed in 1.8%68 and 3.1%74 of participants and the presence of a type III endoleak was observed in
0.3%68 and 1.6% of participants.74 In one study, the proportion of participants with a type II endoleak was
1.5%.68 In both studies, a similar proportion of participants had limb occlusion (3.7% in one study68 and
3.1% in the other study74). Other complications, such as infection68,74 and ischaemia,68 were observed in
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< 1% of participants across the studies. One study reported aneurysm rupture in 0.8% of participants and
stenosis in 4.7% of participants.74
Aneurysm shrinkage Aneurysm shrinkage was observed in > 50% of participants in both studies.
The definitions of aneurysm shrinkage varied between studies despite the availability of reporting standards.
The average decrease in aneurysm size was 9 mm (IQR 3–15mm) at a median follow-up length of 42 months
in one study68 and ≈4 mm at a mean follow-up length of 24.6 months in the other.74
Mortality The proportion of deaths was 17.2% (mean follow-up length of 24.6 months) in one study74
and 28.6% in the other study (median follow-up length of 42 months).68 One study reported an early
mortality rate (< 30 days) of 0.8%.74 The rate of aneurysm-related death was 0.4% in one study.68 The
overall survival rate at 5 years was 67% in one study.68
3. Combination of computed tomography angiography and colour duplex
ultrasound throughout surveillance after endovascular abdominal aortic aneurysm
repair = 10 studies (computed tomography angiography and colour duplex ultrasound)
Table 8 shows the results from the 10 cohort studies, with a total of 3766 patients, that used a combination
of CTA and CDU for surveillance after EVAR.70–72,79,81,83–85,87,88 All but one study81 reported data that could be
tabulated. The frequency of imaging was broadly similar between the studies with follow-up imaging carried
out at 1 month, 6 months, 12 months and annually thereafter in most of them.
Reintervention All but one study84 provided information on the proportion of participants requiring
reintervention. This ranged from 2.9% (mean follow-up length of 14 months)70 to 23.8% of participants
(mean follow-up length of 31.9 months).85 Reinterventions (see Appendix 11) for type I endoleaks occurred
in 1%86 to 8.3% of participants,79 for type II endoleaks in 1.7% of participants,79 for any type of endoleak
TABLE 7 Results of studies that used early CTA, mid-term CDU and long-term CTA surveillance (CTA then CDU
then CTA)
Characteristic
Study, first author (year of publication)
Bisdas (2014)68 Donas (2016)74
Follow-up (months) Median 42 (IQR 31–50) Mean 24.6 (SD 17.4) range 0–61
All-cause mortality, n/N (%) 78/273 (28.6) 22/128 (17.2) at mean follow-up
1/128 (0.8) at 30 days
Aneurysm-related mortality, n/N (%) 1/273 (0.4) NR
Reintervention rate, n/N (%) 26/273 (9.5) 20/128 (15.6)
Clinical complications, n/N (%)
Type I endoleak 5/273 (1.8) 4/128 (3.1)
Type II endoleak 4/273 (1.5) NR
Type III endoleak 1/273 (0.4) at 10 months 2/128 (1.6)
Limb occlusion 10/273 (3.7) 4/128 (3.1)
Aneurysm rupture NR 1/128 (0.8)
Infection 1/273a (0.4) 1/128 (0.8)
Ischaemia 1/273 (0.4) NR
Stenosis NR 6/128 (4.7)
NR, not reported.
a Groin infection.
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TABLE 8 Results of studies that used a combination of CTA and CDU throughout surveillance after EVAR (CTA and CDU)
Characteristic
Study, first author (year of publication)
Bush (2001)70
Carroccio
(2002)71 Cochennec (2007)72
Dominguez
(2010)88 Köcher (2004)79 Meier (2001)81
Parlani
(2002)83
aSchunn
(2000)84 Soler (2015)85 Wolf (2002)87
Mean follow-up
(months)
14.6± 12.4 20± 9
(range 2–54)
28 (NR) NR 20.7 (range 2–60) 23.2 (range 2.0–78.8) 14 (IQR 7–27,
range 1–46)
18 (length of
follow-up 46)
54.8± 35.9 15.8± 11.3
(range 1–48)
Mortality, n/N (%) 12/104 (11.5) NR 18/460 (3.9) 22/1378 (1.6) at
30 days
13/120 (10.8) NR Late mortality:
21/336 (6.3)
AAA related:
1/336 (0.4)
1/190 (0.5) at
30 days
83/197 (42) < 30 days: 2/154
(1.3)
> 30 days: 25/154
(16.2)
Reintervention rate,
n/N (%)
3/104 (2.9) 26/702 (3.7)
procedures
33/460 (7.2) 273/1378 (19.8) 16/120 (13.3) NR 19/336 (5.6) 31/190 (16.3) 47/197 (23.8) 23/154 (15.0)
Clinical complications, n/N (%)
Any endoleak 21/154 (13.7)
Type I 18/104 (17.3)
at 1 month
NR NR 106/1378 (7.7) Total early: 10/120
(8.3) [A 7/120 (5.8);
B 3/120 (2.5)]
NR 4/366 (1.1)
at 30 days
32/190 (16.8) Reintervention
for 21 endoleaks
1/154 (0.6)
Type II 329/1378 (5.7) 9/120 (7.5) NR 22/366 (6.0)
at 30 days
32/190 (16.8)
Type III Early: 1/120 (0.8) NR 1/366 (0.3)
at 30 days
Thrombosis 26/702 limbs 3/120 (2.5) NR
Limb occlusion 33/460 (7.2) at follow-up
9/460 (2.0) at week 1;
14/360 (3.9) at 1 month;
23/460 (5.0) at 6 months;
30/460 (6.5) at 36 months
NR 10/190 (5.3)
at 30 days
Aneurysm rupture NR 1/366 (0.3)
at 30 days
Late: 1/154 (0.6)
Infection 1/104 (≈1) at
3 months
2/104 (≈2) at
26 months
0/120
Stenosis
NR, not reported.
a Schunn et al.84 used either CTA or CDU for long-term surveillance.
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in approximately 14% of participants,87 for limb occlusion in 7.2% of participants,72 for thrombosis in 2%
of participants,79,86 for infection in 1% of participants,70 for hook fracture in 2% of participants,70 for
migration in 0.6% of participants87 and for ischaemia in 1% of participants.86 One study reported that
endoleaks (any type of endoleak) were observed at 1 month in approximately 17% of participants,
but they did not seem to require reintervention throughout the follow-up period.70
Two studies provided information on the type of secondary procedures undertaken.71,85 In one of these
studies, which assessed a total of 351 participants, secondary procedures were performed for 26 limb
occlusions out of 702 limbs evaluated.71 In the other study, which assessed a total of 197 participants,
70 secondary procedures were performed to repair 12 type Ia endoleaks, nine type Ib endoleaks, 29 type II
endoleaks, two type III endoleaks, one endotension, 29 stenosis/occlusions, three infections and three
ruptures.85
Clinical complications Surveillance strategies based on the use of CTA and CDU picked up a type I
endoleak in 1.1%83 to 8.3% of participants79 1 month after EVAR. Type III endoleaks were identified in
< 1% of participants75,79,83 and type II endoleaks were detected in 5.7%88 to 7.5%79 of participants at
30 days. One per cent of these type II endoleaks were detected immediately after EVAR (< 30 days).83
In one study, thrombosis was detected in 2.5% of participants during a mean follow-up length of
≈20 months,79 whereas in another study, the proportion of participants with limb occlusion was reported
to increase during the follow-up period (by 2% in the first week after EVAR, 3.9% at 1 month, 5% at
6 months and 6.5% within 3 years).72 Infection was reported in 2% of participants in one study.70
The results of two studies indicate that aneurysm rupture occurred in <1% of participants.83,87
Aneurysm diameter Five studies reported information on the aneurysm diameter.79,81,83,85,87 A decrease
in aneurysm diameter was detected in > 50% of participants after EVAR.79,83,85 It is worth noting, however,
that the definitions of aneurysm size shrinkage and the duration of the follow-up period varied among
studies. In one study,79 the proportion of participants with shrinkage (i.e. a decrease in aneurysm diameter)
increased as the length of follow-up doubled (58.6% at > 12 months’ follow-up and 67.4% at > 24 months’
follow-up). One study reported a mean aneurysm shrinkage of 7.3 mm during a mean follow-up length of
23 months.81 In another study, there was no change in orthogonal and transverse aneurysm diameter during
a mean follow-up length of 15.8 months.87
Mortality All but one study71 reported information on mortality. The late mortality rate (> 30 postoperative
days) ranged from 3.9%72 during a mean follow-up length of 28 months to 42% during a mean follow-up
length of 54.8 months.85 The mortality rate assessed within 30 days of EVAR ranged from 0.5%84 to 7.7%.83
One study reported a proportion of aneurysm-related deaths of 0.4% at a mean follow-up length of
14 months.83
4. Colour duplex ultrasound-based surveillance (three studies)
Three studies with a total of 886 patients used exclusively CDU-based imaging for surveillance after EVAR.
One of these three studies also used CTA, but for selective cases only.73
Reintervention/complications In one study, 10% of participants required a secondary intervention for
the treatment of limb occlusion (0.4%) and limb outflow impairment (7.5%).78 Kinking was observed in
7.5% of participants, but no reintervention was required.
Across the three studies, the rate of reinterventions ranged from 2%69 to 9% (type I endoleaks = 2%;
type II endoleaks = 7%).73
Aneurysm shrinkage None of the studies reported on aneurysm shrinkage.
Mortality One study reported a mortality rate of 4.4% during a 5-year follow-up period.73
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5. Combination of computed tomography angiography and contrast-enhanced
ultrasound/colour duplex ultrasound throughout surveillance = one study (computed
tomography angiography and colour duplex ultrasound and contrast-enhanced
ultrasound)
In one study with a total of 100 participants, CTA, CEU and CDU were used at 1, 3, 6 and 12 months
after EVAR and annually thereafter. The mean duration of the follow-up period was 23.2 months.86
Reintervention Reinterventions were needed for participants with iliac limb thrombosis (2%), type I
endoleaks (1%), external artery iliac occlusion (2%) and spinal cord ischaemia (1%). The two reinterventions
for the external iliac artery occlusion occurred at 1 month and 8 months.
Clinical complications A type I endoleak was detected in three patients (3%): one on 2 days postoperatively,
one at 4 months and one at 6 months. Within 24 months, type II endoleaks were detected in 26 patients
(26%). At 6 months, four patients (4%) showed signs of thrombosis. No patients had aneurysm ruptures at
any point during the follow-up period.
Aneurysm diameter The mean baseline aneurysm diameter was 55.2 mm and ranged from 45 to
99 mm. During the follow-up period, an increase in aneurysm diameter (of 6 mm) was observed in two
patients (2%). The diameter of the aneurysm was unchanged in 98 patients (98%).
Mortality Six patients died of all-cause mortality during the follow-up period (mean 23.3 months).
6. Early computed tomography angiography, mid-term contrast-enhanced ultrasound
and long-term computed tomography angiography or contrast-enhanced ultrasound
surveillance = one study (computed tomography angiography then contrast-enhanced
ultrasound then computed tomography angiography or contrast-enhanced ultrasound)
In one study with a total of 222 patients, surveillance after EVAR was based on CTA at 1 month, CEU at
6 months and yearly examinations with either CTA or CEU thereafter. The mean duration of the follow-up
period was 29.6 months.75
Reinterventions A total of 24 participants (10.8%) required interventions during the follow-up period
and three participants required interventions within 30 days. The majority of the interventions were
required because of thrombosis (10 participants) and type II endoleaks (eight participants). The rest of
the reinterventions were for the treatment of type Ia and type III endoleaks combined (three participants),
type Ib endoleaks (two participants) and infection (one participant). Details of the reinterventions for the
three patients who suffered complications within the first 30 days were not reported.
Clinical complications Type I endoleaks occurred in four participants (1.8%), type II endoleaks occurred
in 55 participants (24.8%) and type III endoleaks occurred in one participant (0.45%). Of the 55 type II
endoleaks, eight were treated and 47 were managed conservatively with CEU follow-up. Stenosis occurred
in one participant (0.4%) and thrombosis occurred in 10 participants (4.5%).
Aneurysm diameter The study did not report on aneurysm diameter.
Mortality Within 30 days postoperatively, 17 people (7.7%) died. During the follow-up period (mean
29.6 months), 14 of the remaining 205 participants (6.8%) died.
Summary of clinical effectiveness
The evidence for this assessment derives from two non-randomised comparative studies and 25 cohort
studies assessing various surveillance protocols after EVAR based on a combination of CTA and CDU or
CEU. Of the two included non-randomised comparative studies, one was judged to be of moderate
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methodological quality, whereas the other study was considered to be of poor quality. The majority of the
cohort studies were judged to be of low or moderate methodological quality.
The study duration ranged from 3 years to 16 years among the included studies and the mean length of
follow-up ranged from 14 months (IQR 7–27 months; range 1–46 months) to 54.8 months (SD 35.9 months).
The characteristics of the participants and the type of aneurysm varied between the studies.
The majority of the included studies assessed EVAR surveillance protocol based on a combination of CTA
and CDU imaging throughout the follow-up period. Only two studies included CEU as the main imaging
modality and one other study used CEU, but only in selective cases. We did not identify any studies
comparing surveillance protocols based on CEU with those based on CDU.
Non-randomised comparative studies
The two non-randomised comparative studies assessed a total of 750 participants (694 participants in
one study and 56 participants in the other), and compared a CTA and CDU surveillance protocol with a
simplified protocol based on the use of CDU for long-term surveillance after EVAR. The timing of imaging
varied between studies, and one of these did not provide suitable data for statistical comparisons. It is
worth noting that the largest comparative study, which assessed a total of 694 participants, reported that
there was no evidence of a difference between the two surveillance groups in terms of reintervention rate,
clinical incidences, mortality and adverse effects, including renal impairment.
Cohort studies
Twenty-five cohort studies assessed a total of 7196 participants. There was considerable heterogeneity in
terms of frequency of imaging modalities, duration of the follow-up period, outcome measures, definition of
outcomes used (e.g. the definition of decreased aneurysm size) and the time points at which the outcomes
were assessed. Owing to the observed heterogeneity between studies, it was not deemed to be appropriate
to provide a statistical summary of the outcomes considered. We decided to group the studies according to
their similarity in terms of type and frequency of imaging modalities for surveillance after EVAR and created
six different surveillance categories (see Table 5). We tabulated and narratively summarised the results for
each of these categories.
All but one of the included studies included CDU as part of their surveillance protocols. The remaining
study followed up patients using CEU and/or CTA. In the majority of the studies (n = 10), surveillance after
EVAR was based on the use of CTA and CDU throughout the follow-up period. Eight studies used CDU for
long-term surveillance after EVAR and CTA and/or CDU for early and mid-term surveillance. Two studies
used CTA for the long-term surveillance after EVAR (CTA at discharge, CDU at 6 months and then CTA at
12 months and annually thereafter). Two studies included CEU, together with CTA, as part of their surveillance
strategies, and three studies adopted a surveillance protocol based exclusively on the use of CDU.
Overall, in the assessed cohort studies, the proportion of participants requiring reintervention after EVAR
ranged from 1.1% during a mean follow-up period of 24 months to 23.8% in a cohort that included
high-risk patients with hostile neck anatomy who were followed up for a mean length of 32 months. For the
cohort studies that provided information on the type of complications requiring treatment, a reintervention
was required mainly for the treatment of limb occlusion (< 1–7.2% of participants), thrombosis/stenosis
(< 1–5.6% of participants), type II endoleaks (< 1–3.6% of participants), type I endoleaks (< 1–3.1% of
participants) and type III endoleaks (< 1–1.6%). The studies that used a protocol based on assessments with
CTA and/or CDU throughout the follow-up period showed the highest proportion of participants (range
2.9–23.8%) who required reintervention for complications after EVAR, including type I endoleaks, type II
endoleaks, type III endoleaks, thrombosis, limb occlusion, infection and aneurysm rupture. It is worth noting
that the study that reported the highest proportion of participants requiring reinterventions (23.8%) focused
on high-risk patients, some of whom presented with features of hostile neck anatomy and had the longest
follow-up period (mean length 54.8 months). Only limited data were available from studies using CEU as
part of their surveillance protocol or studies based exclusively on CDU.
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Across the included studies, all-cause mortality ranged from 2.7% (during a mean follow-up length of
24 months) to 42% in a cohort that included a proportion of high-risk patients with hostile neck anatomy
(during a mean follow-up length of 54.8 months). Aneurysm-related deaths occurred in < 1% of the
participants in four studies. All-cause mortality was generally higher among surveillance strategies that
used CTA for early and long-term surveillance after EVAR. One study based on long-term CDU surveillance
(median follow-up length of 68 months; range 1–144 months) reported a higher mortality rate and a
higher proportion of participants who required reintervention.
The current evidence from the literature assessing the effect of surveillance after EVAR does not show a
consistent paradigm. The type of imaging modalities, frequency of imaging and length of follow-up vary
considerably between surveillance protocols. Therefore, no firm conclusions can be drawn with regard to
the optimal surveillance strategy after EVAR.
Summary of published endovascular abdominal aortic aneurysm repair
registries data
Data from relevant registries are summarised in Table 9 and the results are described in the following text.
It is worth pointing out that data from existing clinical registries and databases are not organised in
accordance with the imaging modalities used for post-EVAR surveillance.
The Endurant Stent Graft Natural Selection Global Postmarket Registry
The Endurant Stent Graft Natural Selection Global Postmarket Registry (ENGAGE) is a prospective, multinational,
long-term post-market study of the real-world use of the Endurant stent–graft system (Medtronic, Santa Rosa,
CA, USA) for infrarenal AAA repair. The registry, which used only minimal selection criteria to obtain a more
realistic representation of the current clinical practice, commenced in March 2009 and ended in January 2017.
Patients with unruptured infrarenal AAAs who underwent elective EVAR were recruited from 79 clinical centres
in 30 different countries. A minimum of five consecutive patients were enrolled from each centre. An EVAR
surveillance protocol was carried out in accordance with the standard practice at each clinical site, with the
exception of the requirement for 30-day and 1-year imaging.
Five publications reporting data from the ENGAGE registry were identified in the literature93–97 (Table 10).
The study by Tang et al.,93 which compared the 12 outcomes after repair of AAA with bifurcated versus
aorto-uni-iliac configuration of the Endurant stent–graft, used data collected in the ENGAGE registry from
March 2009 to August 2010. Among the total of 1172 participants in this study, 1089 (92.9%) received
bifurcated device stent–graft repair and 83 (7.1%) were treated with an aorto-uni-iliac femorofemoral
bypass. The study by Stokmans et al.94 reported data from 1266 participants from March 2008 to April 2011.
Both of these studies reported similar proportions of participants requiring secondary intervention at 1 month
(1.5%94 and 0.9%93) and at 12 months (4.6%94 and 4.9%93). Reinterventions were needed for the repair of
type I and type III endoleaks in 1.2% of participants in the Stokmans et al. study94 and in 0.6% of participants at
12 months in the Tang et al. study.93 In the Stokmans et al. study,94 at 12 months, secondary procedures were
performed in 2.0% of participants for occlusion/stenosis/kinking and in 0.6% of participants for persistent type
II endoleaks. Overall, at 1 month, the detection rates of type I endoleaks, type II endoleaks, type III endoleaks,
type IV endoleaks, graft occlusion, graft kinking and graft stenosis were similar in both of these studies (see
Table 10). The occurrence of other complications, including bowel ischaemia, myocardial infarction, renal failure
and stroke, was similar in both studies. In both studies, the all-cause mortality rate was 1.3% at 1 month and
≈8.5% at 1 year. In the Tang et al. study,93 the proportion of participants who died from aneurysm-related
causes was 1.2% at 1 month and 1.5% at 1 year.93 In the Stokmans et al. study,94 the 1-year assessment
showed an overall survival rate of 91.6% (SD 1.4%) and an aneurysm-related survival rate of 98.8% (SD 0.5%).
The study by Karthikesalingam et al.95 used data from the ENGAGE registry on reintervention and engraft
complications at 3 years to predict whether patients would be at a low risk or a high risk of complications
after EVAR based on the international validated St George’s Vascular Institute score.95 Overall, there were
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TABLE 9 Characteristics of the identified EVAR registries
Characteristic
Registry
ENGAGE EUROSTAR KPSGR ASERNIP-S Vascunet database
The west of
Scotland
Anaconda
Registry RETA
Lifeline Registry
of Endovascular
Aneurysm Repair
Number of
publications
5 16 5 4 1 4 2 4
Study dates March 2009–
January 2017
1996–2006 Since 2000 and
ongoing
Between November
1999 and May 2001;
January 2009 and
May 2013; ongoing
2005–2009 June 2005–
September 2009
January 1996–
March 2000
1999–2004
Study centres Multinational,
79 centres in
30 countries
European countries 17 Kaiser Permanente
Northern California
medical centres, USA
Australia Nine countries
(Denmark, Hungary,
Italy, Norway,
Sweden, UK,
Australia, Finland
and Switzerland)
Three hospitals in
the west of
Scotland, UK
UK USA
Surveillance
protocol
In accordance
with standard
practice at each
clinical site, with
the exception of
the requirement
for 30-day and
1-year imaging
Post-EVAR protocol
varied within the
centres. Most
frequently, CT
examinations were
used during follow-up
at 1, 6, 12, 18 and
24 months and
annually thereafter
Post-EVAR protocol
varied within the
centres. Patients
generally received a
CT scan at 1 month
and then usually
every 6–12 months,
depending on the
clinical scenario
No standard protocol.
Postoperatively up to
30 days, at 3 months,
6 months, 12 months
and then on an
annual basis
Varied depending
on country
CT and abdominal
radiography
at discharge,
1 month, 6,
12 months and
annually thereafter
Not specified Not specified;
follow-up up to
5 years
ASERNIP-S, Australian Safety and Efficacy Register of New Interventional Procedures – Surgical; KPSGR, Kaiser Permanente Endovascular Stent Graft Registry; RETA, Registry of Endovascular Treatment
of Abdominal Aortic Aneurysms.
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TABLE 10 Results of studies that analysed data from the ENGAGE registry
Characteristic
Study, first author (year of publication)
Stokmans (2012)94 Tang (2013)93
Karthikesalingam
(2015);95 and Bastos
Goncalves (2015)97 Faure (2015)96
Study dates March 2008–April 2011 March 2009–August 2010 March 2009–April 2011 March 2009–April 2011
Mean length of follow-up
(months)
12 29.9 (range 24.0–36.8) 18
Mean (SD) aneurysm diameter
(mm)
60.3 (11.7) Median 58 (IQR 54–65)
Mean age (years) 73.1 (SD 8.1; range 43–93) 73.1 (SD 8.1; range 43–93) Median 74 (IQR 79–68)
Total number of participants 1266 1172 1263 1143
Outcomes
At 1 month,
N = 1151
At 1 month,
N = 1262 (ITT)
At 1 year,
N = 500
1 month,
N = 1089
1 year,
N = 325
Stent–graft kinking, n (%) 20 (1.7) 18 (1.6) 0
Stent–graft occlusion, n (%) 23 (2) 19 (1.7) 1 (0.3) 39 [(92.9) 42 in total]; 13 (31.0) within
30 days and 30 (71.4) within 6 months
Stent–graft stenosis, n (%) 16 (1.4) 13 (1.2) 3 (0.9)
Stent–graft migration, n 0 0
Endoleak, n (%) 138 (12)
Type I 16 (1.4) 10 (0.9) 0 18 [(1.4) Bastos
Goncalves et al.97]
Type II 114 (10) 102 (9.3) 19 (5.8)
Type III 2 (0.2) 2 (0.2) 1 (0.3)
Type IV 1 (0.09) 0 0
Type I and/or III 17 (1.5) 12 (1.1) 1 (0.3)
Undetermined 7 (0.6) 7 (0.6) 0
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TABLE 10 Results of studies that analysed data from the ENGAGE registry (continued )
Characteristic
Study, first author (year of publication)
Stokmans (2012)94 Tang (2013)93
Karthikesalingam
(2015);95 and Bastos
Goncalves (2015)97 Faure (2015)96
All-cause mortality, n (%) 16 (1.3) 42 (8.4) 14 (1.3) 28 (8.6)
Procedure-related mortality
(up to 30 days)
3/325 (0.9) 4/325 (1.2)
Aneurysm-related mortality
(up to 30 days)
– 1 (0.2) 4/325 (1.2) 5/325 (1.5)
Bowel ischaemia, n (%) 3 (0.2) 2 (0.4) 2 (0.2) 0
Myocardial infarction, n (%) 14 (1.1) 9 (1.8) 12 (1.1) 7 (2.2)
Renal failure, n (%) 4 (0.3) 5 (1.0) 3 (0.3) 5 (1.5)
Stroke, n (%) 2 (0.1) 2 (0.4) 2 (0.2) 2 (0.6)
Respiratory failure, n (%) – 1 (0.2)
Conversion to open repair, n (%) 3 (0.2) –
Secondary interventions, n (%) 19 (1.5) 23 (4.6) 3/325 (0.9) 16/325 (4.9) 12 [(1%) for type I
endoleaks]
Endovascular (occlusion,
stenosis or kinking)
8 (0.6) 10 (2.0)
Endovascular (type I/III
endoleak)
4 (0.3) 6 (1.2) 0/325 2/325 (0.6)
Open bypass procedure 6 (0.5) 5 (1.0)
Other 1 (0.07)
Endovascular (persistent type II
endoleak)
– 3 (0.6)
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Characteristic
Study, first author (year of publication)
Stokmans (2012)94 Tang (2013)93
Karthikesalingam
(2015);95 and Bastos
Goncalves (2015)97 Faure (2015)96
Aneurysm rupture – 0 0/325 1/325 (0.3%)
Overall survival rate, % (SD) 91.6 (1.4) at 1 year
Aneurysm-related survival rate,
% (SD)
98.8 (0.5) at 1 year
Aneurysm size Increased by ≥ 5mm (2.8%); stable (55.9%);
decreased by ≥ 5mm (41.3%) at 1 year
Freedom from limb occlusion,
% (SD)
97.9 (0.3) at 2 years
ITT, intention to treat.
Notes
Tang et al.:93 92.9% (n= 1089) received bifurcated device stent–graft repair. Therefore, only outcomes after repair of AAA with bifurcated device are considered here.
Karthikesalingam et al.:95 outcomes in accordance with risk stratification (St George's Vascular Institute score) for predicted low-risk vs. high-risk group, including freedom from reintervention
and freedom from endograft complications (n= 1207 analysed).
Bastos Goncalves et al.:97 secondary intervention 12 out of 18 [corrected by remodelling the stent–graft, n= 2; with extension cuffs (proximal or distal), n= 6; others, n= 4].
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107.6 type I endoleaks, 209.8 type II endoleaks and 86.3 type III endoleaks per 100 patient-years of
follow-up (affecting 4.5%, 19.6% and 0.4% of participants, respectively). Aneurysm expansion that was
greater than 5 mm was observed in 90.1 participants per 100 patient-years of follow-up (affecting 14.8%
of participants). The study by Faure et al.96 reported 97.9% freedom from limb occlusion at 2 years.
The EUROpean collaborators on Stent–graft Techniques for abdominal aortic Aneurysm
Repair registry
The EUROSTAR registry was established in 1996 to collate and analyse data from patients who underwent
endovascular treatment for AAAs. The EUROSTAR standardised case record forms were used to collect data.
Information on patients with AAA enlargements but without detectable endoleaks (known as endotension),
patients who had an elective treatment for AAAs and patients with suitable vascular anatomy for
implantation of a stent–graft were collected from various centres in different European countries. The
EUROSTAR registry is no longer active (patient enrolment was closed in November 2006).
Sixteen publications reporting data from the EUROSTAR registry were identified in the literature.5,9,91,98–110
Post-EVAR protocols varied considerably between centres. In most centres, CTA examinations were used at
1, 6, 12, 18 and 24 months after EVAR and annually thereafter. Other imaging modalities used for EVAR
surveillance were CDU, CEU and magnetic resonance imaging. It is worth noting, however, that these
publications were based on data collected from 1996 to 2006, when CDU and CEU were not in much use
in clinical practice. The results from each EUROSTAR report are outlined in Table 11.
The Kaiser Permanente Endovascular Stent Graft Registry
The Kaiser Permanente Endovascular Stent Graft Registry (KPSGR) is a prospective registry that makes
use of electronic medical records to track device utilisation and to appraise short- and long-term EVAR
outcomes. The data collection started in 2000 and is ongoing. Patients with endovascular repair of AAAs
were identified from a retrospective review of EVARs performed at 17 Kaiser Permanente Northern
California medical centres in the USA.
Five publications reported data from the KPSGR.111–116 No standardised post-EVAR surveillance protocol
existed during the data collection period. In general, patients received CTA at the 1-month follow-up and
then every 6–12 months depending on the clinical scenario.
In three studies, the proportion of participants requiring reintervention was 10.3%,115 10.8%112 and
15% (median of 32.2 months’ follow-up), respectively.116 The study by Hye et al.112 reported an overall
reintervention rate of 10.8%. Of the reinterventions, 4.6% were for endoleaks, 1.7% were for stenosis,
1.5% were for thrombosis, 1.3% were for occlusion, 1.6% were for device malfunction, 1.3% were for
haematoma/seroma, 0.6% were for pseudoaneurysm, 0.6% were for abdominal compartment syndrome,
0.5% were for infection and 0.4% were for rupture. In the study by Walker et al.,114 aneurysm rupture
occurred in 1.2% of participants during a median follow-up length of 32.2 months (IQR 14.2–52.8 months).
Aneurysm-related mortality was 0.6% at 1 month and 0.8% at 1 year, whereas all-cause mortality was
14.3% at 1 year. In the study by Anthony et al.,115 all-cause mortality was 1.2% at the 1-month follow-up.
Australian Safety and Efficacy Register of New Interventional Procedures – Surgical
The Australian Safety and Efficacy Register of New Interventional Procedures – Surgical (ASERNIP-S) is a
national collection of data for the evaluation of EVAR. An audit containing information on patients who
had a Zenith graft repair for AAA between November 1999 and May 2001 was managed and published
by the ASERNIP-S.
No standardised EVAR surveillance protocols were specified. Postoperative follow-up was carried out at
30 days, 3 months, 6 months, 12 months and annually thereafter.
The 787 Zenith graft patients enrolled in the audit were followed up until 2008. Technical success was
93.5% at 30 days. During the 7-year follow-up period, reinterventions were required in 13.5% of
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TABLE 11 Results of studies that analysed data from the EUROSTAR registry (1996–2006)
Study, first
author (year of
publication) Study dates
Total
number of
participants
Mean length of
follow-up
Summary of the major findings that
are relevant to the review
Buth (2003)91 1996–NR 2272 NR In total, 297 (12%) participants had type I
or type III endoleaks
Overall 2-year survival was 90% in the
entire cohort
A total of 0.6% (n = 15) of the participants
had a rupture of their aneurysm at a
mean of 16 months’ follow-up, and 5.4%
of participants reported an increase in the
size of the aneurysm
Secondary intervention was needed in
54% (n = 160) of those with type I and III
endoleaks compared with 6% (n = 118) of
those without endoleaks
Type I and type III endoleaks were
associated with an increased frequency of
open conversion (11% vs. 0.8%) or risk of
rupture of the aneurysm (3.4% vs. 0.25%)
compared with those without endoleaks
Cuypers [(2011)99
reprinted article];
Cuypers [(1999)110
original article]
1994–98 899 Median 6.2 months
(range 0–48 months)
At 18 months, cumulative patient survival
was 88% and persistent endoleak-free
survival was 79%
During follow-up, procedure- or device-
related complications occurred in 7–14%
of patients, 0.7% of patients (n= 6) had
aneurysm rupture and reintervention was
needed in 4–4.7% of patients in each
3-month follow-up interval
Harris (2000)5 1996–2000 2464 12.19 months
(SD 12.3 months)
There were 0.6% of patients (n= 14) with a
confirmed rupture of their aneurysms. The
cumulative rate of rupture was ≈1% per year
The death rate at 30 days was 3.2% (n= 79)
At 1 month, an endoleak was identified in
8.3% of patients (n= 140/1688)
Significant risk factors for rupture included
proximal type I endoleak, type III endoleak,
graft migration and kinking. Significant risk
factors for late conversion were proximal or
distal type I endoleak, type III endoleak,
type II endoleak, graft migration and kinking
Hobo (2006)9 1999–2004 2864 23 months (SD
12 months, range
1–60 months)
Secondary intervention was required in
8.7% of patients (n= 247) at a mean of
12 months after EVAR. The cumulative
incidence of secondary intervention was
6.0%, 8.7%, 12% and 14% at 1, 2,
3 and 4 years, respectively. The most
frequent reasons for secondary procedures
were type I endoleak (n= 144), type II
endoleak (n= 370), type III endoleak
(n= 101), thrombosis/stenosis (n= 100)
and migration/kinking (n= 113)
continued
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TABLE 11 Results of studies that analysed data from the EUROSTAR registry (1996–2006) (continued )
Study, first
author (year of
publication) Study dates
Total
number of
participants
Mean length of
follow-up
Summary of the major findings that
are relevant to the review
Koole (2011)98 1996–2006 6337 24.6 months (range
1–120 months)
Aneurysm rupture and aneurysm-related
mortality occurred in 0.4% of patients
(n= 26) and 2.5% of patients (n= 162),
respectively. At 7 years, 95.9% of patients
had freedom from rupture. A total of
1.3% (n= 83) had conversion to open
AAA repair
Laheij (2000)100 1996–99 1023 20 months In total, 18% of participants (n = 186)
needed secondary intervention, occurring
at a mean of 14 months after initial EVAR.
The rates of freedom from intervention at
1, 3 and 4 years were 89%, 67% and
62%, respectively
The 3-year cumulative survival rate of
patients was 90% (n= 41) in those
without a secondary intervention and 85%
(n= 13) in those who had secondary
intervention
Leurs (2004)103 1996–2004 676 13.5 months (range
1–60 months)
Results were presented for those with an
aneurysm diameter that was < 5.5 cm
[(n= 300) group A] and > 5.5 cm
[(n= 376) group B]
Device migration (0% vs. 2%), type I and
type III endoleak (2% vs. 4%) occurred
more frequently in those with a larger
aneurysm
The overall death rate after 3 years of
follow-up was significantly higher in group
B participants (4% vs. 14%; p= 0.0025).
Aneurysm-related mortality at 3 years was
significantly higher in group B (0.3% vs.
3%; p= 0.02)
Leurs (2005)105 1996–2004 4433 Evaluation of the determinants and
consequences of surveillance completeness.
Results were presented based on patients
who attended all scheduled visits compared
with those who came infrequently
Leurs (2006)104 1999–2005 3499 Analysis of clinical outcomes was based on
infrarenal neck length. Overall results not
presented
Leurs (2007)102 1998–2005 213 18 months
(SD 16.1 months,
range 1–60 months)
In total, 12% of participants (n= 25)
needed secondary intervention occurring at
a mean of 8 months after initial EVAR. The
rates of freedom from intervention at 1 and
2 years were 86% and 83%, respectively
The 2-year cumulative survival rate was
85% in participants without secondary
intervention and 58% in those who had
secondary procedures
Complications, including migration,
occlusion/stenosis and type I and type III
endoleak, occurred more frequently in
those who needed a secondary intervention
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participants. Overall, 4.2% of participants developed type I endoleaks, 14% developed type II endoleaks,
< 2% experienced kinking, stenosis, migration or thrombosis and < 1% developed type III endoleaks
or infection.
All-cause mortality was 0.5% at 1 month, 32% at 5 years and 44% at 7 years. During the follow-up
period (7 years after EVAR) 4.4% of participants (35/787) died from aneurysm-related causes. Ten of these
deaths (1.5%) were due to ruptured aneurysms.
TABLE 11 Results of studies that analysed data from the EUROSTAR registry (1996–2006) (continued )
Study, first
author (year of
publication) Study dates
Total
number of
participants
Mean length of
follow-up
Summary of the major findings that
are relevant to the review
Leurs (2007)101 1994–99 1190 3820 person-years
of follow-up
Overall, all-cause death and aneurysm-
related death occurred in 19.9% and
3.0% of the participants, respectively.
In total, 7.1% of participants had
conversion to open repair and 2.4% of
participants had aneurysm rupture during
the follow-up period. The most frequently
occurring procedure-related complications
were endoleak (13 cases per 100 patient-
years), stenosis/thrombosis (4.6 cases per
100 patient-years), and stent migration
(4.3 cases per 100 patient-years)
Peppelenbosch
(2004)106
1998–2002 4392 Outcomes were presented for three
groups defined by the preoperative
diameter of the aneurysm. Overall results
not presented
Szmidt (2007)107 1998–2006 445 Case studies of three patients
van Marrewijk
(2004)108
1996–2002 3595 15 months (range
0–72 months)
Analysis of risk factors for type II endoleak
and adverse events
Overall, 55% of participants with type II
endoleak had reintervention after EVAR
along with aneurysmal growth compared
with 15% of patients without any
endoleak (p< 0.0001)
Vallabhaneni
(2001)109
1996–2000 2862 Median 12 month
(range 0–72 months)
The mortality rate at 30 days was 2.9%
(n= 85). The cumulative survival rate at
48 months was 77.1%
Late rupture of the aneurysm occurred in
14 out of 2464 participants for an annual
cumulative rate of 1%
Late conversion to open repair occurred in
41 out of 2862 participants for an annual
cumulative rate of 2.1%
NR, not reported.
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A recent publication by Fitridge et al.,117 which combined data from a total of 1647 patients from two
ASERNIP-S audits of EVAR (from 1999 to 2001 and from 2009 to 2013), reported a 1-year survival rate of
93.7% (1544/1647) and a 30-day survival rate of 98.4% (1620/1647).
Vascunet database
The Vascunet registry collected data from national and regional vascular registries in Australia, Denmark,
Finland, Hungary, Italy, Norway, Sweden, Switzerland and the UK on primary AAA repairs performed
between 2005 and 2009.
A total of 31,427 intact AAA repairs were assessed. The overall perioperative mortality rate (in-hospital or
within 30 days) was 2.8% and was stable over time. The perioperative mortality rate varied from 1.6%
(95% CI 1.3% to 1.8%) in Italy to 4.1% (95% CI 2.4% to 7.0%) in Finland. A total of 7040 ruptured
AAA repairs were identified. The overall perioperative mortality rate was 31.6% (95% CI 30.6% to
32.8%), which decreased over time.118
Registry of Endovascular Treatment of Abdominal Aortic Aneurysms
The Registry of Endovascular Treatment of Abdominal Aortic Aneurysms was established in January 1996
to collect data from 41 centres that initially undertook EVAR in the UK.119,120 The data for the first 1000
cases submitted to the registry were published in 2005 by Thomas et al.119 Overall, the mortality rate was
11% at 1 year and 8% at 5 years. The cumulative risk of rupture was 2% at 5 years. Complications
related to the aneurysm or device occurred in 13% of participants at 1 year and in 16% of participants at
5 years. The most common complications were endoleaks or graft migration during a mean follow-up
length of 3.1 years (range 30 days to 5 years). The cumulative freedom from endoleak was 88% at 1 year
and 68% at 5 years. The cumulative freedom from secondary procedures was 87% at 1 year and 62% at
5 years.
Lifeline Registry of Endovascular Aneurysm Repair
The Lifeline Registry of Endovascular Aneurysm Repair was established in 1998 to evaluate the long-term
outcomes of endovascular treatment for patients with AAAs. Four publications have reported outcomes of
EVAR based on the data submitted to the Lifeline Registry of Endovascular Aneurysm Repair from 1999 to
2004.121–124 Outcome data from 2664 endograft patients were published in 2005.124 The overall survival
rate was 74% at 4 years, 66% at 5 years and 52% at 6 years. A survival analysis conducted using 6-year
data revealed freedom from aneurysm rupture in 99% of patients who had undergone EVAR, freedom
from aneurysm-related death in 98% of patients and freedom from surgical conversion in 95% of
patients. Most secondary interventions (85%) were performed < 30 days after EVAR. Freedom from
secondary interventions was 84% at 1 year and 78% at 5 years.
Anaconda Registry
The Anaconda Registry was a prospective database of clinical outcomes of 106 consecutive patients who
underwent endoluminal repair of AAAs using the Anaconda endograft (Vascunet, Inchinnan, UK) in three
hospitals in the west of Scotland between 2005 and 2009. Four publications based on data from the
Anaconda Registry were identified in the literature.76,86,92,125 Three of these publications were included in
the review of clinical effectiveness evidence.76,86,92 During a mean follow-up period of 2 years, 9.4% of
participants died from causes other than aneurysm. There were no aneurysm-related deaths. Type II
endoleaks were detected through CTA scanning at 1, 6, 12, 24, 36 and 48 months in 8.4%, 4.8%,
7.2%, 7.8%, 11.1% and 0% of patients, respectively. There were no type I, III or IV endoleaks. Five
cases of endograft limb thrombosis were observed during follow-up. Four of these cases were treated by
femorofemoral crossover grafting without any further complications. Follow-up CTA detected hypogastric
artery occlusion in three other patients. All three patients remained asymptomatic with no further
intervention required.125
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Diagnostic performance of imaging modalities for surveillance after
endovascular abdominal aortic aneurysm repair
The scoping literature searches identified a number of published systematic reviews assessing the diagnostic
test accuracy of the imaging modalities considered for the purpose of this assessment. Therefore, we adopted
a pragmatic approach and conducted an overview of reviews126 in order to obtain appropriate estimates of
diagnostic test accuracy to populate the economic model. The reviews included in the overview were used as
a source of existing evidence, but were not formally updated.
Methods for assessing the diagnostic test accuracy of colour duplex
ultrasound and contrast-enhanced ultrasound versus computed
tomography angiography
Identification of studies
The literature searches for the clinical effectiveness review were sufficiently broad that they retrieved
nine relevant diagnostic test accuracy reviews.3,62,127–133 Therefore, specific searching to identify additional
reviews was more focused but included appropriate subject headings and text word terms. To combine the
search facets for endovascular aneurysm repair, the imaging modalities under consideration and diagnostic
reviews, MEDLINE and EMBASE were searched from 1996 until March 2016, whereas the CDSR and DARE
were searched on 29 March 2016 without date restrictions. The search strategies are reproduced in
Appendix 1.
Eligibility criteria
We included systematic reviews of diagnostic test accuracy that compared imaging surveillance with CDU
and/or CEU in participants who have undergone EVAR for AAA. CTA, despite not demonstrating perfect
accuracy, is generally considered to be the reference standard for surveillance imaging after EVAR. To be
eligible for inclusion, reviews had to report on the sensitivity and specificity of CDU and/or CDU for the
detection of endoleaks and/or other relevant clinical complications.
Data extraction and management
Two reviewers (PS and CR) independently screened the titles and abstracts of all citations identified by the
search strategies. Full-text copies of all potentially relevant studies were retrieved and assessed for eligibility
independently by the two reviewers. Any disagreements during study selection were resolved by discussion
or in consultation with a third reviewer (MB). A data extraction form was specifically designed and piloted
for the purpose of this assessment (see Appendix 2). Detailed information on study design, participant
characteristics, study settings, characteristics of the index tests and reference standard and estimates of
accuracy was extracted. One reviewer completed the data extraction form (CR) and a second reviewer (MS)
cross-checked the extracted data for possible errors or inaccuracies. There was no disagreement between
the reviewers.
Quality assessment strategy
The risk of bias of included reviews was assessed using both the Assessment of Multiple Systematic
Reviews (AMSTAR) tool for the assessment of the methodological quality of systematic reviews134 and the
recommendations of the York CRD.58 The included reviews were independently assessed by two reviewers
(PS, CR or MS). Disagreements were resolved by consensus or arbitration with a third reviewer (MB). We
did not assess the quality of the abstracts, as the word limit for abstracts is usually insufficient to make
informed judgements about the potential risk of bias of reported reviews.
DOI: 10.3310/hta22720 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 72
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Brazzelli et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
43
Quantity and quality of the evidence
Characteristics of the included reviews
The literature searches retrieved a total of 48 records, and, after deduplication, 45 reports were available
for full-text screening. Nine reviews met the inclusion criteria and were included in this assessment. No
additional reviews were identified. Table 12 shows the characteristics of the identified reviews. Eight of the
included reviews were published in full, but one131 was available as an abstract and was consequently
excluded from the risk-of-bias assessment. The number of studies included in the reviews ranged from 8 to
35, the number of participants ranged from 259 to 4654, and the number of paired scans ranged from
639 to 5343. The review by Cantisani et al.129 included two literature reviews, which are also included in
this overview,62,132 and the review by Howard et al.131 included one literature review, but did not provide its
bibliographic details. Three reviews assessed both CDU and CEU versus CTA,62,132,133 two reviews130,131
assessed CEU versus CTA and one review130 provided sensitivity and specificity estimates for CEU.
Quality assessment of the diagnostic test performance reviews
The eight reviews of diagnostic test accuracy published in full were of mixed methodological
quality.3,62,127–130,132,133 The majority of the included reviews were considered to have searched major
relevant bibliographic data sources, conducted hand-searching of references and provided example of key
text words,3,62,127,128,130,132 specified their inclusion/exclusion criteria62,127,128,130,132,133 and provided sufficient
information on the characteristics of included studies.3,62,127,130,132,133 However, only one study provided
information on the inclusion of grey literature and on a priori design,127 two reported on duplicated
selection and extraction,62,127 two provided a list of excluded studies,130,133 one assessed the presence of
publication bias62 and only two used the results of the risk-of-bias assessment to draw conclusions.62,132
A potential conflict of interest was assessed in half of the included reviews.62,130,132,133 Of the eight reviews
published in full, one, by Cantisani et al.,129 was rated as being at a high risk of bias because, for the
majority of the AMSTAR and CRD criteria, the information was unclear or not reported (Figures 4 and 5).
Four reviews were considered to be of good methodological quality.62,127,130,132 The three remaining reviews
were considered to be of moderate quality.3,128,133
Assessment of diagnostic test performance
All of the included reviews assessed the diagnostic test accuracy of CDU and/or CEU versus CTA for the
identification of endoleaks during post-EVAR surveillance. Sun et al.133 also assessed the accuracy of CDU
for aneurysm sac measurements. Six reviews provided pooled estimates of accuracy for CDU,62,127–129,132,133
five reviews provided these for CEU,62,130–133 and two reviews reported the same accuracy estimates for
CTA.129,132 The systematic review by Ashoke et al.127 provided estimates of accuracy for CDU based on
eight published data sources and also combined the results of the published data with two unpublished
data sources. The review by Karanikola et al.3 did not combine estimates of test accuracy because of the
heterogeneity observed between the included studies.
The pooled estimates of test accuracy for detecting all types of endoleaks are presented in Table 13.
The lowest reported sensitivity estimate for CDU was 62%128 and the highest was 96%;127 the lowest
specificity estimate was 90%129 and the highest was 97%.129 The lowest reported sensitivity estimate for
CEU was 81%133 and the highest was 98%;62,131 the lowest specificity estimate for CEU was 78%130 and
the highest was 88%.62 Two reviews128,132 also reported the test accuracy estimates categorised by type of
endoleak (Table 14 provides further details). The review conducted by Chung et al.130 also presented a
narrative summary of the results of the included studies, indicating that the majority of endoleaks detected
or missed by CEU were characterised as type II endoleaks.
Of the three reviews assessing the diagnostic test accuracy of both CDU and CEU,62,132,133 two62,132 were
rated as being at a low risk of bias.62,132 In particular, the results of the review by Karthikesalingam et al.,132
which included more recent literature searches and provided estimates of accuracy by type of endoleak,
were used to populate the economic model.
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TABLE 12 Characteristics of the systematic reviews of diagnostic test accuracy
Study, first
author (year of
publication) Aim
Databases
searched
Number of
included
studies
Total number
of participants/
paired scans
Surveillance
imaging
modality
Ashoke (2005)127 To synthesise available
evidence regarding the
diagnostic accuracy of
CDU vs. CTA for the
detection and classification
of endoleaks after aortic
endografting
MEDLINE, EMBASE,
PubMed, BioMed,
CENTRAL, Business
Information
Database System
and Ingenta from
1991 to 2004
10 711 participants
1355 paired
scans
CDU and
CTA
Bevis (2012)128 To review the accuracy
of CDU compared with
CTA for endoleak
detection
MEDLINE, Google
Scholar (Google Inc.,
Mountain View,
CA, USA) and the
Current Controlled
Trials register from
1998 to 2011
29 5343 paired
scans
CDU and
CTA
Cantisani (2015)129 To present a
comprehensive overview
of the use of CEU for
post-EVAR surveillance
MEDLINE, EMBASE
and The Cochrane
Library from 1998 to
2015
8 > 259 patients
> 1191 paired
scans
CDU, CEU
and CTA
Chung (2015)130 To assess the accuracy
of CEU vs. CTA for the
detection of endoleaks
during post-EVAR
surveillance
PubMed, EMBASE
and The Cochrane
Library from 1997 to
2013
8 454 patients
639 paired scans
CEU and
CTA
Howard (2011)131 To assess the role of CEU
for EVAR surveillance and
endoleak detection
NR 11 NR CEU and
CTA
Karanikola (2014)3 To review the current
literature for the
effectiveness and safety
of CDU compared with
CTA for post-EVAR
surveillance
PubMed, MEDLINE,
Ovid, EMBASE and
The Cochrane Library
from 1995 to 2013
35 4525 patients CDU and
CTA
Karthikesalingam
(2012)132
To review the diagnostic
accuracy of CEU and
CDU, focusing on the
detection of clinically
relevant type I and
type III endoleaks
EMBASE, MEDLINE,
the Current
Controlled Trials
register, DARE and
The Cochrane Library
from 1996 until
2012
31 4654 paired
scans
CDU, CEU
and CTA
Mirza (2010)62 To determine the
diagnostic accuracy of
CDU and CEU vs. CTA
for endoleak detection
EMBASE, MEDLINE,
Current Controlled
Trials register, DARE
and the Cochrane
Controlled Trials
Register from 1996
to 2009
21 2886 patients
2895 paired
scans
CDU, CEU
and CTA
Sun (2006)133 To investigate the
diagnostic accuracy of
CDU vs. CTA for the
detection of endoleaks
and aneurysm sac
measurements
PubMed and
MEDLINE from 1991
to 2005
21 1534 patients CDU, CEU
and CTA
NR, not reported.
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FIGURE 5 Risk-of-bias assessment using the AMSTAR criteria. N/A, not applicable.
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FIGURE 4 Risk-of-bias assessment using the CRD criteria. N/A, not applicable.
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TABLE 13 Pooled sensitivity and specificity estimates with 95% CIs from included systematic reviews of diagnostic test accuracy for endoleak detection (all endoleaks)
Study, first author
(year of publication)
Imaging modality, % (95% CI)
Number of studies
included in the review
CTA CDU CEU
Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity
Ashoke (2005)127 96 (52 to 87) 91 (87 to 95) 10 (eight published and
two unpublished)
67.4 (47.5 to 87.3) 92.2 (88.3 to 96.1) Eight published
Bevis (2012)128 62 (58 to 65) 94 (93 to 94) 29
Cantisani (2015)129 Reports pooled data from
Karthikesalingam et al.132
62–83 (NR) 90–97 (NR) Reports pooled data from
Mirza et al.62
8
Chung (2015)130 91 (87 to 95) 78 (74 to 82) 8
Howard [(2011)131 abstract] 98 (95% CI NR) 11
Karanikola (2014)3 Pooled estimates not reported because of the observed heterogeneity between studies 35
Karthikesalingam (2012)132 70 (53 to 82) 98 (94 to 100) 74 (62 to 83) 94 (90 to 97) 96 (85 to 99) 85 (76 to 92) 31
Mirza (2010)62 77 (64 to 86) 94 (88 to 97) 98 (90 to 99) 88 (78 to 94) 21
Sun (2006)133 66* (52 to 81) 93 (89 to 97) 81* (52 to 100) 82 (68 to 97) 21
*p< 0.05.
NR, not reported.
D
O
I:10.3310/hta22720
H
EA
LTH
TECH
N
O
LO
G
Y
A
SSESSM
EN
T
2018
VO
L.22
N
O
.72
©
Q
ueen
’s
Printer
and
C
ontroller
of
H
M
SO
2018.
This
w
ork
w
as
produced
by
Brazzelliet
al.
under
the
term
s
of
a
com
m
issioning
contract
issued
by
the
Secretary
of
State
for
H
ealth
and
SocialC
are.
This
issue
m
ay
be
freely
reproduced
for
the
purposes
of
private
research
and
study
and
extracts
(or
indeed,
the
fullreport)
m
ay
be
included
in
professional
journals
provided
that
suitable
acknow
ledgem
ent
is
m
ade
and
the
reproduction
is
not
associated
w
ith
any
form
of
advertising.
A
pplications
for
com
m
ercialreproduction
should
be
addressed
to:
N
IH
R
Journals
Library,
N
ationalInstitute
for
H
ealth
Research,
Evaluation,
Trials
and
Studies
C
oordinating
C
entre,
A
lpha
H
ouse,
U
niversity
of
Southam
pton
Science
Park,
Southam
pton
SO
16
7N
S,
U
K
.
47
TABLE 14 Reported pooled sensitivity, specificity and 95% CIs of the included diagnostic test performance systematic reviews (categorised by type of endoleak)
Study, first author
(year of publication)
Imaging modality, % (95% CI)
Number of studies
providing data
CTA CDU CEU
Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity
Karthikesalingam (2012)132
Types I and III endoleaks 83 (40 to 97) 100 (97 to 100) 99 (25 to 100) 100 (98 to 100) 13 on CDU
Eight on CEU
Accuracy, n/N (%)
Bevis (2012)128 29
Type I endoleaks 43/51 (84)
Type II endoleaks 126/228 (55)
Type III endoleaks 6/10 (60)
Type IV endoleaks 1/2 (50)
CLIN
ICA
L
EFFECTIVEN
ESS
A
N
D
D
IA
G
N
O
STIC
A
CCU
RA
CY
O
F
IM
A
G
IN
G
M
O
D
A
LITIES
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
48
Despite its limitations, CTA is still considered to be the best current imaging modality for the detection of
endoleaks and clinical complications after EVAR. However, it is worth pointing out that the technique of
ultrasound, and in particular of CEU, has fundamentally changed during the last decade. Many studies
included in the identified reviews predate the most recent technical improvements. A mixture of early- and
late-generation ultrasound machines and different CTA phases were used in the primary studies included
in the identified systematic reviews. The impact of this ‘technological heterogeneity’ on the reported
pooled estimates of accuracy is unclear. Two reviews attempted to address this issue. Mirza et al.62
conducted a sensitivity analysis in which studies published prior to 2003 were excluded in order to assess
the potential confounding effect of CEU equipment being more modern than CDU equipment. Similar
sensitivity and specificity estimates were obtained for CDU and CEU. Chung et al.130 reported that CEU
studies that utilised second-generation contrast agents [i.e. SonoVue and Optison (Amersham Health,
Princeton, NJ, USA)] had excellent sensitivity estimates compared with CEU studies that utilised first-
generation contrast agents. They also observed that two studies that used both generations of contrast
agents demonstrated good sensitivity for the detection of type II endoleaks. References for these two
studies were, however, not given. The authors concluded that CEU was as accurate as CTA in detecting
endoleaks when studies that utilised first-generation contrast agents were omitted from the analyses.130
These results are in line with the claim of some investigators that more recent data seem to suggest that
the specificity of CEU is higher than that of CTA (Professor Srinivasa Rao Vallabhaneni, Royal Liverpool
University Hospital, 2017, personal communication). It is therefore possible that the performance of single-
phase CTA as the current accepted reference test was not good enough to assess the accuracy of modern
CEU. To take this into account in the economic model, we have conducted sensitivity analyses using
different sensitivity and specificity estimates to reflect the recent technological improvements of imaging
modalities for surveillance after EVAR.
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Chapter 3 Assessment of cost-effectiveness
The evidence of the cost-effectiveness of using CDU or CEU alone or in conjunction with CTA for thesurveillance of adults after EVAR was explored in the health economic component of this assessment.
A two-step approach was used: (1) a systematic review of economic evaluations to retrieve any readily
available evidence on cost-effectiveness, followed by (2) a de novo decision-analytic model to synthesise the
available evidence on effectiveness, health-care resources used and costs. Review of the cost-effectiveness
studies reports the systematic review of cost-effectiveness studies and Economic analysis with a newly
developed decision model focuses on the economic model exercise.
Review of the cost-effectiveness studies
In order to summarise the available evidence on cost-effectiveness, we conducted a systematic literature
review to identify studies that reported an economic evaluation of surveillance strategies for adult individuals
after an EVAR intervention that included CDU and/or CEU compared with CTA.
Methods for review of the cost-effectiveness studies
Search strategy
Comprehensive search strategies were designed to identify economic evaluations of surveillance after
EVAR (see Appendix 1). Searches were undertaken on 29 March 2016 and updated on 5 September 2016.
The following databases were searched: NHS Economic Evaluation Database (from inception to 31 March
2015), the HTA Database (from inception to 5 September 2016) and MEDLINE In-Process and Epub Ahead
of Print (from 1946 to 5 September 2016), EMBASE (from 1947 to week 36 2016) and Research Papers in
Economics (from inception to 5 September 2016). The websites of HTA organisations were consulted for
additional reports. The reference lists of all included studies were scanned, and appropriate experts were
contacted for details of additional reports of cost-effectiveness.
The titles and abstracts of all citations identified by the search strategies for economic evaluations were
screened for inclusion by a health economist (RH). The full-text papers of potentially relevant studies were
retrieved and formally assessed for inclusion. Any uncertainty regarding study selection was discussed with
the review team.
Inclusion and exclusion criteria
The inclusion criteria required the studies to be full economic evaluations (i.e. to consider the costs and
effects of more than one strategy) in order to be included in the review. No restrictions were imposed on
the way in which costs and/or effects were calculated. In addition, the study should compare post-EVAR
surveillance strategies with at least one of the relevant diagnostic tests (e.g. CDU, CEU and CTA).
Either RCTs or decision-model economic evaluations were included. Studies that did not meet the inclusion
criteria but reported relevant data that could inform the de novo economic model (e.g. costs, quality of
life, model structure, probabilities) were retained for further consultation.
Data extraction
Data were extracted from the included studies using a prespecified data extraction form. The following
information was sought:
l Background information, such as the research question, study design, intervention and comparator details.
l Characteristics of the study population (e.g. age, setting, inclusion criteria, exclusion criteria).
l Costing methodology, in particular the perspective, year, currency and the discount rate applied.
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l Methodology used for the analysis of costs, effectiveness and uncertainty.
l Mean costs and outcomes, incremental costs and outcomes for the differences between groups and
incremental cost-effectiveness ratios (ICERs). The results were reported when uncertainty was explored
(e.g. 95% CI from the bootstrap analysis).
l Study strengths and limitations, as reported by the study authors.
l Conclusions and suggestions for further research, as reported by the study authors.
Quality assessment of the included studies
Cohort-based studies were assessed for quality against the British Medical Journal checklist for referees
of economic evaluations.135 When possible, the results were assessed from the NHS perspective.
No decision-modelling studies matching the inclusion criteria were identified and therefore no studies
were appraised against the NICE reference case.60,136
Data synthesis
No data synthesis was attempted, and a summary of the study characteristics, the costing methods used
and the quality assessment of each study is provided.
Results of the review of cost-effectiveness studies
After deduplication of the records, 278 abstracts were screened for suitability. Seven studies were selected
for full-text assessment, with only five of these studies meeting the inclusion criteria.41,45,66,137,138 Two
studies were conducted in the USA45,137 and three studies were conducted in Europe (in Italy,66 Ireland138
and the UK41). All of these studies considered the effects of crossing from CTA to CDU plus plain
radiography as first-line surveillance test. The studies estimated the difference in the number of CTAs
required by the new surveillance strategy and the replaced strategy.
Beeman et al.45 attempted to determine the cost savings and outcome differences of moving from
both CTA and CDU imaging at 2 weeks, 6 months and 12 months after discharge and yearly thereafter
(group 1 – before 1 July 2004) to CDU imaging as the sole surveillance test after the 2-week scans
(group 2 – after 1 July 2004), with CTA being conducted only if any problem was detected by CDU. The
authors analysed data on 82 patients for group 1 and on 117 patients for group 2. The clinical outcomes
included the number of endoleaks detected and the measurement of the AAA sac diameter. The average
length of the follow-up period was 3.5 years (range 0–9 years) and 1.6 years (range 6 months–4 years) for
groups 1 and 2, respectively. The authors used hospital charges for CTA and CDU and noted that the
decreased charges of US$1595 per patient per year (2008 prices) or US$198 per patient per year using
Medicare reimbursements were realised by eliminating CTA surveillance in group 2. Moreover, the sensitivity
of CDU for detecting endoleaks was 0.71 and the specificity was 0.99, whereas the sensitivity of CTA was
0.731 and the specificity was 0.991. The authors could not find any difference in aneurysm sac diameters
measured by CDU and CTA when these scans were performed within 1 month of each other in group 1.
Although the authors do not advocate eliminating CTA from the surveillance protocols, they state that its use
should be limited to those circumstances in which it could provide other details about problems first detected
by the ultrasound examination.
Bendick et al.137 evaluated the use of an ultrasound contrast agent to enhance imaging for stent–graft
surveillance and compared the costs of this technique with those of CTA. Data on the first 40 patients
received in their vascular laboratory were analysed. The follow-up examinations ranged from 1 to 24 months
after graft placement, with a mean follow-up time of 13.7 ± 6.1 months. Clinical outcomes included type I
or type II endoleaks and costs were calculated using hospital charges with average costs per study that were
equal to US$2779 for CTA, US$525 for CDU (including contrast) and US$147 for plain film abdominal
radiography. No details of the price year were stated. The authors reported a sensitivity to the presence of
any endoleaks of 53% (8/15) for CDU, 93% (14/15) for CEU and 73% (11/15) for CTA. The average 3-year
charges per patient were US$22,232 and US$5376 for CTA-based surveillance and surveillance using CDU
(including contrast) plus radiography, respectively (a saving of US$16,856 per patient over 3 years). The
authors concluded that the technique of duplex ultrasound with an ultrasound contrast agent should
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become the method of choice for stent–graft surveillance if the promising early results shown in their present
series can be demonstrated in a larger patient population.
Chisci et al.66 evaluated whether or not the imaging modality of surveillance influenced the detection
of these conditions affecting the rate of asymptomatic secondary interventions (i.e. endoleaks, AAA
expansion, migration, graft infection, graft thrombosis, conversion to open repair, postoperative renal
impairment, bowel ischaemia and myocardial infarction). The authors followed a cohort of individuals for
whom the follow-up protocol was changed at a given date. Protocol I, performed from January 2003 to
December 2006, consisted of CDU plus CTA at 1 month after the procedure and every 6 months thereafter.
Protocol II, performed from January 2007 to June 2010, included CDU plus CTA at 1 month after operation,
CDU plus plain radiography every 6 months thereafter and CTA carried out during follow-up only for specific
conditions. The authors analysed data for 376 individuals in protocol I and 341 individuals in protocol II
with a mean follow-up of 1148 days (range 1–3204 days) and 942 days (range 1–1512 days), respectively
(p< 0.001). On the 3-year analysis, the authors reported that protocol I cost approximately €3000, whereas
protocol II cost approximately €1000; this was a threefold reduction in overall costs for protocol II (p < 0.0001).
However, there were no details of the costing method used or the cost categories included in this analysis.
The authors concluded that the detection rate of asymptomatic secondary interventions following EVAR is
not affected by the type of surveillance imaging and that a surveillance schedule based primarily on CDU
and radiography appears to be justified.
Gray et al.138 retrospectively reviewed the CDU and CTA scans of all 145 patients who underwent EVAR at
the Mater Misericordiae University Hospital, Ireland, from 1 June 2003 to 1 July 2010 and compared their
results for endoleak detection and determination of residual sac size. The authors’ aim was to assess the
cost savings obtained if CDU was employed as a first-line surveillance tool following EVAR and to compare
CDU and CTA in terms of efficacy. A total of 484 scans (68%) from 114 patients (78.6%) were available
for comparison. The hospital protocol for patients after EVAR included CDU and CTA scans of the aorta
within 7 days of surgery. After discharge, all patients underwent CDU at 1 month and then CDU and CTA
at 6 months, 12 months and annually thereafter, provided that there was no documented endoleak on
either the CDU or CTA. The costs of CTA (€500 per scan) and of radiography (€85) were considered in the
costing calculations (expressed in 2010 prices). However, no details of the unit cost sources were reported.
The authors found that CDU was 100% sensitive and 95.7% specific in the detection of endoleaks, with a
positive predictive value of 28.7% and a negative predictive value of 100%. Furthermore, no statistically
significant difference between the two imaging modalities was detected for the determination of residual
AAA sac diameter. The authors hypothesised that a reduction in costs resulted from a change in protocol
for the year 2010. Adopting a protocol with CDU and abdominal radiography as the first-line surveillance
tool would result in a reduction in the number of postoperative CTA scans from 235 to 36. This would
equate to a reduction in expenditure from €117,500 to €34,915 (a saving of €82,585). The authors
concluded that CDU combined with plain abdominal radiography could safely replace CTA as the primary
long-term imaging modality, resulting in a significant cost saving without the loss of scan accuracy.
The only study conducted in the UK41 was a retrospective review of a prospectively maintained database of all
patients undergoing elective, standard EVAR at a large tertiary referral centre (Royal Liverpool University
Hospital). As with the other studies, the authors assessed the efficacy of a modified post-EVAR surveillance
protocol based, primarily, on CDU and radiography, with CTA triggered only by significant findings on the
CDU scan or radiography. The study included patients who had their EVAR operation between 1 August
2005 and April 2009, for whom at least 1 year’s post-surgical follow-up data were available. The primary
outcome measure considered was aneurysm rupture, whereas the secondary outcome measures included the
requirement for secondary intervention and the number of CTA scans avoided, from which the radiation dose
reduction and cost savings were calculated. The costs were expressed in 2010–11 prices and NHS tariffs were
used to cost the tests (radiography, €35.71; CDU, €187.47; CTA, €269.61; exchange rate: £1= €1.18).41 The
authors analysed data on 194 patients who underwent a total of 606 sets of surveillance imaging: 194 sets
at 1 month (radiography, CDU and CTA) and 412 per protocol sets thereafter (radiography and CDU). No
patient presented with ruptures or aneurysm-related complications that were not identified by the modified
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surveillance protocol. The authors obtained the number of tests performed in the modified protocol and
compared this with those that would have been performed for the same group had the protocol not been
modified: 412 tests would have been conducted for the follow-up period that would have costed €14,711 for
radiography, €77,326 for CDU and €111,078 for CTA. With the modified protocol, the number of tests and
costs for radiography and CDU remained the same. However, only 71 CTA scans were conducted, with a cost
of €19,142, which was a saving of €91,936. The authors concluded that follow-up after EVAR primarily based
on CDU and radiography was feasible and safe, and reduced the use of CTA substantially, with consequent
reductions in exposure to ionising radiation or an intravascular contrast medium, and costs.
Summary
Five studies met the inclusion criteria. All of these compared a surveillance strategy based on CDU or
CEU with a CTA-based strategy. All of the studies assessed the reduction in costs as a result of the smaller
number of CTA scans performed in the modified protocol. Only cohort studies were identified in the
searches. However, the studies by Beeman et al.45 and Chisci et al.66 compared cohorts before and after
the protocol changes took place. In the other studies, an economic analysis was conducted on the basis
of the resources required (i.e. the number of CTA scans performed) if a hypothetical alternative protocol
were to be used. Although all of the studies41,45,66,137,138 fairly agree on the clinical outcomes of interest
(i.e. endoleaks, AAA size and the need for secondary interventions), the reporting of costs and the cost
method was disparate; although one study gave details of the cost categories, the unit cost used, the
sources and the price year used, another study reported only the final cost calculations.
The only study from the UK that could inform NHS policy was the study conducted by Harrison et al.41
However, neither this nor any of the non-UK studies used a preference-based measure of effectiveness.
Moreover, judging from the number of scans used in the authors’ cost calculations, the follow-up period
considered was just over 2 years. This time horizon might not be long enough to consider all of the
costs and consequences that are relevant for the question posed. As such, a new economic model was
developed to assess the relative efficiency of CDU or CEU in the surveillance of individuals after EVAR.
This is reported in the next section.
Economic analysis with a newly developed decision model
None of the available economic evaluations from the systematic review provided a definite answer on
the cost-effectiveness of the use of CDU or CEU compared with that of CTA from the NHS perspective.
Therefore, a de novo economic model was developed. The aim of the economic model was to assess
the relative efficiency of surveillance strategies that used CEU or CDU alone or in combination with CTA.
Methods
Care pathways
Care pathways were discussed and developed within the project management group and the project advisory
group meetings. It was agreed that surveillance involves the search for information about abnormalities
that are relevant to the disease. It was also agreed that, once there is any indication of an abnormality, the
patient status changes and the surveillance stops. After this, the following steps are then part of diagnostic
investigations and/or eventual treatment. Hence, surveillance applies only to those individuals who are deemed
to have no detected EVAR-related abnormalities and, as such, the model considers those patients who were
regarded as not having an EVAR-related complication (e.g. at 6 months post surgery).
Five surveillance strategies were agreed:
1. annual CTA scan plus plain radiography
2. annual CDU scan plus plain radiography
3. annual CEU scan plus plain radiography
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4. colour duplex ultrasound scan together with CTA scan and plain radiography at 1 year, followed by
CDU scan and plain radiography on an annual basis
5. contrast-enhanced ultrasound scan together with CTA scan and plain radiography at 1 year, followed
by CEU scan and plain radiography on an annual basis.
A positive test result in any of the surveillance strategies would trigger either further diagnostic investigations
or treatment. This part of the decision model was identical for all of the strategies.
The economic model
A Markov model approach was selected for the decision-analytic model exercise.135 Markov models have
Markov states in which individuals spend a period of time, which is named a ‘cycle’. At the end of each
cycle, the individuals can remain in their current Markov state or move to another state. The probabilities
of moving to other Markov states or remaining in the current state are named ‘transition probabilities’.
Individuals in the model would accrue costs and benefits (e.g. life-years) depending on the time spent in
each Markov state and the interventions and/or events modelled within each Markov state. Markov models
are particularly suitable to model recurrent issues and chronic diseases. They allow the incorporation of
health states to reflect the movement of patients during surveillance, further diagnosis and treatment.
In the current study, model states reflect the underlying condition (e.g. post-EVAR state with known or
unknown complications), together with the decision on treatment (e.g. reintervention after EVAR). In all of
these models, an absorbing state is included, in which all individuals would end up if the model was run
for a sufficiently long period of time (e.g. Markov death state).
Description of the Markov model and the model structure
The model overall state-transition diagram is reported in Appendix 14. A simpler, schematic representation
of the Markov model is shown in Figures 6–9. In these figures, circles represent the Markov states,
whereas squares represent an event that occurs within a Markov state (e.g. an emergency procedure).
Arrows show the direction of the possible transitions in the model. Unless specified, individuals can remain
in a Markov state for more than one cycle. Eight Markov states are considered in the model:
1. normal (no residual EVAR complication)
2. abnormal Ia (intervention required)
3. abnormal Ib (intervention required – endoleak)
4. abnormal II (no intervention required)
5. enhanced follow-up (normal)
6. elective surgery (one cycle, temporary state)
7. enhanced follow-up (abnormal II)
8. death.
Figure 6 shows the four Markov states that reflect the underlying condition but are yet to be detected
(‘undiagnosed’ states 2–4 above). Figures 7–9 show one of these four Markov states representing the
underlying condition together with the Markov states that individuals can move to (e.g. those states that
result from a diagnosis – the ’diagnosed’ side of the figure – correctly or not). The performance of a
surveillance strategy in this model is given by the correct identification of those individuals with an
abnormal condition and the corresponding transfer of those individuals into the true-positive states on
the right sides of Figures 7–9.
All individuals start in the ‘normal (no residual EVAR complication)’ health state and can develop
abnormalities as the model runs (see Figure 6). The surveillance strategies aimed to detect a variety of
conditions and complications . These were generically described as ‘abnormalities’ and were divided into
two categories: conditions that trigger an elective intervention and conditions that, on clinical assessment,
necessitate closer follow-up (e.g. additional 6-month CTA scans). The first category was subdivided into
two: abnormal 1a includes non-endoleak-triggered interventions (e.g. limb occlusions, graft infections) and
abnormal 1b counts for the endoleak-prompted interventions (e.g. type I, III and IV, type II or endotension
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with sac expansion > 5 mm). Examples of patients with conditions within the close follow-up group
(abnormal II) are those with type II endoleaks with a sac expansion of < 5 mm in 6 months or with
limbs with kinking or partial thrombosis.
These abnormal Markov states are tunnel states. In tunnel states, individuals go through the health states
in a defined sequence. The rationale behind these tunnel states for individuals with an abnormality is to
count the length of time for which the individuals have had the abnormality. Thus, the probability of
experiencing a rupture as a result of, for instance, a type I or III endoleak will increase as length of time for
which the individual has had the endoleak increases (i.e. the length of time that the individual remains in
the undetected health state). Finally, individuals can move from any health state to the absorbing death
state (presented, for simplicity, at the side of the figures).
Death
Normal
(no residual EVAR
complications)
Undiagnosed
Abnormal Ia
(intervention
needed)
Abnormal Ib
(intervention
needed: endoleak)
Abnormal II
(no intervention)
FIGURE 6 Schematic diagram of the surveillance for EVAR Markov model; underlying condition.
Death
Abnormal Ia
(intervention
needed)
Emergency
(e.g. rupture)
Elective
intervention
DiagnosedUndiagnosed
FN
TP
Normal
(no residual EVAR
complications)
TN
FIGURE 7 Schematic diagram of the surveillance for EVAR Markov model (from abnormal Ia, intervention needed
Markov state). FN, false negative; TN, true negative; TP, true positive.
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Abnormal Ia Once an abnormal condition has been identified, individuals move to another Markov state,
in which they can be treated (see Figure 7) or followed up more closely (see Figure 8). Figure 7 shows the
pathway of individuals who developed a non-endoleak abnormality that would require elective surgery. If the
condition is undetected through surveillance (a false-negative result), the person remains in the abnormal Ia
state. This person can experience an event and, as a result, go through an emergency intervention. If the
situation is resolved, the person would move back to the original normal state. If the underlying condition is
detected through surveillance (a true-positive result), the individual would move to the elective surgery state.
This is a temporary state and individuals can remain within this state only for one cycle (to have surgery and
subsequently move on to another health state). Again, once the surgical intervention is successful, the
individual moves back to the original normal state. Moreover, individuals can move to the absorbing death
state from any of the other health states as a result of an emergency (e.g. rupture), surgery (e.g. hospital
mortality) or other comorbidities (general population mortality). A similar structure was followed for
individuals who developed an endoleak abnormality that required an elective intervention (abnormal Ib
Markov health state).
Death
Elective
intervention
(abnormal Ia/b)
TN
Normal
(no residual EVAR
complications)
FP
FP
TN
Develop
abnormality
Enhanced
follow-up
(normal)
Enhanced
follow-up
(abnormal II)
TP
FIGURE 9 Schematic diagram of the surveillance for EVAR Markov model (from normal, no residual EVAR
complications Markov state). FP, false positive; TN, true negative; TP, true positive.
Death
Abnormal II
(no intervention)
Emergency
(e.g. rupture)
Elective
intervention
DiagnosedUndiagnosed
FN
Enhanced
follow-up
(abnormal II)
TP
TN
Normal
(no residual EVAR
complications)
FIGURE 8 Schematic diagram of the surveillance for EVAR Markov model (from abnormal II, no intervention
needed Markov state). FN, false negative; TN, true negative; TP, true positive.
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Figure 8 shows the pathway for the abnormal II health state. Undetected individuals (a false-negative
result) will remain in this state (i.e. represented by the back arrow from the state). These people have the
risk of experiencing an event that would trigger an emergency intervention. If the abnormality is detected
(a true-positive result), the individuals will move to enhanced follow-up, which is defined as 6-month
visits at which a CTA-based assessment is conducted. If the patient is stable and no further interventions
(e.g. elective surgery) are decided after 2 years (four model cycles), the patient returns to the surveillance
pathway (e.g. annual check-ups based on the original surveillance test – CDU, CEU or CTA).
Abnormal II The model also includes a false-positive state for those individuals without an abnormal
condition (see Figure 9) but with a positive test result [e.g. enhanced follow-up (normal)]. If the individual
developed an abnormality while under enhanced follow-up, they would either move straight to elective
intervention (e.g. for abnormal Ia or Ib) or remain under enhanced follow-up but within a different Markov
state (e.g. for abnormal II).
Normal state Individuals can suffer an event between surveillance visits. This is considered in the model
to be an event within a Markov state and is shown in Figures 6–9 as a square (e.g. emergency procedure).
The model assumes that individuals who survive an unsuccessful second intervention could undergo a third
intervention. However, a pragmatic assumption based on small probabilities was made and individuals can
either have a successful third intervention or die.
Parameter estimates used in the economic model
The parameter estimates required to populate the economic model were obtained from the results of the
clinical effectiveness search, which was supplemented by structured and focused searches (e.g. of EVAR
trials with a longer follow-up period). When no suitable data resulted from these searches, expert opinion
was sought. Probabilities gives details of the probabilities, unit costs and utility weights used in the model.
Also provided within this section are details of the probability distributions used for the probabilistic
sensitivity analysis.
Probabilities
The model starts with the whole cohort in the normal state, and therefore no prevalence data were
necessary. The annual incidence of abnormalities was developed from data reported by Tang et al.,93
based on ENGAGE (Table 15). The authors report 1-year data, excluding the first 31 days after EVAR.
From a total of 325 patients, 25 abnormalities were reported (20 endoleaks, one stent–graft occlusion,
three stent–graft stenoses and one other event related to the stent–graft). These data were initially
used to obtain the proportions of cases within each of the model abnormal subgroups (graft occlusion for
abnormal Ia, types I and III endoleaks for abnormal Ib, and type II endoleak for abnormal II). However, in
consultation with the experts in the project advisory group, these figures were revised, as it was believed
that a higher proportion of abnormalities Ia and Ib are currently seen in UK practice (Professor Srinivasa
Rao Vallabhaneni, and Dr Russell Jamieson, NHS Grampian, 2017, personal communication). Beta
distributions were used to assess the uncertainty around the central point estimates.
TABLE 15 Incidence and mortality
Variable Value
Probability
distribution Source
Annual incidence of abnormal cases 0.04 Beta(13,312) Tang et al.93
Proportion of abnormal Ia subgroup from all abnormal individuals 0.15 Beta(15,85) Based on expert opinion
Proportion of abnormal Ib subgroup from all abnormal individuals 0.15 Beta(15,85) Based on expert opinion
Proportion of abnormal II subgroup from all abnormal individuals 0.70 Beta(70,30) Based on expert opinion
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Unfortunately, the systematic review of clinical effectiveness could not identify any studies that directly
compared the performance of alternative CDU and CEU surveillance strategies. Therefore, test performance
data were used to feed the model. Test sensitivity and specificity (Table 16) were obtained from the systematic
review by Karthikesalingam et al.132 Alternative data were available (see Diagnostic performance of imaging
modalities for surveillance after endovascular abdominal aortic aneurysm repair in Chapter 2). However,
Karthikesalingam et al.132 is the only review reporting sensitivity and specificity for all three tests (CDU, CEU
and CTA), and the quality assessment of all of these diagnostic review studies resulted in the Karthikesalingam
et al.132 review being deemed to be of higher quality. Beta distributions were used to address uncertainty
around the central parameter values.
The probability of having a reintervention and the risk of rupture and mortality are reported in Table 17.
The probability of having a reintervention was developed from Tang et al.93 Disregarding the first month
post EVAR, 13 individuals out of 319 had a secondary procedure. The proportion of successful secondary
procedures was based on the proportion of individuals free of a secondary intervention in the EVAR 1 trial –
15-year follow-up data.48 The model allows for individuals with an unsuccessful surgery to go to a third
procedure. We found no data to inform the model parameters related to the third intervention (e.g. the
probability of having a third intervention and the proportion of successful interventions) and therefore the
data as for the second intervention were applied.
The risk of rupture for undetected endoleaks was based on an analysis of early data from the EUROSTAR
registry. Buth et al.91 conducted two cohort analyses comparing a cohort of people with type I and type III
endoleaks (n = 297) with those who had never experienced an endoleak (n = 1975), and a cohort of
people with type II endoleaks (n = 320) with those who had never experienced an endoleak (n = 3275).
The authors state that the cumulative rate of rupture from type I and type III endoleaks was 4% at 2 years
compared with 0.7% for those who had never experienced an endoleak. Moreover, the number of late
ruptures in patients with type II endoleaks was not significantly different from the number of late ruptures
in those who had never experienced an endoleak. The risk of rupture for individuals with type I and type III
endoleaks after 1 year was adjusted based on data reported by Moll et al.31 The authors report the risk
of rupture according to aneurysm size, based on population studies. To calculate the risk in the model,
an aneurysm size of 55 mm at baseline was assumed, together with a growth rate of 5 mm per cycle.
These rupture risks were applied to the undetected abnormal Ib group in the model only.
Table 17 also reports the mortality data assumed in the model. Age- and gender-specific general population
mortality rates were applied to the cohort. The risk of surgical death in an elective setting was based on
expert opinion (Professor Srinivasa Rao Vallabhaneni and Dr Russell Jamieson, personal communication). The
main event that surveillance is trying to avoid is the aneurysm rupture and its associated high mortality rate.
The risk of death from a rupture was calculated based on the systematic review and meta-analysis of late
TABLE 16 Test sensitivity and specificity
Variable Value Probability distribution Source
CDU sensitivity 0.74 Beta(48.8,17.2) Karthikesalingam et al.132
CDU specificity 0.94 Beta(164.5,10.5) Karthikesalingam et al.132
CEU sensitivity 0.96 Beta(28,1.2) Karthikesalingam et al.132
CEU specificity 0.85 Beta(64.3,11.3) Karthikesalingam et al.132
CTA sensitivity 0.70 Beta(26.1,11.2) Karthikesalingam et al.132
CTA specificity 0.98 Beta(81.1,1.7) Karthikesalingam et al.132
Proportion of individuals adhering to
surveillance visits
0.93 Uniform(0.5,1) Assumption based on
expert opinion
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ruptures by Antoniou et al.139 The authors identified 11 studies (case series) that reported a total of 190
ruptures: 30 patients were managed with palliative care or died before surgery. Moreover, the authors
reported a perioperative mortality rate of 32% (95% CI 24% to 41%).
Costs
Unit costs were obtained from NHS Reference Costs 2015 to 2016140 (Table 18). The unit costs for ultrasound
tests (with and without contrast) of < 20 minutes’ duration reported in the NHS reference costs are surprisingly
similar. Moreover, the stated average unit cost for an ultrasound with contrast was lower than an ultrasound
without contrast. Therefore, the unit cost for a vascular ultrasound scan was used to cost CDU and CEU tests.
The clinical experts noted that clinical staff (i.e. a consultant radiologist) should be present to administer the
contrast agent for CEU. In addition, CEU includes a contrast agent [i.e. sulfur hexafluoride or perfluorocarbon
encapsulated by a phospholipid shell (SonoVue)] with an associated cost of £46 for a 10-vial box (Mr Craig Rore,
Grampian Medicines Information Centre, 2017, personal communication). Therefore, the unit cost of CEU was
adjusted to add the cost of 30 minutes (Professor Srinivasa Rao Vallabhaneni, personal communication) of a
medical consultation (based on a cost per hour of £135)141 plus £4.60 for the cost of the contrast. Furthermore,
the cost of a CT scan of one area, with pre and post contrast, was used for CTA. Notably, NHS Reference Costs
2015 to 2016140 does not report the unit cost for a plain radiography. The cost of a plain radiography is absorbed
within other cost categories (e.g. outpatient visit) because of its relatively high volume and low cost. As plain
radiography was considered in all of the strategies in a similar manner (on an annual basis), an executive decision
was made and the unit cost of plain radiography was not incorporated in the model. If a surveillance test
outcome was indeterminate, a further assessment was assumed (i.e. with CTA) and the cost of a visit was added
to the cost of the subsequent test (i.e. non-admitted face-to-face attendance, follow-up – vascular surgery).
Endovascular AAA repair reintervention was costed as a weighted average of the unit costs for elective EVAR
repair (complex and non-complex). The cost of percutaneous transluminal embolectomy or thrombolysis
was used as the cost of other procedures for the abnormal Ia group. Emergency procedures were costed
assuming non-elective categories plus the cost of emergency medicine (i.e. any investigation with category 5
treatment) and ambulance service (i.e. see and treat and convey).
TABLE 17 Reintervention, rupture and mortality
Variable Value
Probability
distribution Source
Probability of having a reintervention 0.020 Beta(13,312) Tang et al.93
Probability of not having a third intervention 0.860 Beta(541,85) Patel et al.48
Probability of rupture (type I or III endoleak) 0.0102 Beta(3,294) Developed from Buth et al.91
Probability of rupture (type I or III endoleak)
after 1 year
0.1 Uniform(0.1,0.2) Moll et al.31
Probability of rupture (type I or III endoleak)
after 2 years
0.3 Uniform(0.3,0.3) Moll et al.31
Probability of rupture (type II endoleak) 0.0018 Beta(3.5,1971.5) Developed from Buth et al.91
Probability of rupture (no endoleaks) 0.0018 Beta(3.5,1971.5) Developed from Buth et al.91
Mortality
Elective surgery 0.007 Beta(12,598) Based on expert opiniona
Emergency surgical intervention (rupture) 0.32 Beta(36.6,77.9) Antoniou et al.139
Rupture 0.16 Beta(30,160) Antoniou et al.139
Age- and gender-specific general population
mortality for the UK
Various Not applicable National Life Tables, UK146 2013–2015.
Office for National Statistics
a Professor Srinivasa Rao Vallabhaneni and Dr Russell Jamieson, personal communication.
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Utility weights
Population-based utility weights for patients aged ≥ 74 years were assumed for individuals after EVAR
(Table 19). These utility weights were calculated using the equation provided by Ara and Brazier142
[i.e. EuroQol-5 Dimensions (EQ-5D) = 0.9508566 + 0.0212126 × (1, if males, or 0, if females)
– 0.0002587 × age – 0.0000332 × age2].142 The rationale behind this is that the condition is mostly
asymptomatic and, as such, would have no effect on the individual’s quality of life. Interestingly, this
utility weight is of a similar value to the one reported by Brown et al.143 on the EVAR 1 RCT for baseline
EQ-5D score [mean 0.75 (SD 0.22); mean age 74 years]. The utility decrement for those going into any
reintervention was developed from the EVAR 1 trial.143 This decrement was calculated as a proportional
reduction from baseline until the first year post EVAR, when patients are assumed to be back to the
population-based utility weight.
TABLE 18 Unit costs
Variable Cost (£)
Probability
distribution Source
CDU 57.53 Gamma(6.23,0.11) RD47Z – vascular ultrasound scan – NHS Reference
Costs 2015 to 2016 (main schedule)140
CEU 57.53 Gamma(6.23,0.11) RD47Z – vascular ultrasound scan – NHS Reference
Costs 2015 to 2016 (main schedule)140
CTA 118.53 Gamma(13.67,0.12) RD22Z – CT scan of one area, with pre and post
contrast – NHS Reference Costs 2015 to 2016
(main schedule)140
Additional cost of CEU 72.10 Uniform(49.6,94.6) 30 minutes of medical consultation (based on an
hourly cost of £135 – PSSRU hospital-based doctors
with qualifications) plus contrast agent at £46 for
10 vials (one vial used per test per person). Probability
distribution based on assumption141
Further assessment visit 140.21 Gamma(8.38,0.06) WF01A – non-admitted face-to-face attendance,
follow-up – vascular surgery – NHS Reference Costs
2015 to 2016140
EVAR intervention
(elective)
11,925.16 Gamma(5.99,0) Weighted average codes YR04Z and YR03Z (AAA
endovascular and complex endovascular elective repair) –
NHS Reference Costs 2015 to 2016140
Other surgical
procedures (elective)
12,707.99 Gamma(4.03,0) Percutaneous transluminal embolectomy or
thrombolysis (weighted average codes YR23A and
YQ11B plus YR12Z – percutaneous and open
procedures plus stent) – elective inpatient – NHS
Reference Costs 2015 to 2016140
EVAR intervention
(emergency)
20,675.86 Gamma(4.3,0.0002) AAA endovascular and complex endovascular repair
(weighted average categories YR04Z and YR03Z – non-
elective) and VB01Z (emergency medicine) and ASS02
(ambulance) – NHS Reference Costs 2015 to 2016140
Other surgical
procedures (emergency)
18,681.87 Gamma(3.65,0.0002) Percutaneous transluminal embolectomy or
thrombolysis (weighted average for codes YR23A
and YQ11B plus YR12Z – percutaneous and open
procedures plus stent) – non-elective inpatient and
VB01Z (emergency medicine) and ASS02 (ambulance) –
NHS Reference Costs 2015 to 2016140
PSSRU, Personal Social Services Research Unit.
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Base-case analyses
The model base-case analysis was run for a cohort of 74-year-old men for a lifetime time horizon. A 6-month
cycle length was defined. The analysis was conducted from the NHS and Personal Social Services perspective.
Costs were expressed in 2015–16 Great British pounds and effectiveness was expressed in quality-adjusted
life-years (QALYs). Costs and QALYs were discounted at an annual rate of 3.5%.60 The cost-effectiveness
analysis results are reported using ICERs.60 ICERs are calculated as the ratio of the difference in expected costs
between two alternative strategies to the difference in expected QALYs. This ratio measures the additional costs
that would have to be paid in order to obtain an extra unit of effectiveness (i.e. an extra QALY). A probabilistic
sensitivity analysis was conducted, in which 10,000 iterations were run. The stability of results was verified by
examining the probabilistic results for a lower number of iterations (e.g. 1000). The probabilistic analysis results
are reported using cost-effectiveness acceptability curves (CEACs).144,145 These curves show the probability that
a particular strategy is cost-effective at alternative values of willingness to pay for an extra QALY.
Assessment of uncertainty (sensitivity analysis)
A number of sensitivity analyses were conducted to address the uncertainty in this economic evaluation
(one-way, two-way, threshold, scenario and probabilistic sensitivity analyses).
Approximately 90% of EVAR procedures in the UK are conducted in males (see Epidemiology of abdominal
aortic aneurysm). Therefore, the base-case analysis was run for a male cohort. Gender-specific data were not
available and the only differing data for men and women were general population mortality rates and utility
weight. Female utility weight for 74-year-olds is lower (0.75) than that for males (mean 0.77), but mortality
data show a longer life expectancy that could result in a longer time for benefits, but also costs. Therefore, a
further analysis was conducted using these data, to observe the effect of longer life expectancy in the model
results. In addition, one-way sensitivity analyses were conducted on all cost categories (e.g. cost of tests, visits
and surgery), test diagnosis sensitivity and specificity, incidence of abnormalities, adherence to surveillance
and mortality as a result of an unexpected event (rupture) and emergency intervention. Ranges to run these
analyses were informed by the lower- and upper-unit cost quartiles published in NHS Reference Costs 2015
to 2016140 (cost variables), the 95% CI reported by Karthikesalingam et al.132 (sensitivity and specificity)
and, for those variables for which there were no published data available, by expert opinion (e.g. adherence
to surveillance).
Given the base-case and sensitivity analyses results, a threshold analysis was conducted for the cost of CEU,
which explored the value that would make CEU cost-effective. Two scenario analyses were developed; the
first assumes that the information from the CEU test is perfect, that is, sensitivity and specificity are equal to 1,
plus no indeterminate or inconclusive results. This scenario corresponds to the notion that CEU could be the
present reference standard.
A further scenario analysis was implemented, which assumed a cohort with a higher proportion (50%) of
individuals belonging to abnormal Ib group together with a higher overall incidence for any abnormality
(up to 10% per 6-month cycle). This scenario explored the effects of monitoring only those individuals at
high risk of developing abnormalities.
TABLE 19 Quality-of-life weights
Variable Value
Probability
distribution Source
All health states – at the start
(74-year-old male cohort)
0.77 Not applicable Age- and gender-specific general population
EQ-5D score142
Surgery QALY weight decrement 2.22 Beta(4.7,209.4) Developed from Brown et al.143 (EVAR 1 RCT)
as difference from baseline
QALY, quality-adjusted life-year.
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The base-case and selected sensitivity analyses results are presented in Results. The full sensitivity analysis
results are reported in Appendix 15.
Results
In Table 20, the base-case analysis results are reported. Annual follow-up with CDU only is the strategy with
the lowest expected cost, followed by CTA only and CEU only. The strategies with higher expected costs are
those that use CDU or CEU in conjunction with CTA at the start. In Table 21, the strategy expected costs are
disaggregated into three cost categories: costs of surgical procedures, costs of surveillance visits and costs of
tests. Consistently throughout the alternative strategies, surgical costs represent a higher proportion of the
total costs. For the strategies involving CTA, the costs of the test represent over 30% of the total costs. The
costs of visits were considered only in the case of a reassessment, and therefore these represent the lowest
proportion in all of the surveillance strategies (i.e. between 6% and 13%).
The CTA-only strategy produces the lowest number of expected QALYs (see Table 20). This can be explained
by the relatively low sensitivity of CTA that was assumed in the model. As such, the CDU-only strategy
dominates the CTA-only strategy (i.e. CDU has lower expected costs and a higher number of expected
QALYs than CTA only). Moreover, adding CTA to CDU or CEU at the start results in more QALYs than using
only one imaging modality. However, either these strategies are dominated (i.e. CDU and CTA, then CDU) or
the incremental cost for an additional QALY is well above the often-accepted cost-effectiveness threshold
[£30,00060 (i.e. CEU and CTA, then CEU)]. Furthermore, CEU-based strategies result in a higher number of
expected QALYs than all of the other strategies, although the ICER to adopt any of the CEU-based strategies
is well above the £30,000 threshold.60
Figure 10 shows the cost-effectiveness plane for the base-case analysis. For ease of interpretation, square
data markers were used for CDU-based strategies, triangle data markers were used for CEU-based strategies
and dots were used for CTA-only strategies. It can be clearly observed that the CEU-based strategies produce
more QALYs, but at higher expected costs, than the CDU-based strategies. Furthermore, it is of note that the
CDU plus CTA and then annual CDU strategy is dominated by the CEU-only strategy. However, the ICERs to
TABLE 20 Base-case cost-effectiveness results: men
Strategy Cost (£) Incremental cost (£) QALYs Incremental QALYs ICER (£)
CDU 3791 6.5532
CTA 3828 37 6.5517 –0.00150 Dominated
CEU 4709 919 6.5594 0.00622 147,626
CDU and CTA, then CDU 4732 22 6.5543 –0.00510 Dominated
CEU and CTA, then CEU 5644 935 6.5598 0.00032 2,912,177
TABLE 21 Base-case cost results: disaggregated
Strategy
Cost of, £ (%)
Total cost,
£ (%)Surgery only Visits only Test only
CDU 2423 (64) 477 (13) 890 (23) 3791 (100)
CTA 2400 (63) 229 (6) 1198 (31) 3828 (100)
CEU 3146 (67) 585 (12) 978 (21) 4709 (100)
CDU and CTA, then CDU 2430 (51) 441 (9) 1861 (39) 4732 (100)
CEU and CTA, then CEU 3148 (56) 550 (10) 1945 (34) 5644 (100)
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move to any of these strategies (either CDU and CTA, then CDU or CEU only) from CDU only are well above
the usual cost-effectiveness threshold.
Table 22 shows the probabilistic sensitivity analysis results for the base case. Annual follow-up with
CDU only has the highest probability of being cost-effective for any value of willingness to pay for an
extra QALY below £50,000 (i.e. a probability of > 58%). Surveillance with CTA only has a probability
of between 32% and 42% of being cost-effective at values of willingness to pay for an extra QALY of
between £10,000 and £50,000. Adding CTA to CDU or CEU has a zero probability of being cost-effective
at any willingness-to-pay values. Finally, as surveillance with CEU only produces more expected QALYs,
this strategy has a growing probability of being cost-effective at increasing willingness-to-pay values.
However, at £50,000, its chance of being cost-effective is just 4.1%. Figure 11 presents the CEACs. It is
worth noting that the probability of CDU being cost-effective stabilises at around 60% for high values of
willingness to pay for a QALY. At higher values than those reported in the figure, surveillance with CEU
increases its chances of being cost-effective compared with CDU- and CTA-only strategies (i.e. 27% at
£100,000 – data not shown). Finally, the ICERs calculated with the probabilistic analysis were lower than
the deterministic base-case analysis reported in Table 20 (i.e. ICER for CEU with respect to CDU: £129,700
and for CEU and CTA; then CEU strategy with respect to CEU only: £2,479,000). However, these ICERs are
all well above the usual threshold used in the UK (e.g. £30,000).
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FIGURE 10 Base-case cost-effectiveness results: men.
TABLE 22 Probabilistic analysis results
Strategy
Proportion cost-effective at alternative willingness-to-pay for a QALY threshold (%)
£10,000 £20,000 £30,000 £40,000 £50,000
CDU 58.0 60.5 62.6 63.5 63.8
CTA 42.0 39.2 36.6 34.6 32.1
CEU 0.1 0.2 0.8 1.9 4.1
CDU and CTA, then CDU 0.0 0.0 0.0 0.0 0.0
CEU and CTA, then CEU 0.0 0.0 0.0 0.0 0.0
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Sensitivity analysis results
Base-case analysis for women
Table 23 shows the results of the base-case analysis for women. General population mortality data146
for women were used for this analysis, as well as the utility weight for women > 74 years of age
(i.e. mean 0.75), using the methods provided by Ara and Brazier 2010.142 Expected costs and QALYs for
women are generally higher than for males, reflecting the longer life expectancy of women. Overall, the
results are very similar to those of the base-case analysis for men, with CDU having the lowest expected
cost, followed by CTA only and surveillance with CTA only being dominated by surveillance with CDU
only. CEU-based strategies have ICERs that are well above the often-used willingness to pay for an extra
QALY threshold.60 Owing to the similarity of these results to those for the males model run, all other
sensitivity analyses were conducted using data for only males.
One-way sensitivity analysis results for the unit cost of the CDU test are reported in Table 24. The upper
quartile for a vascular ultrasound in NHS Reference Costs 2015–16140 is £70. For this reason, a range up to
£80 was used in an attempt to include other plausible values. The base-case unit cost for a CDU test was
£58; thus, for any values below this, the base-case results hold. At a CDU unit cost of £80, CDU is more
costly than CTA, and, therefore, CTA becomes cost-effective. CEU only improves its cost-effectiveness
compared with CDU as the unit cost for CDU increases. However, the ICERs for CEU-based strategies are
still above the £30,000 threshold, at a unit cost of £80 for a CDU test.
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FIGURE 11 Cost-effectiveness acceptability curves, base case: men.
TABLE 23 Base-case analysis: women
Strategy Cost (£) Incremental cost (£) QALYs Incremental QALYs ICER
CDU 4327 7.1460 –
CTA 4367 40 7.1442 –0.0018 Dominated
CEU 5372 1046 7.1536 0.0075 138,707
CDU and CTA, then CDU 5393 20 7.1473 –0.0063 Dominated
CEU and CTA, then CEU 6431 1059 7.1539 0.0004 2,926,141
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Table 25 presents the results for the one-way sensitivity analysis for the unit cost of CEU. The lower
quartile reported in NHS Reference Costs 2015 to 2016140 for a vascular ultrasound was £39; thus, a lower
value was used in order to consider other lower plausible values. In addition to the £72.10 for the contrast
agent and the extra staff involved (who remained unchanged for the present one-way sensitivity analysis),
the ultrasound cost for the CEU base-case analysis was £58, so any values above this would result in
CEU being less cost-effective. The base-case results are robust to changes in the cost of the CEU test. A
threshold analysis was conducted, and, owing to CEU being more sensitive but less specific, CEU needs to
be slightly cheaper than CDU in order to become cost-effective.
Test performance
Two-way sensitivity analyses were conducted for sensitivity and specificity for each compared test. Figure 12
presentd the results for CDU. The figure shows the strategy with the highest net benefit at £30,000 per
QALY according to alternative values of sensitivity and specificity for CDU. The value ranges used were broader
than the 95% CIs reported by Karthikesalingam et al.132 (i.e. sensitivity, 95% CI 0.62 to 0.83; specificity,
TABLE 24 One-way sensitivity analysis for the unit cost of a CDU test
Value (£) Strategy Cost (£)
Incremental
costs (£) QALYs
Incremental
QALYs ICER (£)
55 CDU 3769 6.5532
CTA 3828 58 6.5517 –0.0015 Dominated
CEU 4709 940 6.5594 0.0062 151,067
CDU and CTA, then CDU 4710 1 6.5543 –0.0051 Dominated
CEU and CTA, then CEU 5644 935 6.5598 0.0003 2,912,177
60 CDU 3812 6.5532
CTA 3828 16 6.5517 –0.0015 Dominated
CEU 4709 898 6.5594 0.0062 144,267
CDU and CTA, then CDU 4753 43 6.5543 –0.0051 Dominated
CEU and CTA, then CEU 5644 935 6.5598 0.0003 2,912,177
70 CTA 3828 6.5517
CDU 3896 69 6.5532 0.0015 45,611
CEU 4709 813 6.5594 0.0062 130,667
CDU and CTA, then CDU 4837 128 6.5543 –0.0051 Dominated
CEU and CTA, then CEU 5644 935 6.5598 0.0003 2,912,177
75 CTA 3828 6.5517
CDU 3939 111 6.5532 0.0015 73,755
CEU 4709 771 6.5594 0.0062 123,867
CDU and CTA, then CDU 4879 170 6.5543 –0.0051 Dominated
CEU and CTA, then CEU 5644 935 6.5598 0.0003 2,912,177
80 CTA 3828 6.5517
CDU 3981 153 6.5532 0.0015 101,899
CEU 4709 728 6.5594 0.0062 117,067
CDU and CTA, then CDU 4922 212 6.5543 –0.0051 Dominated
CEU and CTA, then CEU 5644 935 6.5598 0.0003 2,912,177
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TABLE 25 One-way sensitivity analysis for the unit cost of a CEU test
Value (£) Strategy Cost (£)
Incremental
costs (£) QALYs
Incremental
QALYs ICER (£)
20 CDU 3791 6.5532
CTA 3828 37 6.5517 –0.0015 Dominated
CEU 4394 603 6.5594 0.0062 96,889
CDU and CTA, then CDU 4732 338 6.5543 –0.0051 Dominated
CEU and CTA, then CEU 5328 935 6.5598 0.0003 2,912,607
30 CDU 3791 6.5532
CTA 3828 37 6.5517 –0.0015 Dominated
CEU 4478 687 6.5594 0.0062 110,408
CDU and CTA, then CDU 4732 254 6.5543 –0.0051 Dominated
CEU and CTA, then CEU 5412 935 6.5598 0.0003 2,912,493
40 CDU 3791 6.5532
CTA 3828 37 6.5517 –0.0015 Dominated
CEU 4562 771 6.5594 0.0062 123,927
CDU and CTA, then CDU 4732 170 6.5543 –0.0051 Dominated
CEU and CTA, then CEU 5496 935 6.5598 0.0003 2,912,378
50 CDU 3791 6.5532
CTA 3828 37 6.5517 –0.0015 Dominated
CEU 4646 855 6.5594 0.0062 137,446
CDU and CTA, then CDU 4732 86 6.5543 –0.0051 Dominated
CEU and CTA, then CEU 5581 935 6.5598 0.0003 2,912,264
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FIGURE 12 Two-way sensitivity analysis: CDU test sensitivity and specificity (net benefit, willingness-to-pay
threshold of 30,000).
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95% CI 0.90 to 0.97), in order to explore the effects of alternative plausible figures. At low levels of sensitivity
and specificity for CDU, the imaging strategy that has the highest net benefit is CTA. Surveillance with CDU
only has the highest net benefit at 93% specificity (or higher), regardless of the CDU sensitivity.
Perfect information from contrast-enhanced ultrasound
There was an indication from the clinical experts that the CEU test might have become the reference
standard. A scenario analysis was conducted, assuming perfect information from CEU. That is, it was
assumed that sensitivity and specificity were equal to 100% and that no indeterminate or inconclusive
results were possible. Moreover, a threshold analysis was conducted to explore the difference in cost
between CEU and CDU that would make CEU cost-effective. The results of this analysis are reported in
Table 26 and show that, if the test performance from CEU is assumed to be perfect, a cost difference
of up to £55 between CEU and CDU could make CEU cost-effective at a threshold value of willingness
to pay for a QALY of £30,000. Larger cost differences would shift the ICER above the frequently used
cost-effectiveness threshold (i.e. £30,000).
TABLE 26 Scenario analysis assuming perfect information from CEU. Value refers to the cost difference between
CEU and CDU
Value (£) Strategy Cost (£)
Incremental
costs (£) QALYs
Incremental
QALYs ICER (£)
40 CDU 3791 6.5532
CTA 3828 37 6.5517 –0.0015 Dominated
CEU 3943 152 6.5614 0.0082 18,682
CDU and CTA, then CDU 4732 788 6.5543 –0.0070 Dominated
CEU and CTA, then CEU 4947 1004 6.5614 0.0000 > 29 million
50 CDU 3791 6.5532
CTA 3828 37 6.5517 –0.0015 Dominated
CEU 4027 237 6.5614 0.0082 28,978
CDU and CTA, then CDU 4732 704 6.5543 –0.0070 Dominated
CEU and CTA, then CEU 5032 1004 6.5614 0.0000 > 29 million
55 CDU 3791 6.5532
CTA 3828 37 6.5517 –0.0015 Dominated
CEU 4069 279 6.5614 0.0082 34,126
CDU and CTA, then CDU 4732 662 6.5543 –0.0070 Dominated
CEU and CTA, then CEU 5074 1004 6.5614 0.0000 > 29 million
60 CDU 3791 6.5532
CTA 3828 37 6.5517 –0.0015 Dominated
CEU 4111 321 6.5614 0.0082 39,274
CDU and CTA, then CDU 4732 620 6.5543 –0.0070 Dominated
CEU and CTA, then CEU 5116 1004 6.5614 0.0000 > 29 million
70 CDU 3791 6.5532
CTA 3828 37 6.5517 –0.0015 Dominated
CEU 4195 405 6.5614 0.0082 49,569
CDU and CTA, then CDU 4732 536 6.5543 –0.0070 Dominated
CEU and CTA, then CEU 5200 1004 6.5614 0.0000 > 29 million
Note
‘Value’ refers to the cost difference between CEU and CDU.
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High-risk patient group
A relatively more sensitive test can be beneficial when a higher proportion of individuals have the condition
under study. A scenario analysis was considered in which half of the abnormal individuals belonged to the
abnormal Ib group (e.g. types I and III endoleaks, plus other conditions necessitating elective intervention).
Table 27 presents the results from a one-way sensitivity analysis for the incidence of any abnormality. The
base-case analysis assumed circa 4% incidence per 6-month cycle. In the present analysis, this incidence of
abnormalities implies that 2% of abnormalities are type Ib. Alternatively, the percentages in Table 27 could
be broadly interpreted as the annual incidence of Ib abnormalities. To facilitate the comparison between
CDU- and CEU-only strategies, in Table 27 the ICER for the CEU-only strategy has been calculated with
respect to the CDU-only strategy and not the strategy with an immediately lower cost (i.e. CDU and CTA,
then CDU). The results show that CEU is more cost-effective than CDU when the incidence of group Ib
abnormalites is > 6% per year (3% incidence per 6-month cycle, which corresponds to 6% in Table 27).
Summary of cost-effectiveness
This chapter reported on a systematic review of economic evaluations and a model-based economic
evaluation of alternative strategies to monitor individuals after an EVAR intervention. Similarly to the
systematic review of clinical effectiveness, only cohort studies were identified in the systematic review of
economic evaluations. Five studies met the inclusion criteria. Although two studies45,66 compared outcomes
before and after a surveillance protocol took place, the three remaining studies hypothesised the resource
use implications (i.e. the number of CTA scans performed) of moving to surveillance strategies, using
ultrasound as first-line test. Only one study gave full details of the cost calculations. Moreover, none of
the studies assessed the relative efficiency of CDU and CEU, which is addressed by the current assessment.
As such, the studies identified were unsuitable to fully inform the study question posed and therefore
unlikely to help decision-making in the UK. Thus, a new model was developed following UK
methodological guidelines.60
The developed model included five strategies. Three of these were CTA, CDU or CEU used on an annual
basis, and the two other strategies considered CTA in addition to CDU or CEU for the first surveillance
visit, with CTA scans being conducted afterwards only if further investigations were needed. Plain
radiography was included in all of the strategies as part of the surveillance assessment.
The model base-case results show that, once the primary EVAR surgical complications have been discarded,
surveillance with CDU as a first-line test becomes the less expensive option. This strategy is less expensive
and produces more expected QALYs than a strategy that uses CTA only. Adding CTA to CDU in the first
surveillance visits is not worthwhile. Moreover, surveillance strategies based on CEU result in more expected
QALYs, but are also more expensive, and the ICERs are well above the usual threshold used in the UK
(i.e. £30,000). The our base-case probabilistic analyses show that the CDU-only strategy has a probability of
being cost-effective of between 57% and 64%, depending on the cost-effectiveness threshold (e.g. 62%
at £30,000).
Extensive sensitivity analyses were conducted (see Appendix 15), with the base-case results being robust
for the great majority of these. The sensitivity analysis showed that a CEU-only strategy could become
cost-effective at very high rates of test sensitivity and specificity (e.g. when it was assumed to produce
perfect information – sensitivity and specificity of 100% and no indeterminate results). Even in this case,
the cost difference between CDU and CEU should not be above £55 for CEU to be cost-effective at a
£30,000 threshold of willingness to pay for an additional QALY.
As risk stratification of patients might become a feasible option, a further sensitivity analysis was
conducted to explore the effect of using these surveillance strategies in a very high-risk group only.
Incidence rates of > 2% per 6-month cycle were considered for the abnormal Ib group (i.e. types I and III
endoleaks, together with type II endoleaks with sac expansion > 5 mm and other conditions commonly
detected by non-radiography imaging modalities). At an annual incidence rate of 7% for this group,
CEU-only surveillance becomes cost-effective with an ICER of £29,756 with respect to CDU-only
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TABLE 27 Scenario analysis assuming that 50% of abnormalities are Ib (e.g. types I and III endoleaks)
Value Strategy Cost (£) Incremental costs (£) QALYs Incremental QALYs ICER (£)
4% CDU 5966 6.5018
CTA 5991 25 6.4961 –0.0057 Dominated
CDU and CTA, then CDU 6918 952 6.5057 0.0038 248,084
CEU 6929 963 6.5258 0.0240 40,126
CEU and CTA, then CEU 7875 946 6.5270 0.0011 849,127
5% CDU 6902 6.4818
CTA 6919 17 6.4751 –0.0068 Dominated
CDU and CTA, then CDU 7854 952 6.4866 0.0047 200,797
CEU 7910 1008 6.5105 0.0287 35,167
CEU and CTA, then CEU 8852 942 6.5119 0.0014 683,732
6% CDU 7748 6.4635
CTA 7757 9 6.4557 –0.0078 Dominated
CDU and CTA, then CDU 8701 953 6.4691 0.0056 169,359
CEU 8801 1053 6.4964 0.0329 31,965
CEU and CTA, then CEU 9740 939 6.4980 0.0016 573,576
7% CDU 8516 6.4465
CTA 8517 2 6.4378 –0.0087 Dominated
CDU and CTA, then CDU 9470 954 6.4530 0.0065 146,967
CEU 9612 1096 6.4833 0.0368 29,756
CEU and CTA, then CEU 10,548 936 6.4852 0.0019 494,974
8% CTA 9209 6.4212
CDU 9215 6 6.4308 0.0095 642
CDU and CTA, then CDU 10,172 957 6.4381 0.0073 130,221
CEU 10,353 1138 6.4712 0.0404 28,159
CEU and CTA, then CEU 11,287 934 6.4733 0.0021 436,083
9% CTA 9840 6.4059
CDU 9853 14 6.4162 0.0103 1316
CDU and CTA, then CDU 10,813 959 6.4244 0.0082 117,233
CEU 11,031 1178 6.4599 0.0437 26,964
CEU and CTA, then CEU 11,964 932 6.4623 0.0024 390,326
10% CTA 10,417 6.3916
CDU 10,437 21 6.4026 0.0110 1884
CDU and CTA, then CDU 11,400 963 6.4116 0.0090 106,873
CEU 11,655 1217 6.4494 0.0467 26,045
CEU and CTA, then CEU 12,586 931 6.4520 0.0026 353,758
Note
CEU only Incremental cost and QALYs and ICER are calculated with respect to CDU only strategy.
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surveillance. It is worth noting that, although an incidence of 7% for type I or type III endoleaks is unlikely
to be observed in clinical practice, an incidence of 6% for type II endoleaks with sac expansion is perhaps
possible.
We can conclude that the use of CDU as a first-line test for the surveillance of individuals after EVAR is
cost-effective, with a probability of > 58% at the usual cost-effectiveness threshold used in the UK.60
The analysis results are driven by the interplay of the test performance data (i.e. sensitivity and specificity)
and the cost of the test. Lower unit costs together with higher specificity are needed for CEU to become
cost-effective.
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Chapter 4 Discussion and conclusions
Statement of principal findings
Clinical effectiveness
To our knowledge, this is the first assessment that considers the effectiveness and cost-effectiveness of
CTA, CDU and CEU for surveillance after EVAR. The clinical evidence base for this assessment consists of
two non-randomised comparative studies (with a total of 750 participants) and 25 observational cohort
studies (with a total of 7196 participants), assessing various surveillance protocols after EVAR. The
surveillance protocols were based on the use of either CDU and/or CEU in combination with CTA.
The majority of the included studies assessed EVAR surveillance protocols based on a combination of CDU
and CTA. Three studies used CDU as the main imaging modality for surveillance after EVAR, two studies
used CEU as the main imaging modality and one study used CEU in selected cases only. There were no
studies that compared CDU surveillance with CEU surveillance.
The risk of bias was rated as being high or moderate for the majority of the included studies, with only
three cohort studies rated as being at a low risk of bias according to the prespecified criteria for the
risk-of-bias assessment (ReBIP checklist).76,84,87
There was considerable heterogeneity among the included studies in terms of the surveillance protocols
(imaging modality, frequency of imaging, duration of follow-up, reported outcomes, definition of clinical
outcomes – for example, the definition of decreased aneurysm size, the axis of the diameter measured and
the time points at which outcomes were assessed). Owing to the observed clinical heterogeneity, it was
deemed to be inappropriate to perform a statistical synthesis of the reported outcomes.
We conducted a narrative synthesis of the main clinical findings and grouped studies according to their
similarities in terms of modality and frequency of imaging. A combination of CTA and CDU was the most
commonly implemented surveillance strategy. Studies that used a combination of CTA and CDU for
surveillance after EVAR were published between 2001 and 2010. The second most common surveillance
strategy involved CTA and/or CDU for early and mid-term assessments and CDU for long-term surveillance
after EVAR. Studies assessing this type of strategy were published more recently, between 2009 and 2016.
This may indicate a growing trend towards a CDU-based surveillance. It is worth noting that one study
that followed up 494 patients who underwent EVAR using CTA and CDU for early and mid-term imaging
assessments and CDU for long-term surveillance reported the highest mortality and reintervention
rates.90 However, any comparisons between cohort studies are tentative, owing to the observed clinical
heterogeneity. In this particular case, it is difficult to ascertain whether or not the reported high mortality
and reintervention rates were observed because of the length of the follow-up period (12 years), the
characteristics of the patient population or the imaging modalities used for surveillance.
Three of the included cohort studies were conducted in the UK.41,78,82 Evidence from these studies was
considered to be of moderate methodological quality, as the studies did not satisfy all of the criteria of the
ReBIP checklist. One of these studies used CDU exclusively for surveillance after EVAR,78 whereas the other
two studies used a strategy based on a combination of CDU and CTA.41,82 In particular, Harrison et al.,41
who followed up a total of 194 patients using a combination of CDU and CTA for early surveillance and
CDU for long-term surveillance after EVAR, reported a mortality rate of 13% at 12 months. In contrast, a
non-UK-based study that assessed 494 EVAR patients using a similar surveillance strategy reported 19.7%
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mortality during a median follow-up of 68 months.90 In general, the proportion of patients requiring
reintervention in the study by Harrison et al.41 was similar to that reported by other non-UK-based studies
that used a combination of CTA and CDU for early surveillance and CDU for long-term surveillance. The
study by Karthikesalingam et al.78 used CDU at 1.5, 3, 5, 9, 12 and 18 months and annually thereafter
to assess the role of peak systolic velocity provided by CDU for the prediction of limb complications in a
cohort of 478 EVAR patients. The authors found that serial increases in the peak systolic velocity recorded
during CDU surveillance were associated with an increased risk of stent–graft limb complications.78
The proportion of patients with type I endoleaks identified by a surveillance strategy based on early
and mid-term CTA and/or CDU and long-term CDU was comparable to that identified by a surveillance
strategy based on a combination of CTA and CDU throughout the follow-up period (range 0–7.9% vs.
0.8–8.3%). No type III endoleaks were reported in the eight cohort studies that used early and mid-term
CTA and/or CDU and long-term CDU for the surveillance after EVAR. It is worth noting that all but one
study76 were rated as being at a high or moderate risk of bias. The study by Freyrie et al.,76 which was the
only study that was rated as being at a low risk of bias in this surveillance category, reported two cases
(1.1%) of type I endoleak, 23 cases (13%) of type II endoleak and no cases of type III or IV endoleak
during a mean follow-up of 33 months.
Detection of limb occlusion was lower among cohort studies that used CDU for long-term surveillance after
EVAR (range 0–1.1%) than cohort studies that used either CTA for long-term surveillance (range 3.1–3.7%)
or a combination of CTA and CDU throughout surveillance (range 5.3–7.2%). This is, however, only an
observation and not a causal association.
The study by Chaer et al.40 evaluated the safety of long-term CDU for surveillance after EVAR. One hundred
and eighty-four patients with shrinking or stable aneurysms who received CTA at 1 and 12 months after
EVAR were followed up annually with CDU for up to 4 years. Freedom from endoleaks was 96% and
freedom from secondary interventions was 95% at 4 years. The authors concluded that CDU-based
surveillance after EVAR is safe in patients with stable aneurysms.
Similarly, the comparative study by Chisci et al.,66 which compared CDU and CTA 1 month after EVAR and
every 6 months afterwards (protocol I, 367 patients) with CDU and CTA 1 month after EVAR and CDU and
radiography every 6 months afterwards (protocol II, 341 participants), reported no significant differences
between the two surveillance strategies during the course of the study (3-year follow-up) in terms of
reinterventions, clinical complications and mortality. The authors concluded that the current post-EVAR
surveillance protocol could be simplified by adopting CDU as the main follow-up imaging modality and
restricting the use of CTA to selective cases, when adverse events are suspected.
Cost-effectiveness
This assessment is the first model-based economic evaluation to consider the role of CDU, CEU and CTA
for post-EVAR surveillance. Only the study by Bendick et al.137 provided a head-to-head comparison of the
three imaging modalities as first-line surveillance using data from a cohort of 40 individuals and considered
both costs and clinical outcomes. All of the other economic evaluation studies identified in the systematic
review compared the use of CTA as first-line monitoring with CDU only, with CTA being used after CDU
for selected cases only, to provide further diagnostic information. Moreover, all of the studies assessed
the reduction in costs as a result of the fewer number of CTA scans conducted in the ultrasound-based
protocols. The model considered a broader measure of effectiveness based on a preference-based measure
of utility in accordance with the UK economic evaluation methodological guidelines,60 as well as a lifetime
time horizon with all relevant consequences from the NHS perspective. None of the retrieved studies
attempted an incremental analysis of the costs and clinical outcomes. For this reason, any comparison
between the study’s results and those of the earlier economic evaluations should be conducted with
caution.
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The model results show that a surveillance strategy based on CDU as the imaging modality of choice
becomes the strategy with the lowest expected costs, in addition to producing more QALYs than a
strategy based exclusively on CTA. By comparison, although a surveillance strategy based exclusively on
CEU would generate more QALYs, it would be more expensive, and the ICER would be well above the
usual threshold used in the UK (i.e. £30,000). In addition, the base-case probabilistic analysis shows that a
CDU-only strategy would have a probability of being cost-effective of between 57% and 64%, depending
on the cost-effectiveness threshold (e.g. 62% at £30,000). Adding CTA to CDU or CEU in the first annual
surveillance visit is not worthwhile, as it generates more QALYs but at a very high cost per QALY.
The base-case results, which show that CDU is the least expensive option, are in general agreement with
those of previous economic evaluations that reported savings because fewer CTA tests were conducted in
ultrasound-based protocols.41,45,66,137,138 However, although Bendick et al.137 reported savings for a 3-year
cost comparison between CEU- and CTA-based protocols, the model results indicate a higher expected
cost for a CEU-only strategy than for a CTA-only strategy. This can be explained by the relatively lower
specificity assumed for CEU in the economic model, which generates a higher proportion of false-positive
results. These false-positive results will trigger further testing for a period of up to 2 years.
Extensive sensitivity analyses were conducted (see Appendix 15), with the base-case results being robust
for the great majority of these. The sensitivity analysis showed that a CEU-only strategy could become
cost-effective at very high rates of test sensitivity and specificity (e.g. when it was assumed to produce
perfect information – sensitivity and specificity of 100% and no indeterminate results) and with a
difference in the cost of CEU and CDU of < £55.
A further sensitivity analysis considered higher incidence rates for the abnormal Ib group (e.g. types I and III
endoleaks and other abnormalities commonly detected by non-radiography imaging modalities). Annual
incidence rates of 4% and above were used in this analysis. Compared with CDU-only surveillance, CEU-only
surveillance becomes cost-effective, with an ICER of £29,756, when the annual incidence rate for this group
is 7%. Although in clinical practice it is unlikely that an incidence rate of 7% for type I or type III endoleaks
would be observed, an incidence rate of 6% for type II endoleaks with sac expansion is perhaps possible.
The interplay of sensitivity, specificity and unit costs of the test drives the results in the study’s model. For
instance, a lower unit cost for CEU helps to make the CEU-based strategies relatively more cost-effective;
however, cost on its own will not make a CEU-only strategy a cost-effective option. A higher specificity is
also necessary in order to reduce the expected cost of the strategy as a result of the follow-up of individuals
without an abnormality. In addition, a higher sensitivity triggers further interventions (e.g. secondary
interventions for the abnormal Ia and Ib groups and further monitoring for the abnormal II group). As such,
although these interventions might result in higher expected QALYs, they also add to the expected costs,
with an uncertain final effect on cost-effectiveness.
The majority of patients in the cohort considered in the model will have no further need for subsequent
interventions. Furthermore, in the base-case analysis, 70% of patients with an abnormality correspond
to the abnormal II group. Because a large proportion of patients are elderly with multiple comorbidities,
there are instances when a secondary intervention, which is considered to be technically indicated based
on surveillance imaging, may not be carried out because the risk associated with the intervention is
considered prohibitively high. Furthermore, in the cost–utility analysis, there is no benefit attributed to the
reassurance that the abnormality is minor or from any information provided by the test. From the point of
view of the economic model, following up individuals for whom no further interventions are possible just
adds to the expected cost of the strategy, with no effects on QALYs. Future research should explore more
broadly the effects of the information generated by the surveillance strategies and incorporate this within
the economic analysis.
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Uncertainties from the assessment
Clinical effectiveness
The clinical evidence identified for this assessment demonstrates that surveillance practice after EVAR is
currently heterogeneous and the most effective method for surveillance has yet to be established.
Since the advent of EVAR, CTA has been the main imaging modality for long-term surveillance. A survey of
current clinical practice after EVAR published by Uthoff et al.147 in 2012, which involved 674 respondents
from 52 countries worldwide, found that CTA was the imaging modality used most often for standard
surveillance. A CTA scan at 1 year was scheduled by 64.5% of the respondents.
The use of CTA presents important drawbacks, including exposure to ionising radiation, which may result
in an increased risk of cancer.30 Moreover, the intravenous iodinated contrast medium used in CTA may
damage renal function over time and increase the risk of contrast nephropathy. A study by Mitchell et al.,148
published in 2010, found that the incidence of contrast-induced nephropathy was 11% among a cohort
of 633 patients who received contrast-enhanced CT in the emergency department. Six patients with
contrast-induced nephropathy developed severe renal failure and four (0.6%) died.148 In most EVAR
patients, these risks could be eliminated or reduced by modifying the surveillance protocol and limiting
the number of CTA scans.11,26,35,149
As the main purpose of surveillance is to identify complications and direct treatments, most surveillance
protocols involve CTA scans at 1, 6 and 12 months and annually thereafter; however, some investigators
have challenged the utility of the 6-month CTA in patients with a normal 1-month CTA.46 The authors of the
5-year US Zenith multicentre trial have proposed a reduced surveillance protocol, with no 6-month CTA, for
patients without early endoleaks.36 According to the European Society for Vascular Surgery 2010 guideline,31
CTA and radiography should be used to categorise patients with and without endoleaks. Patients without
an endoleak should be followed up with CTA at 12 months and with CDU and plain radiography thereafter,
whereas those with a type II endoleak should receive CTA at 6 and 12 months and annual CTA and plain
radiography thereafter.31 Similarly, the Society for Vascular Surgery practice guidelines recommend CTA at
1 and 12 months during the first year after EVAR. CTA at 6 months is added to the surveillance schedule
only if the 1-month CTA identifies an endoleak or other abnormalities of concern.19 In the survey of current
clinical practice after EVAR published by Uthoff et al.147 in 2012, 48.6% of the 674 respondents agreed
that, in the absence of an endoleak or AAA sac enlargement after initial CTA, no further CTA follow-up at
6 months is required.
Although the current trend is to reduce the frequency of CTA for early surveillance after EVAR or replace
it with other imaging modalities, there is limited information on the optimal duration of long-term
surveillance and if annual surveillance should continue indefinitely. A systematic review published by
Nordon et al.26 in 2010, assessed the rates of secondary interventions in 32 studies (17,987 EVAR patients)
and reported the evidence in favour of a modified EVAR practice. The authors have observed a mean time
to secondary intervention of approximately 1–1.5 years and have suggested that patients who have
completed 3 years of surveillance without detection of endoleaks or sac enlargement can be discharged
from standard surveillance.26
Some investigators and clinical guidelines now recommend annual post-EVAR surveillance with CDU if the
first annual CTA does not demonstrate an endoleak or residual sac enlargement.12,19,73,150 Compared with
CTA, CDU is less invasive, less expensive, easily available and less risky as it does not require the use of a
contrast agent and does not expose the patient to repeated radiation. A number of studies and systematic
reviews have confirmed the role of CDU in the evaluation of endoleaks.42,62,73,78,129,151–154 CDU can be
regarded as a feasible and safer alternative to CTA, especially in patients with a stable aneurysm. Indeed,
the number of centres using CDU seems to be increasing. In the survey by Uthoff et al.147 published in 2012,
the use of CDU during surveillance was reported by 36.3% of centres. High-volume, experienced centres
were more likely to opt for CDU surveillance after 1 year than less experienced centres with fewer cases.
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Moreover, centres with a lot of EVAR experience were more likely to favour ultrasound for the follow-up of
type II endoleaks.147 Similarly, a UK telephone survey administered to 41 centres with 10 years’ experience in
EVAR showed that 14 out of 41 (34.1%) centres used CDU as the primary surveillance modality.155
In general, the evidence identified for this assessment showed no significant differences in terms of
reinterventions and clinical complications between strategies based on the use of CDU for long-term
surveillance after EVAR and those based on the use of CTA or CTA and CDU; however, the identified
studies were clinically heterogeneous and any attempt to compare surveillance strategies should be
considered to be tentative.
Current evidence on the use of CEU is limited, and CEU technology has evolved considerably over the past
decade. A number of studies in the literature have reported a high accuracy of CEU in comparison with
single and biphasic CTA.57,156,157 A systematic review published in 2015,130 which assessed the accuracy of
CEU versus CTA for the detection of endoleaks during post-EVAR surveillance, concluded that, compared
with CTA, CEU that utilises second-generation contrast agents is a highly sensitive modality for the detection
of endoleaks and especially for the detection of type II endoleaks. Similarly, a study of 539 patients published
by Millen et al.43 in 2013, suggests that CEU may be useful for the resolution of clinical uncertainties that
arise from conventional imaging modalities, especially in the classification of endoleaks.
There is growing evidence that the majority of reinterventions post EVAR are triggered by symptoms
and are independent of standard surveillance.39 Among the cohort studies included in this assessment,
the proportion of patients requiring reintervention during surveillance ranged from 1.1% during a mean
follow-up of 24 months40 to 23.8% in a cohort of high-risk patients who presented with hostile neck anatomy
after a mean follow-up of 32 months,85 indicating that the risk of reintervention was not homogeneous and
was related to patients’ characteristics. Karthikesalingam et al.,39 who followed a cohort of 553 patients for a
median follow-up period of 31 months (range 1–97 months) and assessed the extent to which surveillance
after EVAR triggers reinterventions, found that 5.1% of asymptomatic patients underwent reintervention
prompted exclusively by surveillance imaging, whereas 8.3% of patients presented symptomatically. Black
et al.37 assessed the number of secondary interventions after EVAR among 417 patients and reported that
reinterventions were performed in 31 (7.4%), of whom only six (1.4% (6/417) had abnormalities that were
detected by standard surveillance. Similarly, Dias et al.38 found that the majority of follow-up CTA scans post
EVAR did not lead to reintervention, and only 9.3% of asymptomatic patients (26/279) underwent a secondary
procedure based on imaging findings detected by routine surveillance. The systematic review by Nordon et al.,26
which assessed secondary interventions after EVAR from 32 papers and included a total of 17,987 cases,
reported that surveillance practice alone initiated a secondary intervention in only 1.4–9% of cases.
It is possible that current surveillance practice is poorly targeted and that most patients do not benefit from
an unstratified surveillance programme that does not take into account the individual risk of developing
complications.11 There is a growing interest in risk-stratified surveillance, whereby the frequency of imaging
is directed by the preoperative risk of complications. Risk factors for early and late complications post EVAR have
been documented.158–160 Such an approach would allow more intense surveillance regimes to be targeted to
those patients with greater risk, with less frequent surveillance in patients at low risk (Alan Karthikesalingham,
St. George’s Vascular Institute, St. George’s University of London, 2016, personal communication).
Schanzer et al.161 assessed a large population of US Medicare beneficiaries (19,962 patients) who underwent
EVAR between 2001 and 2008 and found that 50% of patients were lost to annual imaging follow-up by
5 years post EVAR. For the subset of patients with 8 years of follow-up, substantive declines in imaging
follow-up continued, with only 37% undergoing an imaging study between year 6 and year 8.161 In the UK,
Karthikesalingam and Holt,162 as part of the Multicentre Post-EVAR Surveillance Evaluation Study (EVAR-
SCREEN), assessed 1539 patients who underwent EVAR in 10 EVAR-SCREEN collaborator centres. Five years
after EVAR, 39.7% of patients remained compliant with the surveillance programme, whereas 21.4% were
deliberately removed from surveillance. The authors reported that, compared with 131 compliant patients,
non-compliant patients were more likely to undergo reintervention (5-year freedom from reintervention was
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76.6% vs. 62.7% in compliant and non-compliant patients, respectively), but demonstrated similar
all-cause mortality rates (5-year survival rate of 65.6% vs. 54.7% in compliant and non-compliant patients,
respectively).162 These findings suggest that patients who undergo EVAR should receive appropriate
information and counselling about the lifelong risk of complications and the need for annual imaging
surveillance. UK centres that have adopted a comprehensive informative approach towards EVAR patients
have reported satisfactory compliance rates (Professor Srinivasa Rao Vallabhaneni, 2016, personal
communication). These findings also highlight that the current challenge facing EVAR surveillance is the
frequency/timing of imaging, which currently is not targeted to patients’ risk of developing complications.
It is possible that current imaging surveillance is performed too frequently for low-risk patients and not
frequently enough for high-risk patients.
Patient perspectives of endovascular abdominal aortic aneurysm
repair surveillance
We invited two lay patient representatives to join the advisory group for this assessment. We sought their
opinion on receiving surveillance following EVAR to better understand the patient experience of undergoing
surveillance. Both representatives were men who had received EVAR between 6 and 3 years prior to joining
the advisory group and had received 6-monthly CTA or CDU surveillance. Both men indicated that they
had no preference for the type of imaging modality they received; however, they felt that continuity of the
professional conducting and interpreting the results of the imaging procedure was important, to give them
reassurance that they were receiving adequate monitoring and that their test results were being correctly
interpreted. Both men stated that they would welcome more information about the reasons underlying the
frequency of their surveillance schedule, with one man stating that he would be willing to undergo more
frequent assessments, either for the added reassurance given by a normal surveillance imaging result or for
the reassurance that any abnormality would be detected (and treated) early. It is, however, possible that other
patients would feel more anxious by the prospect of more intense surveillance regimens. These concerns
highlight the potential need to ensure that patients have a greater understanding of the purpose of their
surveillance programme after EVAR, as well as of the required frequency of imaging. Travel to surveillance
appointments was mentioned as a possible constraint, as the men lived between 8 and 16 miles from their
nearest surveillance centre. Both men felt that it would be impossible to attend surveillance appointments
solely by public transport and, therefore, relied upon travel by car for all or part of the distance. Practical
issues, like travel limitations (especially for elderly people), could explain poor compliance with EVAR
surveillance in some cases.
Cost-effectiveness
With regard to the reported economic model and cost-effectiveness analyses, there are a number of
limitations that are worth mentioning. Both the identification and the selection of the input data were
challenging. In order to identify the relative effect of different surveillance strategies, it was necessary to
model a baseline situation (e.g. the cost and consequences of a situation without surveillance). Unfortunately,
data to model the natural history of the disease were scarce. For this reason, the attention was turned to
studies that analysed registry data. When particular input data were available from more than one source,
the newest study was selected in an attempt to capture the technical developments of the modalities under
consideration. Moreover, in the economic model, it was assumed that the imaging modalities differentiate
the same conditions, that is, the tests identify a proportion of ‘abnormalities’ according to test sensitivity and
specificity data. Once the overall abnormality proportion was defined, this proportion was divided among the
abnormal Ia, Ib and II groups in the same proportions, regardless of the original test performed. In addition,
the performance data used (i.e. sensitivity and specificity) were based on the detection of endoleaks (all types)
that was reported by Karthikesalingam et al.132 Unfortunately, there were no sensitivity and specificity data
available by type of abnormality and test, and therefore this is a limitation of the analysis.
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A further assumption in the model is the perfect identification of certain abnormalities by plain radiography.
In effect, all individuals developing a type Ia abnormality (e.g. non-endoleak needing elective intervention) are
assumed to be correctly identified in the next surveillance visits through a plain radiography. Unfortunately,
there were no data to inform the test performance for plain radiography in this context. Moreover, although
plain radiography shows graft migration and kinking, the abnormal Ia group includes graft infection and limb
thrombosis, which will not be seen on plain radiography. In fact, plain radiography in the model is always
conducted alongside another imaging test. Therefore, the underlying assumption is that the conditions in the
abnormal Ia group are perfectly identified by either plain radiography or the imaging test. A corollary of this is
that the differences between the surveillance strategies are a result of the test performances for the abnormal
Ib and II subgroups. This is in line with the project brief, as its main interest was related to the detection and
management of endoleaks.
There are a number of structural assumptions in the study‘s model. First, no patients present with symptoms
between surveillance visits. Individuals presenting with symptoms make surveillance less worthwhile. Hence,
the assumption in the study’s model works in favour of surveillance. However, up to 8% of individuals could
present with symptoms in a non-emergency situation (Professor Srinivasa Rao Vallabhaneni, 2016, personal
communication), and the magnitude of the effect of this assumption on the model results is limited. Second,
the model did not include a ‘do nothing’ alternative. Although this is recommended by a number of economic
evaluation methodological guidelines,60 a no-surveillance strategy was regarded as unacceptable and unrealistic
for the UK context. Third, none of the strategies considered a partial use of CEU in a search for further
information if the results from the CDU test were inconclusive. This is a limitation of the present analysis
and material for further research. Fifth, all strategies considered surveillance on an annual basis. This was
agreed with the clinical advisors, as annual surveillance frequency was deemed to be the only acceptable
option. Finally, there was no risk stratification of the cohort. An alternative model could consider different
surveillance strategies with differing visit frequencies, as well as alternative test arrangements, depending
on the patient’s risk of developing complications.
The model might overestimate overall survival for this patient group compared with the results of the EVAR
1 trial (EVAR trial arm).48 A higher overall survival rate would make any surveillance programme relatively
more attractive, as people would enjoy the benefits for a longer period of time. The EVAR 1 trial includes
individuals who are under surveillance. As a result, the lower mortality rate in the study’s model might
correspond to events and conditions that cannot be avoided through a surveillance programme. Therefore,
our model might overestimate the overall expected costs and QALYs because of a higher overall survival
rate; the relative effect of this issue on the modelled strategies is ultimately unclear, although it is believed
to be small in magnitude.
Conclusions
The current evidence assessing the effect of surveillance after EVAR is very heterogeneous, with
surveillance protocols based on different imaging modalities, frequency of imaging and length of follow-up.
Consequently, no firm conclusion can be drawn with regard to the optimal surveillance strategy after EVAR.
There is a need to improve current surveillance protocols to reduce radiation exposure, risk of contrast
nephropathy and costs, while ensuring that the patients are adequately followed up to minimise their risk
of secondary complications, especially aneurysm rupture. CDU may be a safe alternative to CTA, with CTA
reserved for abnormal or inconclusive CDU cases that require further investigation. Further research is
required, however, to validate the safety of modified surveillance protocols after EVAR based on the use
of CDU and/or CEU. Access to modern equipment and highly experienced operators remains a crucial
requirement for the adoption of CDU surveillance. The study’s economic evaluation shows that CDU is the
most cost-effective option for post-EVAR surveillance, with a 63% probability of being cost-effective at a
threshold of willingness to pay per QALY of £30,000. Surveillance strategies based on CEU produce more
QALYs, but are also more expensive, and might be cost-effective only for higher-risk patient groups.
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Suggested research priorities
l Further research is needed to assess the value of targeted surveillance (i.e. patients with a greater
risk of complications may receive more frequent surveillance, whereas those with uncomplicated EVAR
may undergo less frequent assessments or be discharged from surveillance). A large, multicentre trial
with an extended follow-up period (over many years) would be required to answer the question of
the optimal surveillance strategy after EVAR; therefore, the identification of high-risk EVAR patients
mandating close follow-up may be a more realistic recommendation.
l If surveillance is to be targeted, is ultrasound-based surveillance (CDU and/or CEU) satisfactory for all
patient groups, or are there groups for which CTA is required to avoid excessive risk?
l The criteria for identifying patients who are at a high risk of complications (e.g. use of validated score
systems, risk prediction models) require further investigation.
l There is a need to clarify the role of plain radiography as part of EVAR surveillance. If CTA is to be
performed less frequently or avoided, should plain radiography be mandatory or reserved for patients
with abnormalities on ultrasound imaging?
l Future research should explore more broadly the effects of the information generated by the imaging
modalities used for surveillance and incorporate this within the economic analyses.
Various aspects of EVAR surveillance may also warrant further consideration, for example it would be
useful if:
l some indication of patients’ compliance with surveillance could be documented across centres in order
to identify best surveillance practice and ensure that surveillance protocols are engaging with patients
l national clinical registries and databases could consider recording data on complications and mortality
after EVAR according to the imaging modalities used for surveillance.
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Appendix 1 Search strategy
Clinical effectiveness
Databases
EMBASE (1996 to week 36 2016), Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid
MEDLINE(R) Daily and Ovid MEDLINE(R) (1946 to 5 September 2016).
Last date of search: 5 September 2016.
Search strategy
1. Endoleak/di [Diagnosis]
2. endoleak/ or endoleak?.tw,kw.
3. evar.tw,kw.
4. (endovascular adj5 repair? adj5 abdominal).tw,kw.
5. or/2-4
6. Ultrasonography/ use ppez
7. Echography/ use emef
8. (duplex adj2 (ultrasound or ultrasono$)).tw.
9. Ultrasonography, Doppler, Duplex/ use ppez
10. Doppler echography/ use emef
11. (contrast enhanced adj2 (ultrasound or ultrasono$)).tw
12. (cdu or ceu).tw,kw.
13. Tomography, X-Ray Computed/ use ppez
14. Multidetector Computed Tomography/
15. Computer Tomography Scanner/ use emef
16. (computed adj3 tomograph$).tw.
17. Endoleak/us [Ultrasonography]
18. 5 and (6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16)
19. 1 or 17 or 18
20. Aortic Aneurysm, Abdominal/ use ppez
21. Abdominal Aorta Aneurysm/ use emef
22. endovascular procedures/ use ppez
23. endovascular surgery/ use emef
24. evar.tw,kw.
25. (endovasc$ adj5 repair?).tw.
26. (20 or 21) and (22 or 23 or 24 or 25)
27. 26 or endovascular aneurysm repair/
28. exp Epidemiological Monitoring/ use ppez
29. Patient monitoring/ use emef
30. surveillance.tw,kw.
31. monitor$.tw,kw.
32. 27 and (28 or 29 or 30 or 31)
33. 19 or 32
34. randomized controlled trial.pt.
35. controlled clinical trial.pt.
36. randomi?ed.ab.
37. randomization/ use emef
38. placebo.ab.
39. drug therapy.fs.
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40. randomly.ab.
41. trial.ab.
42. groups.ab.
43. (chang$ or evaluat$ or reviewed or baseline).tw.
44. major clinical study/ use emef
45. exp clinical trial/ use emef
46. comparative study/
47. follow-up studies/
48. time factors/
49. (prospective$ or retrospective$).tw.
50. (cohort$ or case series).tw.
51. (compare$ or compara$).tw.
52. (registry or registries or register?).tw.
53. (anaconda or eurostar or karbase or lifeline or renu or swedvasc or uk reta or vascunet).tw.
54. or/34-53
55. 33 and 54
56. 55 not (editorial or letter or comment or case reports).pt.
57. limit 56 to yr=1996-2016
58. remove duplicates from 57
Databases
Science Citation Index (1997 to 5 September 2016).
Web of Knowledge ISI (http://wok.mimas.ac.uk/).
Last date of search: 5 September 2016.
Search strategy
1. TS=endoleak*
2. TS=evar
3. TS=(endovascular N/5 repair* N/5 abdominal)
4. #1 OR #2 OR #3
5. TS=(duplex NEAR/3 (ultrasound OR ultrasono*))
6. TS=(‘contrast enhanced’ NEAR/3 (ultrasound OR ultrasono*))
7. TS=(CDU OR CEU)
8. TS=(Computed NEAR/3 tomograph*)
9. #5 OR #6 OR #7 OR #8
10. #4 AND #9
11. TS=(abdominal NEAR/5 aort* NEAR/5 aneurysm*)
12. TS=evar
13. TS=(endovascular NEAR/5 repair*) Indexes=SCI-EXPANDED, IC Timespan=1997-2016
14. #11 AND (#12 OR #13)
15. TS=monitor*
16. TS=surveillance
17. #16 OR #15
18. #17 AND #14
19. #18 OR #10
Database
The Cochrane Library: Issue 3 2016 [CENTRAL, CDSR, DARE (www3.interscience.wiley.com/)].
Last date of search: 5 September 2016.
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Search strategy
1. MeSH (medical subject heading) descriptor: [Endoleak] explode all trees and with qualifier(s):
[Diagnosis – DI]
2. MeSH descriptor: [Endoleak] explode all trees
3. endoleak*:ti,ab,kw (Word variations have been searched)
4. (endovascular near/5 repair* near/5 abdominal):ti,ab,kw (Word variations have been searched)
5. #2 or #3 or #4
6. MeSH descriptor: [Ultrasonography] this term only
7. (duplex near/2 (ultrasound or ultrasono*))
8. MeSH descriptor: [Ultrasonography, Doppler, Duplex] this term only
9. (contrast enhanced near/2 (ultrasound or ultrasono*))
10. cdu or ceu:ti,ab,kw (Word variations have been searched)
11. MeSH descriptor: [Tomography, X-Ray Computed] this term only
12. MeSH descriptor: [Multidetector Computed Tomography] this term only
13. MeSH descriptor: [Endoleak] explode all trees and with qualifier(s): [Ultrasonography - US]
14. #5 and (#6 or #7 or #8 or #8 or #9 OT #10 or #11 or #12)
15. #1 or #13 or #14
16. MeSH descriptor: [Aortic Aneurysm, Abdominal] this term only
17. MeSH descriptor: [Endovascular Procedures] this term only
18. evar or (endovasc* near/5 repair*):ti,ab,kw (Word variations have been searched)
19. #16 and (#17 or #18)
20. MeSH descriptor: [Epidemiological Monitoring] explode all trees
21. (surveillance or monitor*):ti,ab,kw (Word variations have been searched)
22. #19 and (#20 or #21)
23. #15 or #22
Database
Scopus’ Articles-In-Press (www.scopus.com/).
Last date of search: 5 September 2016.
Search strategy
( TITLE-ABS-KEY ( endoleak* ) AND DOCTYPE ( ip ) ) OR ( TITLE-ABS-KEY ( abdominal aortic aneurysm* )
AND DOCTYPE ( ip ) ) ) AND ( TITLE-ABS-KEY ( surveillance OR monitor* OR ultraso* OR tomograph* )
AND DOCTYPE ( ip ) ).
Database
Clinical Trials (http://clinicaltrials.gov/ct/gui/c/r).
Date searched: 27 January 2016.
Search strategy
Abdominal Aortic Aneurysm And endoleak.
Database
EU Clinical Trials Register (www.clinicaltrialsregister.eu/).
Date searched: 27 January 2016.
Search strategy
Abdominal Aortic Aneurysm And endoleak.
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Database
The World Health Organization’s ICTRP (www.who.int/ictrp/en/).
Date searched: 27 January 2016.
Search strategy
Abdominal Aortic Aneurysm And endoleak.
Diagnostic reviews
Databases
EMBASE (1996 to week 13 2016), Ovid MEDLINE(R) without Revisions (1996 to week 3 2016),
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations (28 March 2016) Ovid multifile search
(https://shibboleth.ovid.com/).
Date searched: 29 March 2016.
Search strategy
1. Endoleak/di [Diagnosis]
2. endoleak/ or endoleak?.tw,kw.
3. evar.tw,kw.
4. (endovascular adj5 repair? adj5 abdominal).tw,kw.
5. or/2-4
6. Ultrasonography/ use medf
7. Echography/ use emef
8. (duplex adj2 (ultrasound or ultrasono$)).tw.
9. Ultrasonography, Doppler, Duplex/ use medf
10. Doppler echography/ use emef
11. (contrast enhanced adj2 (ultrasound or ultrasono$)).tw.
12. (cdu or ceu).tw,kw.
13. Tomography, X-Ray Computed/ use medf
14. Multidetector Computed Tomography/
15. Computer Tomography Scanner/ use emef
16. (computed adj3 tomograph$).tw.
17. Endoleak/us [Ultrasonography]
18. 5 and (6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16)
19. ‘sensitivity and specificity’/
20. roc curve/
21. receiver operating characteristic/ use emef
22. predictive value of tests/
23. diagnostic errors/ use emef
24. false positive reactions/ use medf
25. false negative reactions/ use medf
26. diagnostic accuracy/ use emef
27. diagnostic value/ use emef
28. du.fs. use medf
29. sensitivity.tw.
30. distinguish$.tw.
31. differentiat$.tw.
32. identif$.tw.
33. detect$.tw.
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34. diagnos$.tw.
35. (predictive adj4 value$).tw.
36. accura$.tw.
37. comparison.tw.
38. or/19-37
39. 18 and 38
40. 1 or 17 or 39
41. systematic$ review$.tw.
42. systematic review/ use emef
43. systematic review as topic/ use emef
44. Meta analysis as topic/
45. meta analysis/ use emef
46. meta analysis.tw,pt.
47. metanalysis.tw.
48. metaanalysis.tw.
49. meta synthesis.tw.
50. metasynthesis.tw
51. Meta regression.tw.
52. metaregression.tw.
53. (synthes$ adj3 (literature or evidence)).tw.
54. (systematic study or systematic studies).tw.
55. evidence based review.tw.
56. comprehensive review.tw.
57. or/41-56
58. review.pt,ti.
59. (medline or pubmed or cochrane or embase or cinahl or psyc?lit or psyc?info).ab.
60. (search adj3 (literature or database? or bibliographic or electronic or internet or computeri?ed)).ab.
61. included studies.ab.
62. (inclusion adj3 studies).ab.
63. ((inclusion or selection or predefined or predetermined) adj criteria).ab.
64. (assess$ adj3 (quality or validity)).ab.
65. (select$ adj3 (study or studies)).ab.
66. (data adj3 extract$).ab.
67. extracted data.ab.
68. (data adj2 abstracted).ab.
69. (data adj3 abstraction).ab.
70. or/59-69
71. 58 and 70
72. 57 or 71
73. (letter or editorial or comment).pt.
74. 72 not 73
75. 74 and 40
76. remove duplicates from 75 (36)
Databases
Database of Abstracts of Reviews of Effects and CRD (www.crd.york.ac.uk/CRDWeb/).
Date searched: 29 March 2016.
Search strategy
MeSH DESCRIPTOR Endoleak EXPLODE ALL TREES.
DOI: 10.3310/hta22720 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 72
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Brazzelli et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
99
Database
The Cochrane Library Issue 1 2016 [CDSR (www3.interscience.wiley.com/)].
Date searched: 29 March 2016.
Search strategy
1. MeSH descriptor: [Endoleak] explode all trees and with qualifier(s): [Diagnosis – DI]
2. MeSH descriptor: [Endoleak] explode all trees
3. endoleak*:ti,ab,kw (Word variations have been searched)
4. (endovascular near/5 repair* near/5 abdominal):ti,ab,kw (Word variations have been searched)
5. #2 or #3 or #4
6. MeSH descriptor: [Ultrasonography] this term only
7. (duplex near/2 (ultrasound or ultrasono*))
8. MeSH descriptor: [Ultrasonography, Doppler, Duplex] this term only
9. (contrast enhanced near/2 (ultrasound or ultrasono*))
10. cdu or ceu:ti,ab,kw (Word variations have been searched)
11. MeSH descriptor: [Tomography, X-Ray Computed] this term only
12. MeSH descriptor: [Multidetector Computed Tomography] this term only
13. MeSH descriptor: [Endoleak] explode all trees and with qualifier(s): [Ultrasonography - US]
14. #5 and (#6 or #7 or #8 or #8 or #9 OT #10 or #11 or #12)
15. #1 or #13 or #14
Cost-effectiveness
Databases
EMBASE (1996 to week 36 2016), Epub Ahead of Print, In-Process & Other Non-Indexed Citations,
Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) (1946 to 5 September 2016).
Last date of search: 5 September 2016.
Search strategy
1. exp ‘costs and cost analysis’/ use mesz
2. exp economic evaluation/ use emcz
3. economics/
4. health economics/ use emcz
5. exp health care cost/ use emcz
6. exp economics,hospital/ use mesz
7. exp economics,medical/ use mesz
8. economics,pharmaceutical/ use mesz
9. pharmacoeconomics/ use emcz
10. exp models, economic/ use mesz
11. exp decision theory/
12. monte carlo method/
13. markov chains/
14. exp technology assessment, biomedical/
15. (cost$ adj2 (effective$ or utilit$ or benefit$ or minimis$)).ab.
16. economics model$.tw.
17. (economic$ or pharmacoeconomic$).tw
18. (price or prices or pricing).tw.
19. budget$.tw.
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20. (value adj1 money).tw.
21. (expenditure$ not energy).tw.
22. markov$.tw.
23. monte carlo.tw.
24. (decision$ adj2 (tree? or analy$ or model$)).tw.
25. or/1-24
26. (metabolic adj cost).tw.
27. ((energy or oxygen) adj (cost or expenditure)).tw.
28. 25 not (26 or 27) (1521739)
29. (letter or editorial or note or comment).pt.
30. 28 not 29
31. exp animals/ not humans/ use mesz
32. (animal/ or nonhuman/) not exp human/ use emcz
33. 30 not (31 or 32)
34. Endoleak/di [Diagnosis]
35. endoleak/ or endoleak?.tw,kw
36. evar.tw,kw)
37. (endovascular adj5 repair? adj5 abdominal).tw,kw.
38. or/35-37
39. Ultrasonography/ use mesz
40. Echography/ use emcz
41. (duplex adj2 (ultrasound or ultrasono$)).tw.
42. Ultrasonography, Doppler, Duplex/ use mesz
43. Doppler echography/ use emcz
44. (contrast enhanced adj2 (ultrasound or ultrasono$)).tw.
45. (cdu or ceu).tw,kw.
46. Tomography, X-Ray Computed/ use mesz
47. Multidetector Computed Tomography/
48. Computer Tomography Scanner/ use emcz
49. (computed adj3 tomograph$).tw.
50. Endoleak/us [Ultrasonography]
51. 38 and (39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49)
52. 34 or 50 or 51
53. Aortic Aneurysm, Abdominal/ use mesz
54. Abdominal Aorta Aneurysm/ use emcz
55. endovascular procedures/ use mesz
56. endovascular surgery/ use emcz
57. evar.tw,kw.
58. (endovasc$ adj5 repair?).tw
59. (53 or 54) and (55 or 56 or 57 or 58)
60. 59 or endovascular aneurysm repair/
61. exp Epidemiological Monitoring/ use mesz
62. Patient monitoring/ use emcz
63. surveillance.tw,kw.
64. monitor$.tw,kw.
65. 60 and (61 or 62 or 63 or 64)
66. 52 or 65
67. 33 and 66
68. Aortic Aneurysm, Abdominal/ec use mesz
69. 67 or 68
70. remove duplicates from 69
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Databases
NHS Economics Evaluations Database.
Centre for Reviews and Dissemination.
Date of last search: 9 September 2016.
Search strategy
1. MeSH DESCRIPTOR Aortic Aneurysm, Abdominal IN NHSEED
2. MeSH DESCRIPTOR Endoleak IN NHSEED
3. (endoleak*) OR (evar) OR (repair*)
4. (surveillance) OR (monitor*)
5. #2 OR #3 OR #4
6. #1 AND #5
Database
Health Technology Assessment Database [Canadian (www.crd.york.ac.uk/PanHTA/HistoryPage.asp)].
Date of last search: 9 September 2016.
Search strategy
1. MeSH DESCRIPTOR Aortic Aneurysm, Abdominal EXPLODE ALL TREES IN PCHTA 9 Delete
2. MeSH DESCRIPTOR Endoleak EXPLODE ALL TREES IN HTA
3. #1 or #2
Database
Research Papers in Economics (http://repec.org/).
Date of last search: 9 September 2016.
Search strategy
Abdominal aortic aneurysm* or endoleak*.
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Appendix 2 Study eligibility and data extraction
forms
Full-text screening form
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Data extraction form
Reviewer
Date
Administration details
Study ID
Publication status
Study IDs of linked reports
Study aim
Study details
Study design
Setting
Country
Number of centres
Sample identification
Method of recruitment
Allocation method
Study dates
Duration of the study
Length of follow-up
Eligibility criteria
Inclusion criteria
Exclusion criteria
A
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w
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Interventions and comparators
Details of the intervention CDU CEU CDU and CEU
With plain
radiography
Without plain
radiography
Other
(describe)
Frequency of imaging
(frequency and duration – e.g.
imaging at 1 month, 6 months,
12 months post EVAR)
Details of the operator, including
experience level if reported
Details of the comparator CTA multiphase CTA single phase CDU/CEU (specify)
With plain
radiography
Without plain
radiography
Other
(describe)
Frequency of imaging
(frequency and duration – e.g.
imaging at 1 month, 6 months,
12 months post EVAR)
Details of the operator, including
experience level if reported
Outcomes
Primary outcomes reported
Secondary outcomes reported
Adverse events reported
Other information
Additional information on
intervention and comparators
Data analysis – did the analysis
adjust for any confounding
factors [if yes, please state the
confounding factor(s)]? How
was the confounding factor
categorised?
Source of
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Number of participants, n (%) Total Intervention Comparator
Enrolled
Randomised
Received treatment
Post-randomisation exclusions
Discontinued study
Lost to follow-up
Analysed
Reasons for dropouts
Pre randomisation
Post randomisation
Participant baseline
characteristics Intervention n N Comparator n N Total n N
Age
Male/female (%)
Aneurysm type
Abdominal aortic (AAA)
Iliac aortic
Infrarenal
Ruptured AAA
Other (specify)
BMI
A
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Renal insufficiency
None
Mild
Moderate
Severe
End stage
Hypertension
Coronary heart disease
Ischaemic heart disease
Cerebrovascular disease
Hyperlipidaemia
Diabetes
Smoking
Aneurysm diameter/sac size (mm)
Time since EVAR (months)
Type of endograph
Insert name of graft
Insert name of graft
Insert name of graft
Insert name of graft
Additional information
Clinical outcomes
Time
point
Specify measures
(mean %, median %,
etc.) and variance
(SD, range, 95% CI,
etc.)
Intervention Control
Difference
between groups
(include type of
difference) p-value
Additional
informationValues Variance n Values Variance n
Type of reintervention
Type of secondary
intervention
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Mortality
Time
point
Specify measures
(mean %, median %,
etc.) and variance
(SD, range, 95% CI,
etc.)
Intervention Control
Difference
between groups
(include type of
difference) p-value
Additional
informationValues Variance n Values Variance n
Adverse events (EVAR
related)
Time
point
Specify measures
(mean %, median %,
etc.) and variance
(SD, range, 95% CI,
etc.)
Intervention Control
Difference
between groups
(include type of
difference) p-value
Additional
informationValue Variance n Values Variance n
Type I endoleak –
attachment site
A (proximal)
B (distal)
C (iliac occluder)
Type II endoleak –
branch leak
A (simple – one
branch)
B (complex – two or
more branches)
Type III endoleak – graft
defect
A (junctional leak or
modular defect)
B (fabric disruption/
graft hole)
Type IV endoleak – fabric
porosity within 30 days
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Type V endoleak – endotension
A (no endoleak)
B (sealed endoleak)
C (type I or 3
endoleak discovered
at the time of open
redo surgery)
D (type II endoleak
discovered at the
time of open redo
surgery)
Graft migration
Graft kinking
Graft stenting
Limb outflow impairment
Limb occlusion
Aneurysm rupture
Aneurysm diameter/sac
size
BMI, body mass index; ID, identification.
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Appendix 3 Review Body for Interventional
Procedures tool for assessing the quality of
non-randomised studies
Checklist for the quality assessment of non-randomised studies
(comparative and cohort studies)
Items specific to comparative studies are in italic.
Assessor initial:
Date evaluated:
Study ID:
Criteria Yes No Unclear Comments
1. Were participants a representative sample selected from a relevant patient
population, e.g. randomly selected from those seeking for treatment despite of age,
duration of disease, primary or secondary disease and severity of disease?
2. Were the inclusion/exclusion criteria of participants clearly described?
3. Were participants entering the study at a similar point in their disease progression,
i.e. severity of disease?
4. Was selection of patients consecutive?
5. Was data collection undertaken prospectively?
6. Were the groups comparable on demographic characteristics and clinical features?
7. Was the intervention (and comparison) clearly defined?
8. Was the intervention undertaken by someone experienced at performing the
procedure?a
9. Were the staff, place, and facilities where the patients were treated appropriate for
performing the procedure? (e.g. access to back-up facilities in hospital or special clinic)
10. Were any of the important outcomes considered, i.e. on clinical effectiveness,
cost-effectiveness, or learning curves?
11. Were objective (valid and reliable) outcome measures used, including
satisfaction scale?
12. Was the assessment of main outcomes blind?
13. Was follow-up long enough (≥ 1 year) to detect important effects on outcomes
of interest?
14. Was information provided on non-respondents, dropouts?b
15. Were the withdrawals/dropouts having similar characteristics as those completed
the study and therefore unlikely to cause bias?c
16. Was length of follow-up similar between comparison groups?
continued
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Criteria Yes No Unclear Comments
17. Were the important prognostic factors identified, e.g. age, duration of disease,
disease severity?d
18. Were the analyses adjusted for confounding factors?
a ‘Yes’ if the practitioner received training on conducting the procedure before or conducted the same kind of procedure
before (i.e. no learning curve).
b ‘No’ if participants were from those whose follow-up records were available (retrospective).
c ‘Yes’ if no withdrawal/dropout; ‘No’ if dropout rate ≥ 30% or differential dropout (e.g. those having the most severe
disease died during follow-up, but the death was not because of treatment; no description of those lost).
d ‘Yes’ if two or more than two factors were identified.
The same form was adapted to assess the quality of the case series after taking out questions 6, 12, 16
and 18.
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Appendix 4 Included primary studies
Clinical effectiveness
Comparative
Chisci E, Setacci F, Iacoponi F, de Donato G, Cappelli A, Setacci C. Surveillance imaging modality does not
affect detection rate of asymptomatic secondary interventions following EVAR. Eur J Vascular Endovasc Surg
2012;43:276–81.
Nyheim T, Staxrud LE, Rosen L, Slagsvold CE, Sandbaek G, Jørgensen JJ. Review of postoperative CT and
ultrasound for endovascular aneurysm repair using Talent stent graft: can we simplify the surveillance
protocol and reduce the number of CT scans? Acta Radiol 2013;54:54–8.
Cohort
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in patients undergoing endovascular abdominal aortic aneurysm repair. J Vasc Surg 2014;60:1125–31.
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TABLE 28 Individual study-level quality assessment of the non-randomised comparative studies
Study, first
author (year
of publication)
Representative
sample
Inclusion/
exclusion
criteria clearly
defined
Participants at
a similar point
in disease
progression
Selection of
patients was
consecutive
Data
collection
undertaken
prospectively
Groups
comparable
Intervention(s)
clearly defined
Intervention
delivered by
an experienced
person
Chisci et al. (2012)66 1 1 2 1 2 1 1 1
Nyheim et al. (2013)67 0 2 0 0 1 0 1 0
ID, identification.
0= unclear; 1= yes; 2= no/not reported.
TABLE 29 Individual study-level quality assessment of the single cohort studiesa
Study, first author
(year of publication) Representative sample
Inclusion/exclusion
criteria clearly
defined
Participants at a
similar point in
disease progression
Selection of
patients was
consecutive
Data collection
undertaken
prospectively
Bisdas et al. (2014)68 1 2 0 1 1
Blom et al. (2012)69 0 2 0 0 1
Bush et al. (2001)70 0 0 2 1 2
Carroccio et al. (2002)71 0 0 0 0 1
Chaer et al. (2009)40 0 1 1 0 1
Cochennec et al. (2007)72 0 2 0 0 1
Collins et al. (2007)73 0 2 0 0 2
Donas et al. (2016)74 0 1 1 0 1
Fossaceca et al. (2013)75 0 1 1 0 2
Freyrie et al. (2014)76 1 1 0 0 1
Ghotbi et al. (2010)77 2 1 1 1 0
Harrison et al. (2011)41 0 1 0 0 2
Karthikesalingam et al. (2012)78 1 1 0 1 2
Köcher et al. (2004)79 1 1 1 0 0
Kray et al. (2015)80 1 2 1 0 2
Meier et al. (2001)81 0 1 0 0 1
Oshin et al. (2010)82 1 2 0 0 2
Parlani et al. (2002)83 0 1 0 1 1
Schunn et al. (2000)84 1 1 1 2 1
Soler et al. (2015)85 2 1 2 1 2
Stella et al. (2009)86 1 1 0 0 1
Wolf et al. (2002)87 0 1 0 1 0
ID, identification.
0= unclear; 1= yes; 2= no/not reported.
a Only ReBIP items suitable for the assessment of observational cohort studies are tabulated; ReBIP items applicable to comparative studies are not presented
in the table.
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Intervention
delivered
in an
appropriate
setting
Important
outcomes
considered
Objective
outcome
measures
used
Assessment
of main
outcomes
blind
Follow-up
long
enough
Information on
non-respondents,
dropouts
Withdrawals
likely to
introduce
bias
Length of
follow-up
similar between
comparison
groups
Important
prognostic
factors
identified
Analyses
adjusted for
confounding
factors
1 1 1 0 1 1 0 2 1 0
1 1 0 0 1 2 0 0 1 0
Intervention(s)
clearly defined
Intervention
delivered by
an experienced
person
Intervention
delivered in an
appropriate
setting
Important
outcomes
considered
Objective
outcome
measures
used
Follow-up
long enough
Information on
non-respondents,
dropouts
Withdrawals
likely to
introduce bias
Important
prognostic
factors
identified
1 0 0 1 0 1 1 1 1
1 1 1 1 1 1 1 1 2
1 0 1 1 0 1 2 1 1
1 0 0 1 0 1 2 0 2
1 1 1 1 2 1 2 0 1
1 0 1 1 0 1 2 0 1
1 1 1 1 0 1 2 0 2
1 0 1 1 0 1 2 0 1
1 0 1 1 0 1 2 0 1
1 1 1 1 1 1 1 0 1
1 0 1 1 1 1 2 0 1
1 0 1 1 1 1 2 0 1
1 0 1 1 1 1 2 0 1
1 1 1 0 1 0 2 0 1
1 0 1 1 0 1 1 0 1
1 0 1 1 1 1 2 0 1
1 0 1 1 1 1 2 0 1
1 0 1 1 1 1 2 0 1
1 1 1 1 1 1 1 0 1
1 0 1 1 1 1 1 0 1
1 0 1 1 1 1 2 0 1
1 0 1 1 1 1 1 1 1
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Appendix 7 Review-level quality assessment of
the diagnostic test performance systematic reviews
TABLE 30 Review-level quality assessment of the diagnostic test performance systematic reviews assessed using the
CRD criteria
Study, first author
(year of publication)
CRD criteria
Inclusion/
exclusion
criteria
Substantial
search effort
Validity
adequately
assessed
Sufficient details
of individual
studies
Primary
studies
summarised
Ashoke et al. (2005)127 1 1 1 1 1
Bevis and Cooper (2012)128 1 2 2 2 0
Cantisani et al. (2015)129 2 2 2 2 2
Chung et al. (2015)130 1 1 1 1 1
Karanikola et al. (2014)3 2 1 2 1 1
Karthikesalingam et al. (2012)132 1 1 1 1 1
Mirza et al. (2010)62 1 1 1 1 1
Sun (2006)133 1 2 0 1 0
ID, identification.
0= unclear; 1= yes; 2= no/not reported.
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TABLE 31 Review-level quality assessment of the diagnostic test performance systematic reviews assessed using the AMSTAR criteria
Study, first author
(year of publication)
AMSTAR criteria
A priori
design
Duplicate
selection and
extraction
Comprehensive
literature search
Grey
literature
included
List of included
and excluded
studies
Characteristics
of included
studies
Scientific quality
assessed and
documented
Scientific quality
included in
formulating
conclusions
Appropriate
methods to
combine
studies
Likelihood of
publication
bias assessed
Conflict of
interest
included
Ashoke et al. (2005)127 1 1 1 1 2 1 2 0 1 2 2
Bevis and Cooper (2012)128 0 0 1 2 2 2 2 2 2 2 2
Cantisani et al. (2015)129 2 0 0 2 2 2 2 2 2 2 2
Chung et al. (2015)130 2 0 1 2 1 1 1 2 1 2 1
Karanikola et al. (2014)3 0 0 1 2 2 1 2 0 3 2 2
Karthikesalingam et al.
(2012)132
2 0 1 2 2 1 1 1 1 2 1
Mirza et al. (2010)62 2 1 1 2 2 1 1 1 1 1 1
Sun (2006)133 2 2 2 2 1 1 2 2 1 2 1
ID, identification.
0= unclear; 1= yes; 2= no/not reported; 3= not applicable.
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Appendix 8 Characteristics of the included
primary studies
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TABLE 32 Characteristics of the included primary studies
Study, first
author (year
of publication) Type of study Setting
Number of
centres
Geographic
location
Study duration,
mean/median
follow-up SD
(range unless
otherwise noted)
Total
analysed Age (years)
Number
of male
participants Frequency
Imaging modality
sequence
Aneurysm type
(%)
Aneurysm
diameter
(mm) Type of endograph
Comparative cohort studies
Chisci et al.
(2012)66
Retrospective Tertiary referral
centre
1 Italy Protocol I: 4 years
Protocol II: 3.5
years
Protocol II:
376
Protocol II:
341
Protocol I:
76.8 (±8.7,
range 67–90)
Protocol II:
77.7 (±7.0,
range 66–92)
p= 0.239
Protocol 1:
327 (87%)
Protocol II:
286 (84%)
p= 0.285
Protocol I:
1 month post
operation, every 6
months thereafter
Protocol I: CTA,
CDU and clinical
examination
Iliac artery
aneurysm:
l Protocol I:
86 (23)
l Protocol II:
61 (18)
p= 0.119
Bilateral iliac
aneurysm:
l Protocol I:
41 (11)
l Protocol II:
48 (14)
p= 0.241
Protocol I:
64 (+6)
Protocol II:
61 (+8)
p<0.001
Talent (Medtronic,
Santa Rosa, CA, USA):
l Protocol I:
242 (64%)
l Protocol II:
144 (43%)
p<0.0001
Zenith:
l Protocol I:
51 (13%)
l Protocol II:
16 (5%)
p<0.0001
Endurant:
l Protocol I:
168 (49%)
Anaconda:
l Protocol I:
17 (4%)
l Protocol II:
4 (1%)
p<0.05
Excluder (W L Gore &
Associates, Inc.,
Flagstaff, AZ, USA):
l Protocol I:
64 (19%)
l Protocol II:
9 (2%)
p<0.0001
Protocol I mean:
1148 days
(1–3204 days)
Protocol II mean:
942 days
(1–1512 days)
Protocol II:
1 month post
operation
Protocol II: CTA,
CDU and plain
radiography, clinical
examination
Every 6 months CDU, plain
radiography and
clinical examination
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Study, first
author (year
of publication) Type of study Setting
Number of
centres
Geographic
location
Study duration,
mean/median
follow-up SD
(range unless
otherwise noted)
Total
analysed Age (years)
Number
of male
participants Frequency
Imaging modality
sequence
Aneurysm type
(%)
Aneurysm
diameter
(mm) Type of endograph
Nyheim et al.
(2013)67
Prospective Vascular centre 1 Norway 5 years 56 74 (range
55–87)
50 (89.3%) 6–8 weeks CDU and plain
radiography
AAA: 56 (100) Median 60
(range 51–80)
Talent stent–graft
Median:
41.5 months
(2–94 months)
1 year CTA, CDU and plain
radiography
Poor visibility,
presence of
endoleak, AAA
diameter increase
on ultrasound or
migration on PFA
CTA
Non-comparative cohort studies
Bisdas et al.
(2014)68
Prospective Outpatient
department of
hospital and
university clinic
2 Germany 3 years 273 73 (±9) 246 (90%) Before discharge,
after 1 year,
annually up to
5 years
CTA Ruptured AAA (2)
Symptomatic
aneurysms: (7)
AAA (91)
Maximal AAA:
57 (range
40–87)
Endurant stent–graft
(100%)
Median:
42 months (IQR
30.7–50.7 months)
At 6 months CDU
Blom et al.
(2012)69
Prospective Hospital 1 USA 12 years 248 NR NR 1 week,
6 months and
annually
Duplex ultrasound AAA (100) NR Ancure [(Guidant
Cardiac and Vascular
Division, Menlo Park,
CA, USA) 4.8%]
AneuRx [(AneuRx, Inc.,
Sunnyvale, CA, USA)
41.5%]
Excluder (16.5%)
Endologix [(Endologix
Inc., Irvine, CA, USA)
5.2%] Zenith (31.9%)
Mean:
22.3 months
(1–123 months)
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TABLE 32 Characteristics of the included primary studies (continued )
Study, first
author (year
of publication) Type of study Setting
Number of
centres
Geographic
location
Study duration,
mean/median
follow-up SD
(range unless
otherwise noted)
Total
analysed Age (years)
Number
of male
participants Frequency
Imaging modality
sequence
Aneurysm type
(%)
Aneurysm
diameter
(mm) Type of endograph
Bush et al.
(2001)70
Retrospective University hospital 1 USA 5.5 years 104
High-risk
group: 51
Low-risk
group: 53
High-risk
group: 72.2
(±7.2)
Low-risk
group: 73.8
(±7.1)
NR 1 month CEU Infrarenal AAA:
(100)
High-risk
group: 58.2
(± 11.3)
Low-risk
group: 52.2
(± 11.5)
EVT/Guidant endograft
(Guidant Corp, Menlo
Park, CA, USA) 71
(68.3%)
AneuRx: 16 (15.4%)
Excluder: 17 (16.3%)
High-risk group:
Mean 14.6±
12.4 months
Low-risk group:
Mean 17.7 ±15.0
months
6 months,
12 months,
annually thereafter
CTA, CDU and plain
radiography
Carroccio et al.
(2002)71
Prospective Medical centre 1 USA 4 years 351 NR NR 1, 3, 6,
12 months,
annually thereafter
Duplex scan and
3-mm slice CTA
Infrarenal aortic
aneurysms: (100)
NR AneuRx: 35 (10.0%)
Ancure: 8 (2.3%)
Gore (W L Gore &
Associates, Sunnyvale,
CA, USA) 25 (7.1%)
Talent: 255 (72.6%)
TERAMed (TERAMed
Inc., Miami, FL, USA):
10 (2.8%)
Vanguard (Boston
Scientific, Marlborough,
MA, USA): 18 (5.1%)
Mean:
20±9 months
(2–54 months)
Chaer et al.
(2009)40
Prospective University medical
centre
1 USA 3 years 184 73.9
(±7.1, range
52.6–96.4)
159 (86.4%) Annually CDU AAA: (100) 54 (±8) Ancure: 76 (41.3%)
Zenith: 58 (31.5%)
Excluder: 39 (21.2%)
AneuRx: 7 (3.8%)
Lifepath (Edwards
Lifesciences, Irvine,
CA, USA): 4 (2.2%)
Mean:
24±13 months
(12–48 months)
1 month and
12 months, and
only selectively
thereafter
Helical CT
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Study, first
author (year
of publication) Type of study Setting
Number of
centres
Geographic
location
Study duration,
mean/median
follow-up SD
(range unless
otherwise noted)
Total
analysed Age (years)
Number
of male
participants Frequency
Imaging modality
sequence
Aneurysm type
(%)
Aneurysm
diameter
(mm) Type of endograph
Cochennec et al.
(2007)72
Prospective Department of
vascular surgery at
hospital
1 France 10 years 460 72.3 (±8,
range 47–88)
435 (94.6%) 1, 6 and 12 months,
annually thereafter
Plain radiography,
CDU and CTA
Bifurcated: 369
Aortomonoiliac: 91
NR Zenith: 310
Vanguard: 60
Gore: 31
AneuRx: 21
Stenford (Stenford
Groupe, Valendos S.A.,
Nanterre, France): 9
Stentor (MinTec, La
Ciotat, France): 8
Talent (World Medical
Inc., Medtronic Vascular,
Sunrise, FL, USA): 7
Mean:
28 months,
median:
23.4 months
Clinical symptoms
suggesting
endograft
thrombosis
CT scans or
angiography and
duplex scan
Collins et al.
(2007)73
Retrospective University
department of
surgery
1 USA 5 years (NR) 160 NR NR Every 6 months,
first study within
1 month of EVAR
Ultrasound AAA: (100) NR Ancure: 82 (51.3%)
AneuRx: 63 (39.4%)
Other: 15 (9.4%)Select cases,
enlargement of the
AAA sac and
evidence of an
endoleak
CT
Dominguez et al.
(2010)88 (abstract
only)
Unclear NR NR USA 8 years (NR) 1378 NR EVAR with
Palmaz (Cordis
Corp, Miami
Lakes, Fl, USA)
stent: 90
(61.6%)
EVAR only:
969 (78.7%)
1 and 6 months,
and every
12 months
thereafter
CTA and duplex
ultrasound
AAA: (100) NR NR
Donas et al.
(2016)74
Prospective Vascular centres 2 Europe 4 years 128 76.6 (±7.7) 113 (88.3%) 6 and 12 months,
annually thereafter
CTA AAA: (100) 64.8 (±14.6,
range 48–135)
Endurant stent–graft
(100%)
Mean:
24.6 months±
SD 17.4 months
(0–61 months)
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TABLE 32 Characteristics of the included primary studies (continued )
Study, first
author (year
of publication) Type of study Setting
Number of
centres
Geographic
location
Study duration,
mean/median
follow-up SD
(range unless
otherwise noted)
Total
analysed Age (years)
Number
of male
participants Frequency
Imaging modality
sequence
Aneurysm type
(%)
Aneurysm
diameter
(mm) Type of endograph
Fargion et al.
(2016)89
(abstract only)
Retrospective University hospital 1 Italy 16 years 289 NR NR Within 3 months
post operation
CTA and duplex
ultrasound
AAA: (100) NR NR
Median:
30 months
(1–168 months)
Every 6 months Duplex ultrasound
Fossaceca et al.
(2013)75
Retrospective Hospital 1 Italy 6 years 222 76 (range
54–97)
213 (95.9%) 1 month,
12 months
CT (contrast
enhanced)
Urgent cases:
Ruptured AAA –
34 (15.3)
Symptomatic AAA
– 20 (9.0%)
Elective cases –
168 (75.7)
59 (range
40–100)
Excluder: 85 (38.3%)
Zenith: 74 (33.3%)
Endurant: 35 (15.8%)
Evita (JOTECH GmbH,
Hechingen, Germany):
24 (10.8%)
Talent: 2 (0.9%0
LeMaitre (LeMaitre
Vascular, Inc.,
Burlington, MA, USA):
1 (0.5%)
Aorfix (Lombard
Medical, Didcot, UK):
1 (0.5%)
Mean:
29.6 months
6 months CEU
Annually thereafter Either CT
angiography or CEU
Freyrie et al.
(2010)92
[secondary study
to Freyrie
et al. (2014)76]
Prospective Hospital NR Italy 2 years 127 73.5±6.9
(range 55–89)
120 (94.4%) 1, 3, 6 and
12 months
and annually
thereafter
CTA, CEU and CDU AAA (100) Group A:
58.9± 12.8
Group B:
55.0± 8.2
Anaconda: 127
(100%)
Freyrie et al.
(2014)76
Prospective Hospital 1 Italy 3 years 177 73.3±7.4
(range 47–89)
167 (94.4%) Discharge, 6 and
12 months, yearly
thereafter
CDU NR 55± 9.7 (range
45–99)
Anaconda: 177
(100%)
Mean: 32.9±
23.3 months
(1–77 months)
1 and 12 months CTA
Ghotbi et al.
(2010)77
Unclear Clinic 1 Germany 4 years 100 74.1 (range
44–91)
91 (91%) 1, 3 and
12 months,
annually thereafter
CDU Asymptomatic
aneurysm: 91 (91)
Symptomatic
aneurysm: 9 (9)
56.1 (range
45–70)
Excluder: 100 (100%)
Mean: 20 months 3 and 12 months CTA
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Study, first
author (year
of publication) Type of study Setting
Number of
centres
Geographic
location
Study duration,
mean/median
follow-up SD
(range unless
otherwise noted)
Total
analysed Age (years)
Number
of male
participants Frequency
Imaging modality
sequence
Aneurysm type
(%)
Aneurysm
diameter
(mm) Type of endograph
Harrison et al.
(2011)41
Retrospective Tertiary referral
centre
1 UK 4 years 194 76 (range
47–93)
165 (85%) 1 month Abdominal
radiography, CDU
and CTA
NR NR NR
12 months after
EVAR, annually
thereafter
Abdominal
radiography and
CDU
Median:
36 months
(12–57 months)
Inadequate DUS,
abnormality
identified
CTA
Karthikesalingam
et al. (2012)78
Retrospective NR NR UK 6 years 478 75±7 425 (88.9%) 1.5, 3, 6, 9, 12 and
18 months and
annually thereafter
CDU AAA: (100) 65± 13 Zenith: 295 (61.7%)
Talent: 98 (20.5%)
Other: 85 (17.8%)
Median:
43 months
(1–92 months)
Köcher et al.
(2004)79
Unclear NR NR Czech
Republic
6 years 120 70.7 (range
49–89)
102 (85.0%) 3, 6 and
12 months,
annually thereafter
CTA and CDU AAA: 120 (100) <50:
18 (15%)
50–65:
73 (61%)
>65:
29 (24%)
Ella stent–graft (Ella-CS
Hradec Králové, Czech
Republic): 120 (100%)Mean:
20.7 months
(2–60 months)
Type I AAA:
6 (5)
Type II AAA:
105 (87)
Type III AAA:
9 (8)
Asymptomatic:
104 (86.6)
Symptomatic:
16 (13.4)
Kray et al.
(2015)80
Retrospective Medical centre 1 USA 4 years 191 74.4±7.4
(range 53–92)
161 (84.3%) 1, 6 and
12 months
CTA and CDU AAA: 191 (100) NR Zenith, Excluder and
AneuRx
Maximum
follow-up of
12 months
Mazzaccaro et al.
[201190 (abstract
only)]
Unclear NR NR NR 12 years 391 73 (range
49–91)
363 (92.8%) 2 months,
12 months
and annually
thereafter
CDU AAA: 391 (100) NR NR
Median:
68 months
(1–144 months)
6 months CEU
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TABLE 32 Characteristics of the included primary studies (continued )
Study, first
author (year
of publication) Type of study Setting
Number of
centres
Geographic
location
Study duration,
mean/median
follow-up SD
(range unless
otherwise noted)
Total
analysed Age (years)
Number
of male
participants Frequency
Imaging modality
sequence
Aneurysm type
(%)
Aneurysm
diameter
(mm) Type of endograph
Meier et al.
(2001)81
Prospective Clinic 33 USA 5.5 years 476 NR NR 3, 6 and
12 months,
annually thereafter
CTA, CDU and plain
radiography
AAA: 476 (100) Major axis
diameter:
57.5± 9.9
(range
34.8–92.7)
Minor axis
diameter:
51.6± 9.2
(range
30.9–86.4)
Ancure endograft:
476 (100%)
Mean:
23.2 months
(2.0–78.8)
Oshin et al.
(2010)82
Retrospective NR NR UK 8 years 295 75 (±7) 261 (88.5%) 1 month, annually
thereafter
Abdominal
radiograph, CEU
and CDU
AAA: 295 (100) NR Zenith: 295 (100%)
Maximum
follow-up:
27 months (median
24 months)
Duplex ultrasound
and radiography
(CT selectively)
Parlani et al.
(2002)83
Prospective NR 1 Italy 4 years 336 Group A: 70
Group B: 71
p=NS
Group A: 260
(94%)
Group B:
56 (95%)
p=NS
1 month, annually
thereafter
CTA Concomitant
iliac aneurysm:
40 (11.9)
Bilateral CIA
aneurysm:
19 (5.7)
AAA: 277 (82.4)
Group A: 50
(IQR 45± 55;
range 40±86)
Group B: 52
(IQR 48±56;
range 40±74)
p=NS
AneuRx: 228 (68%)
Anaconda: 27 (8%)
Zenith: 2 (0.6%)
Excluder Gore-Tex
(W L Gore & Associates,
Inc., Flagstaff, AZ,
USA): 29 (9%)
Endologix: 39 (12%)
Mean: 14 months
(IQR 7–27 months;
range
1–46 months)
1, 6 and
12 months,
every 6 months
thereafter
Clinical evaluation,
abdominal
radiography and
CDU
Schunn et al.
(2000)84
Prospective Tertiary care NR Germany 3 years 190 68.7 (range
40–87)
176 (92.6%) 3–6 months CEU and CDU
(if possible),
abdominal
radiography
Intrarenal AAA:
190 (100)
NR Stentor system (August
1994 to May 1996):
190 (100%)
Vanguard aortic
stent–graft (May 1996
to July 1997):
190 (100%)
Mean:18 months,
range to 46
6 to 12 months,
1 CTA scan
per year in
subsequent year
CTA and/or CDU
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Study, first
author (year
of publication) Type of study Setting
Number of
centres
Geographic
location
Study duration,
mean/median
follow-up SD
(range unless
otherwise noted)
Total
analysed Age (years)
Number
of male
participants Frequency
Imaging modality
sequence
Aneurysm type
(%)
Aneurysm
diameter
(mm) Type of endograph
Soler et al.
(2015)85
Retrospective
analysis of
prospective
registry
Centre 1 France 11 years 197 74.8 190 (96.4%) 6, 12, 18 and
24 months,
annually thereafter
CTA, plain
abdominal
radiography, CDU
and a standard
blood test
Intrarenal AAA:
197 (100). From
2003, EVAR was
performed only
for the patients
who met the
high-risk criteria
defined by the
French Agency
for the Safety of
Health Products
56.7± 9.4
(range
42–110)
Zenith: 124 (62.9%)
PowerLink (Endologix,
Irvine, CA, USA):
35 (17.8%)
AneurX: 15 (7.6%)
Talent: 9 (4.6%)
Lifepath: 6 (3.0%)
Home-made: 6 (3.0%)
Excluder: 1 (0.5%)
Bard device (Bard,
Murray Hill, NJ, USA):
1 (0.5%)
Mean:
54.8 ±35.9 months
Stella et al.
(2009)86
Prospective Hospital 1 Italy 3 years 100 73.9 (range,
55–89)
94 (94%) 1, 3, 6 and
12 months,
annually thereafter
CTA, CDU and CEU AAA:
100 (100)
55.2 ±3.4
(range 45–99)
NR
Mean:
23.2 ±11.0 months
(1.4–38.6 months)
Wolf et al.
(2002)87
Unclear University hospital 1 USA 3.5 years 154 NR NR 6 months,
12 months,
annually thereafter
CTA, CDU,
abdominal
radiograph and
clinical examination
AAA:
154 (100)
57.9± 9.4
a
Bifurcated AneuRx
(Medtronic):
154 (100%)Mean: 15.8±
11.3 months
(1–48 months)
CIA, common iliac artery; ID, identification; NR, not reported; NS, nonsignificant; PFA, plain film abdomen radiography.
a Orthogonal diameter.
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Appendix 9 Type of clinical complications
reported in the included studies
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TABLE 33 Type of clinical complications reported in the included studies
Study, first author
(year of publication)
Endoleak Graft
Stenosis Thrombosis
Limb
occlusion
Aneurysm
rupture Infection IschaemiaType I Type II Type III Type IV Migration Kinking
Comparative cohort studies
Chisci et al. (2012)66 ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
Nyheim et al. (2013)67 ✗ ✗ ✗ ✗ ✗
Non-comparative cohort studies
Bisdas et al. (2014)68 ✗ ✗ ✗ ✗ ✗ ✗
Blom et al. (2012)69 ✗
Bush et al. (2001)70 ✗ ✗
Carrocio et al. (2002)71 ✗
Chaer et al. (2009)40 ✗ ✗ ✗
Cochennec et al. (2007)72 ✗ ✗ ✗ ✗
Collins et al. (2007)73 ✗ ✗
Dominguez et al. (2010)88
(abstract only)
✗ ✗ ✗
Donas et al. (2016)74 ✗ ✗ ✗ ✗ ✗ ✗
Fargion et al. (2016)89
(abstract only)
✗ ✗
Fossaceca et al. (2013)75 ✗ ✗ ✗ ✗ ✗
Freyrie et al. (2014)76 and
Freyrie et al. (2010)92
✗ ✗ ✗ ✗ ✗ ✗ ✗
Ghotbi et al. (2010)77 ✗ ✗ ✗ ✗
Harrison et al. (2011)41 ✗ ✗ ✗ ✗ ✗ ✗
Karthikesalingam et al. (2012)78 ✗ ✗
Köcher et al. (2004)79 ✗ ✗ ✗ ✗ ✗ ✗ ✗
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Study, first author
(year of publication)
Endoleak Graft
Stenosis Thrombosis
Limb
occlusion
Aneurysm
rupture Infection IschaemiaType I Type II Type III Type IV Migration Kinking
Kray et al. (2015)80 ✗ ✗
Mazzaccaro et al. (2011)90 ✗ ✗ ✗ ✗
Oshin et al. (2010)82 ✗ ✗
Parlani et al. (2002)83 ✗ ✗ ✗ ✗
Schunn et al. (2000)84 ✗ ✗ ✗
Soler et al. (2015)85 ✗ ✗ ✗ ✗ ✗ ✗ ✗
Stella et al. (2009)86 ✗ ✗ ✗ ✗
Wolf et al. (2002)87 ✗ ✗
ID, identification.
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Appendix 10 Endovascular abdominal aortic
aneurysm repair-related clinical complications
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TABLE 34 Endovascular AAA repair-related clinical complications
Study, first
author (year
of publication)
Time point
(follow-up if
time point not
reported)
Endoleak (specify subtypes, e.g. proximal, distal), n/N
Stenosis,
n/N
Thrombosis,
n/N
Aneurysm
rupture, n/N
Limb occlusion,
n/N
Infection,
n/N
Ischaemia,
n/N NotesType I Type II Type III Type IV
Comparative cohort studies
Chisci et al. (2012)66 Protocol I
< 30 days 2/376 Migration (> 1 cm): 2/376
Conversion to open repair:
3/376
> 30 days 5/376 57/376 3/376 2/376 10/376 0/376 (graft) 2/376
(bowel)
Protocol II
< 30 days 1/341 Migration (> 1 cm): 1/341
Conversion to open repair:
1/341
> 30 days 4/341 45/341 3/341 1/341 8/341 0/341 (graft) 0/341
(bowel)
Nyheim et al.
(2013)67
< 30 days 2/56 (4%) 9/56 (16%) 1/56 (2%) 2/56 Migration (> 10mm): 4/56
(7%) (> 30 days)
6 months 1/56 (2%)
Non-comparative cohort studies
Bisdas et al. (2014)68 NR [median
42 months (IQR
31–50 months)]
5/273 (1.8%) 4/273 (1.5%) 10/273a (3.7%) 1/273
[0.4 (groin)]
1/273
[0.4 (bowel
ischaemia)]
Renal artery occlusion:
1/273
False aneurysm: 1/273
Progression of aneurysmal
disease: 1/273
Distal popliteal artery
embolisation: 1/273
10 months 1/273 (0.4%)
Blom et al.
(2012)69
46 months (range
1 month–10 years)
0/248
Bush et al.
(2001)70
1 month 18/104 (17.3%) Endoleak detected by CTA
2 months 1/104
[1.0% (graft)]
26 months 2/104
[2.0% (hook
fracture)]
Data combined for two
groups
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Study, first
author (year
of publication)
Time point
(follow-up if
time point not
reported)
Endoleak (specify subtypes, e.g. proximal, distal), n/N
Stenosis,
n/N
Thrombosis,
n/N
Aneurysm
rupture, n/N
Limb occlusion,
n/N
Infection,
n/N
Ischaemia,
n/N NotesType I Type II Type III Type IV
Carroccio et al.
(2002)71
Mean time to
occlusion 5.2± 6.5
months (range 1
day to 23 months)
26/702 limbs
(3.7%)
13/26 (50%) identified
within 30 days
24/26 (92.3%) identified
within 1 year
Chaer et al.
(2009)40
NR [mean: 24±
13 months (range
12–48 months)]
2/184 (1.1%) 1/184 (0.5%) 0/184 0/184 (graft
occlusion)
Graft occlusion: 0; one
type II endoleak with
stable sac size could not
be identified on the CTA
obtained 3 months later
Cochennec et al.
(2007)72
During
follow-up (mean:
28 months)
33/460 (7.2%) 9/33 (27%)
Intraoperative 2/460 (0.4%) Graft migration: 9/460
(1.96)
Graft limb kink: 13/460
(2.82)
Within the first
week
9/460 (2.0%)
Within 1 month 14/460 (3.0%)
Within
6 months
23/460 (5.0%)
Within 3 years 30/460 (6.5%)
NR Symptomatic: 27 Acute ischaemia: (n= 9);
rest pain: (n= 8);
claudication (n= 10)
NR Asymptomatic: 4 Found on systematic
duplex scan
continued
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TABLE 34 Endovascular AAA repair-related clinical complications (continued )
Study, first
author (year
of publication)
Time point
(follow-up if
time point not
reported)
Endoleak (specify subtypes, e.g. proximal, distal), n/N
Stenosis,
n/N
Thrombosis,
n/N
Aneurysm
rupture, n/N
Limb occlusion,
n/N
Infection,
n/N
Ischaemia,
n/N NotesType I Type II Type III Type IV
Collins et al.
(2007)73
Ultrasound, NR
(scans performed
every 6 months
until AAA sac
resolved)
7/359 scans 26/359 Ultrasound scans: n= 359;
CTA scans: n= 35;
Combine types I and II:
l Ultrasound – 8/359
l CTA – 4/35
CTA discovered three
endoleaks that were not
seen with CDU. However,
these scans were
inadequate because of
additional factors
Of the 41 endoleaks
found on CDU, only 14
were found on CTA
CTA scans 9/35 9/35
Dominguez et al.
(2010)88
NR (follow-up NR) 106/1378
(7.7%)
329/1378
(23.9%)
29/1378
[2.1%
(ischaemic
colitis)]
Data combined for ‘EVAR
only’ and ‘EVAR with
Palmaz stent’
Stent–graft explant:
16/1378
Donas et al.
(2016)74
NR mean: 24.6
(SD 17.4 months;
range 0–61 months)
4/128 (3.1%) 2/128 (1.6%) 6/128 [4.7%
(high grade)]
8/128 (6.25%) 1/128 (0.8%)
27 months 1/128 (0.8%) Procedure-related late
aortic rupture caused by
the dislocation of iliac
limbs and type III
endoleaks; endotension,
n= 1
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Study, first
author (year
of publication)
Time point
(follow-up if
time point not
reported)
Endoleak (specify subtypes, e.g. proximal, distal), n/N
Stenosis,
n/N
Thrombosis,
n/N
Aneurysm
rupture, n/N
Limb occlusion,
n/N
Infection,
n/N
Ischaemia,
n/N NotesType I Type II Type III Type IV
Fargion et al.
(2016)89 (abstract
only)
NR [median:
30 months (range
1–168 months)]
9/289 38/289 Total number of
procedures, n= 289
Fossaceca et al.
(2013)75
> 30 days’
follow-up (mean
29.6 months)
4/222 (1.8%) 55/222
(24.8%)
1/222
(0.45%)
1/222
[0.45%
(stent–graft
explant)]
10/222 (4.5%) Type II endoleaks:
eight treated; 47 managed
conservatively with CEU
follow-up; thrombosis
in seven cases at the
1-month follow-up and
in three cases at the
6-month follow-up
Freyrie et al.
(2010)92
Second
postoperative day
1/127
6 months 1/127
9 months 2/127
1 year 1/127
NR 1/127
Freyrie et al.
(2014)76
NR [32.9±
23.3 months
(range
1–77 months)]
2/177 (1.1%) 23/177 (13%) 0/177 1/177 [0.6%
(iliac leg)]
10/177 [5.6%
(iliac leg, n= 8;
external iliac
artery, n= 1;
endograft,
n= 1)]
2/177 (1.1%) Endoleaks observed at
completion angiography
Renal artery occlusion:
2/177 (12-month follow-up)
Migration: 0/177
Ghotbi et al.
(2010)77
Intraoperative 3/100 (3%) 24/100 (24%) 0/100 (0%) Migration: 1/100 (after
2 years)
After 3 months 0/100 15/100 (15%)
After 12 months 0/100 7/100 (7%)
Harrison et al.
(2011)41
During 4 years’
follow-up [median:
36 months (range
12–57 months)]
1/194 (0.5%) 4/194 (2.1%) 1/194
(0.5%)
1/194 (0.5%) 2/194 (1.0%) Kinking: 1/194 (0.5)
Indeterminant endoleaks:
3/194 (1.54)
Karthikesalingam
et al. (2012)78
NR [median:
34 months (range
1–92 months)]
2/478 (0.4%) Kinking: 36/478 (7.5)
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TABLE 34 Endovascular AAA repair-related clinical complications (continued )
Study, first
author (year
of publication)
Time point
(follow-up if
time point not
reported)
Endoleak (specify subtypes, e.g. proximal, distal), n/N
Stenosis,
n/N
Thrombosis,
n/N
Aneurysm
rupture, n/N
Limb occlusion,
n/N
Infection,
n/N
Ischaemia,
n/N NotesType I Type II Type III Type IV
Köcher et al.
(2004)79
Early complications 10/120 (8.3%);
A: 7/120
(5.8%); B: 3/120
(2.5%)
1/120 (0.8%)
During follow-up
[mean 20.7 months
(range 2–60
months)]
9/120 (7.5%) 0/120 3/120 (2.5%) 0/120 (graft
infection)
Migration: 0/120
Kray et al.
(2015)80
1 month 17/191
(8.9%)
6 month 18/191
(9.4%)
0/191
Meier et al.
(2001)81
23.2 (range
2.0–78.8 months)
Mazzaccaro et al.
(2011)90
Long-term
[median:
68 months
(range 1–144
months)]
31/391 (7.9%) 3/391 (0.8%) 8/391 (2.0%) 5 (three
fatal)/391
(1.3%)
At 30 days 3/488 (0.6%)
Oshin et al.
(2010)82
27 months 11/583 limbs
(1.83%)
Stent–graft limb occlusions
Parlani et al.
(2002)83
At 30 days 4/366 (1.1%) 22/36 (6.0%) 1/366 (0.3%) 1/366 (0.3%) Data combined for two
groups
Schunn et al.
(2000)84
Intraoperatively
or at the first
postoperative
imaging study
32/190 (16.8%) 32/190
(16.8%)
30 days 10/190 (5.3)
Soler et al.
(2015)85
NR (mean: 54.8
± 35.9 months)
21/197 (10.6%) 29/197
(14.7%)
2/197 (1.0%) 1/197
(0.5%)
4/197 (2.0%) Limb occlusion
and stenosis:
29/197 (14.7%)
3/197 (1.5%) Data combined for two
groups
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Study, first
author (year
of publication)
Time point
(follow-up if
time point not
reported)
Endoleak (specify subtypes, e.g. proximal, distal), n/N
Stenosis,
n/N
Thrombosis,
n/N
Aneurysm
rupture, n/N
Limb occlusion,
n/N
Infection,
n/N
Ischaemia,
n/N NotesType I Type II Type III Type IV
Stella et al.
(2009)86
NR (mean:
23.3 months)
0/100 0/100
Postoperative
day 2
1/100 (1%)
3 months 26/100
4 months 1/100 (1%)
6 months 1/100 (1%) 4/200 (2%)
Wolf et al. (2002)87 Late [mean: 15.8
± 11.3 months
(range 1–48
months)]
1/154 (0.6%) 1/154 (0.6%)
ID, identification; NR, not reported.
a Iliac limb thrombosis.
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Appendix 11 Reintervention and type of
secondary procedures performed
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TABLE 35 Reintervention and type of secondary procedures performed
Study, first
author (year
of publication)
Time point
(follow-up if time
point not reported)
Total reintervention,
n/N
Type of reintervention
(specify open, endovascular,
revision, secondary/other)
Complication
needing
reintervention
Number of
patients receiving
reintervention
Health state
(A, B or C)
Comparative cohort studies
Chisci et al.
(2012)66
Protocol I Protocol II Protocol I Protocol II Secondary interventions, number of
interventions = 124 (Protocol I: n= 68;
Protocol II: n= 56)a
Protocol I Protocol II Protocol I Protocol II
< 30 days
(early secondary
intervention)
2/68 1/56 Type I endoleak 2 1
0/68 1/56 Type III endoleak 0 1
3/68 2/56 Limb occlusion 3 2
2/68 0/56 Limb ischaemia 2 0
1/68 1/56 Stent–graft limb
kink
1 1
1/68 0/56 Bowel ischaemia 1 0
8/68 5/56 Access site-related
problems
8 5
1/68 0/56 Blue toe syndrome 1 0
0/68 1/56 Renal infarction 0 1
> 30 days
(late secondary
intervention)
5/68 4/56 Type I endoleak 5 4
21/68 17/56 Type II endoleak 21 17
1/68 1/56 Impending rupture,
type II endoleak
1 1
3/68 2/56 Type III endoleak 3 2
2/68 4/56 Limb occlusion 2 4
3/68 2/56 Limb ischaemia 3 2
5/68 10/56 Stent–graft limb
kink
5 10
2/68 1/56 Rupture 2 1
1/68 0/56 Bowel ischaemia 1 0
5/68 4/56 Access site-related
problems
5 4
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Study, first
author (year
of publication)
Time point
(follow-up if time
point not reported)
Total reintervention,
n/N
Type of reintervention
(specify open, endovascular,
revision, secondary/other)
Complication
needing
reintervention
Number of
patients receiving
reintervention
Health state
(A, B or C)
Nyheim 201367 > 30 days 14/56 (25%) patients Secondary interventions Endoleaks 7
Endotension 5
Migration 2
Non-comparative cohort studies
Bisdas et al.
(2014)68
NR [median
42 months (IQR
31–50 months)]
26/273 (9.5%)
patients
Explanation of the endograft and open
repair (open)
Type Ia endoleak 1 A (1)
NR Proximal cuff (NR) Type Ia endoleak 1 A (1)
NR Chimney endografting and use of Onyx
(Endovascular Inc., Plymouth, MN, USA)
(endovascular)
Type Ia endoleak 1 A (1)
NR Iliac side branch device (NR) Type Ib endoleak
and progression
of aneurysmal
disease distal
2 A (1)
NR Embolisation of the inferior mesentric
artery (NR)
Type II endoleak 3 A (2)
NR Open repair (open) Type II endoleak 1 A (2)
10 months Implantation of an additional endurant
limb (endovascular)
Type III endoleak 1 A (1)
NR Iliac-to-renal bypass [no dialysis (NR)] Renal artery
occlusion
1 A (1)
NR Thrombectomy and stenting (NR) Limb occlusion 6 A (1/2)
NR Crossover bypass (NR) Limb occlusion 4 A (1/2)
NR Hemicolectomy (NR) Bowel ischaemia 1 A (1)
NR Overstitch of the common femoral artery
(NR)
False aneurysm 1 A (1)
continued
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TABLE 35 Reintervention and type of secondary procedures performed (continued )
Study, first
author (year
of publication)
Time point
(follow-up if time
point not reported)
Total reintervention,
n/N
Type of reintervention
(specify open, endovascular,
revision, secondary/other)
Complication
needing
reintervention
Number of
patients receiving
reintervention
Health state
(A, B or C)
NR Thrombectomy, distal extension of the
iliac limb with Advanta V12 stent–graft
(Atrium Europe, Mijdrecht, the
Netherlands) (NR)
Distal popliteal
artery
embolisation
1 A (1)
NR Vacuum-assisted closure device (NR) Groin infection 1 Not a surveillance
issue
NR Early reintervention (< 1 year) (NR) NR 13 Inadequate
information
NR Late secondary procedures
[> 4 years (NR)]
NR 4b Inadequate
information
Blom et al.
(2012)69
At mean follow-up
[46 months (range,
1 month–10 years)]
12/496 limbs (2.4%)
required intervention
in 248 patients
NR NR NR Inadequate
information
Bush et al.
(2001)70
2 months 3/104 (2.9%) patients Late conversion (NR) Graft infection 1 A (1/2)
26 months Late conversion (NR) Hook fracture 2 A (1/2)
Carroccio et al.
(2002)71
NR [mean: 20±
9 months (range
2–54 months)]
26/702 limbs (3.7%)
in 351 patients
Thrombolysis and stent [endovascular
(NR)]
Limb occlusion 2 A (1)
Axillary femoral bypass (NR) 1 A (1/2)
Femorofemoral bypass (NR) 13 A (1/2)
Axillary bifemoral bypass (NR) 2 A (1/2)
Observation (NR) 8
cChaer et al.
(2009)40
NR [mean: 24±
13 months (range
12–48 months)]
2/184 (1.1%) patients Limb extension (secondary intervention) Type Ib endoleak 2 A (1/2)
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Study, first
author (year
of publication)
Time point
(follow-up if time
point not reported)
Total reintervention,
n/N
Type of reintervention
(specify open, endovascular,
revision, secondary/other)
Complication
needing
reintervention
Number of
patients receiving
reintervention
Health state
(A, B or C)
Cochennec et al.
(2007)72
NR (mean: 28 months;
median: 23.4 months)
33/460 (7.2%)
patients
Thrombectomy and stent (endovascular) Limb occlusion 3 A (1/2)
NR Thrombolysis and stent (endovascular) NR 6 A (1)
NR Femorofemoral bypass (NR) NR 19 A (1/2)
NR Axillofemoral bypass (NR) NR 3 A (1/2)
NR Conservative (NR) NR 2 B
Collins et al.
(2007)73
NR (follow-up NR) 33/359 (9.2%)
procedures
NR Type I endoleak 7 A1
NR NR Type II endoleak 26 A2
Dominguez et al.
(2010)88 (abstract)
NR (follow-up NR) 273/1378 (19.8%)
patients
Secondary intervention (NR) NR NR Inadequate
information
Donas et al.
(2016)74
NR [24.6±
SD 17.4 months
(range 0–61 months)]
20/128 (15.6%)
patients
Endovascular management (NR) High-grade
stenosis of renal
chimney
6 Not a complication of
standard EVAR
2 months Endovascular management (NR) Chimney graft
occlusion
(majority of the
occlusions were
identified during
the first
2 months)
4 Not a complication of
standard EVAR
45 days post
operation
Ileorenal extra-anatomic bypass (NR) NR 1 A1
NR Conservative treatment (NR) NR 1 B
NR Surgical ligation of the aneurysm sac (NR) Endotension 1 A2
2.5 and 4 years Transformation of single to multiple
chimneys and tube placement (NR)
Type Ia endoleak 2 A1
NR Distal iliac limb extension (NR) Type Ib endoleak 1 A1
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TABLE 35 Reintervention and type of secondary procedures performed (continued )
Study, first
author (year
of publication)
Time point
(follow-up if time
point not reported)
Total reintervention,
n/N
Type of reintervention
(specify open, endovascular,
revision, secondary/other)
Complication
needing
reintervention
Number of
patients receiving
reintervention
Health state
(A, B or C)
NR Surgical conversion (NR) Type Ib endoleak
and infection
1 A (1/2)
27 months Iliac limb placement (NR) Type III endoleak 2 A1
NR Endovascular management (NR) Inadvertent
coverage of the
superior mesentric
artery
1 Not a surveillance
issue
Fargion et al.
(2016)89 (abstract
only)
NR [median:
30 months (range
1–168 months)]
47/289 (16.3%)
procedures
Reintervention (type NR) Type II endoleak
with significant
sac enlargement
38 A2
Up to 3 months NR NR 17 Inadequate
information
> 3 months NR NR 21 Inadequate
information
NR Reintervention, as type I developed after
reintervention owing to type II endoleak
(NR)
Type I endoleak 9 A1
Up to 3 months NR NR 5 Inadequate
information
More than 3 months NR NR 4 Inadequate
information
Fossaceca et al.
(2013)75
NR (mean:
29.6 months)
24/222 (10.8%)
patients
Fibrinolysis (NR) Thrombosis 10 A (1)
Iliac extension (NR) Type Ib endoleak 2 A (1)
Cuff (NR) Type Ia and III
endoleaks
3 A (1)
Thrombin injections (NR) Type II endoleak 8 A (2)
Stent–graft removal (NR) Infection 1 A (1/2)
Up to 30 days 3/222 (1.4%)
patients
Surgical conversion (NR) NR 3 A (1/2)
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Study, first
author (year
of publication)
Time point
(follow-up if time
point not reported)
Total reintervention,
n/N
Type of reintervention
(specify open, endovascular,
revision, secondary/other)
Complication
needing
reintervention
Number of
patients receiving
reintervention
Health state
(A, B or C)
Freyrie et al.
(2010)92
6 months 3/127 (2.4%) patients Iliac extension (NR) Type Ib endoleak 1 A (1)
9 months Thrombolytic therapy and percutaneous
angioplasty (NR)
Iliac limb
thrombosis
1 A (1/2)
9 months Surgical conversion (NR) Iliac limb
thrombosis
1 A (1/2)
Freyrie et al.
(2014)76
0, 0, 4, 4, 4, 4, 6,
23 and 31 months
20/177 (11.3%)
procedures
Percutaneous balloon angioplasty iliac leg
and stenting of external iliac artery or
adjunctive urokinase (Urokinase medac,
Medac Pharma GmbH, Wedel, Germany)
and percutaneous balloon angioplasty
stenting of external iliac artery
(endovascular)
Iliac leg stenosis/
thrombosis
9 A (2)
6 months Renal artery chimney (endovascular) Type Ia endoleak 1 A (1)
9 months Conversion (open repair) Iliac leg
thrombosis
1 A (1/2)
32 and 36 months Conversion (open repair) Contained aortic
rupture
2 A (1)
33 months Iliac leg surgical repair (open repair) Type Ib endoleak 1 A (1)
7, 35 and 45 months Iliac leg extension (endovascular) Type Ib endoleak 3 A (1)
22 and 35 months Inferior mesentric artery clipping
(open repair)
Type II endoleak
and AAA sac
enlargement
2 A (2)
0 months Surgical drainage (open repair) Retroperitoneal
haematoma
1 A (1/2)
continued
D
O
I:10.3310/hta22720
H
EA
LTH
TECH
N
O
LO
G
Y
A
SSESSM
EN
T
2018
VO
L.22
N
O
.72
©
Q
ueen
’s
Printer
and
C
ontroller
of
H
M
SO
2018.
This
w
ork
w
as
produced
by
Brazzelliet
al.
under
the
term
s
of
a
com
m
issioning
contract
issued
by
the
Secretary
of
State
for
H
ealth
and
SocialC
are.
This
issue
m
ay
be
freely
reproduced
for
the
purposes
of
private
research
and
study
and
extracts
(or
indeed,
the
fullreport)
m
ay
be
included
in
professional
journals
provided
that
suitable
acknow
ledgem
ent
is
m
ade
and
the
reproduction
is
not
associated
w
ith
any
form
of
advertising.
A
pplications
for
com
m
ercialreproduction
should
be
addressed
to:
N
IH
R
Journals
Library,
N
ationalInstitute
for
H
ealth
Research,
Evaluation,
Trials
and
Studies
C
oordinating
C
entre,
A
lpha
H
ouse,
U
niversity
of
Southam
pton
Science
Park,
Southam
pton
SO
16
7N
S,
U
K
.
185
TABLE 35 Reintervention and type of secondary procedures performed (continued )
Study, first
author (year
of publication)
Time point
(follow-up if time
point not reported)
Total reintervention,
n/N
Type of reintervention
(specify open, endovascular,
revision, secondary/other)
Complication
needing
reintervention
Number of
patients receiving
reintervention
Health state
(A, B or C)
Ghotbi et al.
(2010)77
NR (mean: 20 months) 6/100 (6%) patients Stentangioplasty of the iliac artery (NR) Plication at the
distal end of the
endoprosthesis
3 A (2)
NR Thrombectomy and TEA of the inguinal
artery (NR)
Occlusion of iliac
artery
1 A (1/2)
NR Proximal banding (NR) NR 1 A (1)
NR Proximal cuff implantation (NR) Migration and
type I endoleak
1 A (1)
Harrison et al.
(2011)41
Up to first year of
follow-up [median:
36 months
(range 12–57
months)]
9/194 (4.6%) Embolisation (NR) Type II endoleak 1 A (2)
Iliac angioplasty (NR) Stenosis 1 A (2)
Iliac stent (NR) Kinked graft 2 A (2)
Open revision (NR) Graft migration 3 A (1)
Bridging stent (NR) Limb dislocation 1 A (1)
Stent (NR) Graft angulation 1 A (2)
Karthikesalingam
et al. (2012)78
NR [median:
34 months (range
1–92 months)]
38/478 patients
(7.9%)
NR Limb outflow
impairment
36 B
NR Limb occlusion 2 A (1/2)
Köcher et al.
(2004)79
Early reinterventions
[mean 20.7 months
(range 2–60 months)]
11/120 (9.2%)
patients
Additional stent–graft Type Ia 2 A (1)
Extra large Palmaz stent Type Ia 1 A (1)
Surgical conversion Type Ia 1 A (1)
Surgical banding neck Type Ia 3 A (1/2)
Spontaneous seal (NR) Type Ib 1 C
Additional stent–graft Type Ib 1 A (1)
Surgical conversion Type Ib 1 A (1)
Endovascular conversion Type IIIa 1 A (1)
During follow-up, NR 5/120 (4.2%) patients Laparoscopic clipping (NR) Type II endoleaks 2 A (2)
Femorofemoral crossover bypass Thrombosis 3 A (1/2)
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Study, first
author (year
of publication)
Time point
(follow-up if time
point not reported)
Total reintervention,
n/N
Type of reintervention
(specify open, endovascular,
revision, secondary/other)
Complication
needing
reintervention
Number of
patients receiving
reintervention
Health state
(A, B or C)
Kray et al.
(2015)80
Up to 6 months
(maximum follow-up
of 12 months)
0/191 (0%) patients NR NR NR Inadequate
information
> 6 months 13/191 (6.8%) NR NR NR Inadequate
information
Mazzaccaro et al.
(2011)90
Long-term [median:
68 months (range
1–144 months)]
45/391 (11.5%)
patients
NR NR NR Inadequate
information
Oshin et al.
(2010)82
27 months 11/583 limbs (1.8%) Conservative management Stent–graft limb
occlusions
3 C
Femorofemoral crossover graft 7 A
Mechanical thrombectomy and secondary
adjunctive stenting
1 A
Parlani et al.
(2002)83
NR [mean: 14 months
(IQR 7–27 months;
range 1–46 months)]
19/336 (5.6%)
patients
NR NR NR Inadequate
information
Schunn et al.
(2000)84
Early (< 7 days) 14/190 (7.4%) Conversion to conventional
transabdominal repair
Malpositioned
graft
4
Prosthetic defect 5
Endoleak 2
Occlusion and
endoleak
1
Arterial disruption 2
Late [mean:
20.9 months (range
1.7–35.6 months)]
17/190 (8.9%) Prosthetic defect 1
Endoleak11
Occlusion and
endoleak
3
Distal secondary
aneurysm
2
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TABLE 35 Reintervention and type of secondary procedures performed (continued )
Study, first
author (year
of publication)
Time point
(follow-up if time
point not reported)
Total reintervention,
n/N
Type of reintervention
(specify open, endovascular,
revision, secondary/other)
Complication
needing
reintervention
Number of
patients receiving
reintervention
Health state
(A, B or C)
dSoler et al.
(2015)85
During follow-up
(mean: 31.9 months)
70 procedures 47/197
patients (23.8%)
NR Type Ia endoleak 11 A (1)
NR
NR NR Type Ib endoleak 7 A (1)
NR NR Type II endoleak 24 A (2)
NR NR Type III endoleak 1 A (1)
NR NR Endotension 1 A (2)
NR NR Stenosis and
occlusions
21 A (1/2)
NR NR Infection 2 A (1/2)
NRe NR Rupture 3 A (1)
Stella et al.
(2009)86
4 months 6/100 (6%) patients Iliac extension (NR) Type I endoleak 1 A (1)
Up to 6 months Thrombolytic therapy (unsuccessful) and
surgical conversion (NR)
Iliac limb
thrombosis
1 A (1/2)
Thrombolytic therapy and percutaneous
angioplasty iliac limbs (NR)
Iliac limb
thrombosis
1 A (1)
1 and 8 months Thrombectomy (NR) External iliac
artery
obstructions
2 A (1/2)
NR [mean:
23.2± 11.0 months
(range 1.4–38.6
months)]
Endograft extended to both external iliac
arteries and surgical revascularisation of
the right hypogastric artery (NR)
Spinal cord
ischaemia
1 A (1)
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Study, first
author (year
of publication)
Time point
(follow-up if time
point not reported)
Total reintervention,
n/N
Type of reintervention
(specify open, endovascular,
revision, secondary/other)
Complication
needing
reintervention
Number of
patients receiving
reintervention
Health state
(A, B or C)
Wolf et al.
(2002)87
During follow-up
period [mean: 15.8 ±
11.3 months (range
1–48 months)]
23/154 (15.0%)
patients
NR Presence of
endoleak with
expanding or
non-shrinking
aneurysm
21 A (2)
NR NR Volume increased
without a
demonstrable
endoleak
1 A (2)
NR NR Migration
occurred and
proximal fixation
appeared to be
insecure
1 A (1)
ID, identification; NR, not reported; TEA, thromboendarterectomy.
a Numbers as reported in the report; do not add up.
b Numbers do not add up to 26.
c During CDU-only surveillance.
d Data combined for both groups [Soler et al. (2015),85 group 1: aneurysm was reduced by ≥10mm; group 2: aneurysm did not reduce. Parlani et al. (2002),83 group 1: without
concomitant iliac aneurysm; group 2: with concomitant iliac aneurysm].
e Numbers do not add up to 70.
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Appendix 12 Results on aneurysm shrinkage,
enlargement and stability, as reported in cohort
studies
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TABLE 36 Results on aneurysm shrinkage, enlargement and stability as reported in cohort studies
Study, first
author (year of
publication)
Total number
of patients
Mean/median follow-up
± SD (range, unless specified
otherwise)
Aneurysm diameter/sac size (mm)
Change Other indicatorsAt baseline At last follow-up
Comparative cohort studies
Nyheim et al.
(2013)67
56 Median: 41.5 months
(2–94 months)
57 (range 30–87) NR NR Identified increased diameter (≥ 5 mm)
without evidence of an endoleak: 6/56
Non-comparative cohort studies
Bisdas et al.
(2014)68
273 Median: 42 months
(IQR 30.7–50.7 months)
NR NR AAA shrinkage
Median: 9 mm
(IQR 3–15mm)
Aneurysm shrinkage of > 5mm:
158/273 (57.8%)
Chaer et al.
(2009)40
(CTA-US)
184 Mean: 24± 13 months
(1–4 years)
Mean: 54± 8 Mean: 39± 11 Mean AAA diameter
decreased by 15mm
NR
Donas et al.
(2016)74
128 Mean: 24.6± 17.4 months
(0–61 months)
Mean: 64.8± 14.6
(range 48–135)
Mean:
60.1 ± 16.3a
NR Aneurysm shrinkage: 87/128 (68%)
Stable aneurysm: 29/128 (23%)
Aneurysm enlargement: 12/128 (9%)
Freyrie et al.
(2014)76
Ultrasound and
CTA-ultrasound
177 Mean: 32.9± 23.3 months
(1–77 months)
Mean: 55± 9.7
(range 45–99)
NR AAA shrinkage
Mean: 10± 8.7
(range –10 to 44)
Aneurysm shrinkage: 130/177 (73.4%)
Stable aneurysm: 40/177 (22.6%)
Aneurysm enlargement of > 5mm:
7/177 (4%)
Harrison et al.
(2011)41
Ultrasound and
CTA-ultrasound
194 Median: 36 months
(12–57 months)
NR NR NR Aneurysm expansion: 2/194 (≈1%)
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Study, first
author (year of
publication)
Total number
of patients
Mean/median follow-up
± SD (range, unless specified
otherwise)
Aneurysm diameter/sac size (mm)
Change Other indicatorsAt baseline At last follow-up
Köcher et al.
(2004)79
120 Mean: 20.7 months
(2–60 months)
NR NR NR Follow-up of > 12 months:
l Shrinkage 44/75 (58.6%)
l Enlargement 7/75 (9.3%)
l No change 24/75 (32%)
Follow-up of > 24 months:
l Shrinkage 31/46 (67.4%)
Meier et al.
(2001)81
476 Mean: 23.2 months
(2–78.8 months)
Major axis diameter:
l Mean – 57.5 ± 9.9
(range 34.8–92.7)
Minor axis diameter:
l Mean – 51.6 ± 9.2
(range 30.9–86.4)
NR AAA shrinkage:
Mean: –7.3± 9.2
(range –50.6 to 32.6)
Rate of overall aneurysm contraction:
(–3.75 mm/year)
Parlani et al.
(2002)83
366 Mean: 14 months (IQR 7–27;
range 1–46 months)
Group A: 50 (IQR
45± 55; range 40± 86);
group B: 52 (IQR
48± 56; range 40± 74)
p= NS
NR AAA diameter
l Group A: –4.3 mm
l Group B: 4.5 mm
(p= NS)
Decrease of diameter of > 2mm:
182/366 (56%)
Unchanged diameter: 127/366 (39%)
Increase of > 2mm: 21/366 (6%)
Of the 77 iliac aneurysms treated
without immediate death and/or
conversion:
l Decrease of diameter of > 2 mm:
46/77 (60%)
l Unchanged diameter: 28 (36%)
l Increase of > 2 mm: 3 (4%)
continued
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TABLE 36 Results on aneurysm shrinkage, enlargement and stability as reported in cohort studies (continued )
Study, first
author (year of
publication)
Total number
of patients
Mean/median follow-up
± SD (range, unless specified
otherwise)
Aneurysm diameter/sac size (mm)
Change Other indicatorsAt baseline At last follow-up
Soler et al.
(2015)85
197 Mean: 54.8 ± 35.9 months Group A: 55.8 mm
Group B: 57.7 mm
Population: 56.7 mm
NR NR Reduction of ≥ 10mm of the maximum
aneurysmal diameter after EVAR in
51.8% of the patients
Stella et al.
(2009)86
100 Mean: 23.2 ± 11.0 months
(1.4–38.6 months)
Mean: 55.2 ± 3.4
(range 45–99)
NR NR Diameter of AAA was unchanged:
98/100 (98%)
Increase in aneurysmal sack of 6 mm:
2/100 (2%)
Wolf et al.
(2002)87
154 Mean: 15.8± 11.3 months
(1–48 months)
57.9± 9.4b 58.3 ± 8.9 Overall change in
transverse diameter
after endovascular
repair: –0.29
mm/month ± 0.73
Absolute changes in
transverse diameter
during mean follow-up
of 7± 3 months (range
3–24 months) after
endovascular repair
No endoleak:
–2.7 mm± 4.5
Endoleak present:
1.0 mm± 3.9
ID, identification; NR, not reported; NS, non significant.
a Change is during follow-up, not at last follow-up.
b Orthogonal diameter.
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Appendix 13 Mortality rates reported in the
included cohort studies
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TABLE 37 Mortality rates reported in the included cohort studies
Study, first
author (year of
publication)
Time point (follow-up if
time point not specified)
Mortality, n/N (%) Survival
NotesAll-cause AAA-related Overall rate
Disease-free
rate, n/N (%)
Comparative cohort studies
Chisci et al.
(2012)66
Protocol I
30 days 8/376 (2.1)
3 years 64/376 (17) 19/376 (5.1) 357/376 (94.9)
Protocol II
30 days 6/341 (1.8)
3 years 55/341 (16.1) 15/341 (4.4) 326/341 (95.6)
Nyheim et al.
(2012)67
> 30 days 9/56 (16) All died of other causes
Non-comparative cohort studies
Bisdas et al.
(2014)68
Median: 42 months
(IQR 31–50 months)
78/273 (28.6) 1/273 (0.4) All-cause mortality (including AAA-related mortality):
cardiac (n= 29), carcinoma (n= 13), pulmonary
(n= 14), sepsis (n= 6), stroke (n = 4), suicide (n= 1),
unknown (n= 10)
AAA related: technical failure to advance the endograft.
The patient was denied open repair because of severe
heart insufficiency and the aneurysm ruptured 2 weeks
later
3 years post operation 77%
4 years post operation 73%
5 years post operation 67%
Bush et al.
(2001)70
High-risk group: mean
14.6 months (± 12.4 months)
Low-risk group: mean
17.7 months (± 15.0 months)
12/104 (11.5) 0/104 (0) NR NR All-cause mortality: conversion from endovascular to
open repair (n= 1), aborted procedure and severe
coronary artery disease (n= 1), successful endovascular
repair without evidence of postoperative endoleak
(n= 1), severe heart failure (n= 1). None of the reported
late deaths were related to the initial endovascular
procedure, device failure or late aneurysm ruptureUp to 30 days post operation 5/104 (4.8)
Chaer et al.
(2009)40
Mean: 24 months
(± 13 months,
range 1–4 years)
5/184 (2.7) 1/184 (0.5) All-cause mortality (including AAA-related mortality):
deaths from lung cancer (n= 2), acute coronary event
with post-infarction heart failure and a prolonged stay
in the coronary care unit (n = 2); AAA related: (n= 1)
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Study, first
author (year of
publication)
Time point (follow-up if
time point not specified)
Mortality, n/N (%) Survival
NotesAll-cause AAA-related Overall rate
Disease-free
rate, n/N (%)
Cochennec
et al. (2007)72
Mean: 28 months; median:
23.4 months
18/460 (3.9) NR NR
Collins et al.
(2007)73
NR (study duration 5 years) 7/160 (4.4) NR NR
aDominguez
et al. (2010)88
Up to 30 day post operation 22/1378 (1.6) NR NR
Donas et al.
(2016)74
Up to 30 day post operation 1/128 (0.8) NR NR Cause of death: cardiac decompensation
Mean: 24.6 months, ± SD
17.4 months (range
0–61 months)
22/128 (17.2) NR NR All-cause mortality: cardiac insufficiency and tumour as
major causes
Fossaceca
et al. (2013)75
Up to 30 days post operation 17/222 (7.7) NR NR All-cause mortality: heart failure, respiratory failure and
aspiration pneumoniab
During follow-up (mean:
29.6 months)
14/205 (6.8) 0/205 (%) NR NR Unrelated to aneurysm
Freyrie et al.
(2014)76
Up to 30 days post operation 2/177 (1.1) NR NR
3 years 86.2%
Ghotbi et al.
(2010)77
> 30 days post operation 0/100 (0)
Harrison et al.
(2011)41
1 year post operation 25/194 (12.9) 1/194 (0.5) All-cause mortality (includes AAA-related mortality):
ischaemic heart disease (n= 6), malignancy (n= 10),
gastrointestinal disease (n= 2), respiratory illness (n= 3),
cerebrovascular accident (n= 2), renal failure (n= 1)
AAA-related mortality: (n= 1)
Köcher et al.
(2004)79
Perioperative 4/120 (3.3)
During follow-up
[mean: 20.7 months
(range 2–60 months)]
13/120 (10.8) All-cause mortality: cardiac, pulmonary or malignancyc
Kray et al.
(2015)80
Up to 12 months’ follow-up 0/191d (0)
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TABLE 37 Mortality rates reported in the included cohort studies (continued )
Study, first
author (year of
publication)
Time point (follow-up if
time point not specified)
Mortality, n/N (%) Survival
NotesAll-cause AAA-related Overall rate
Disease-free
rate, n/N (%)
Mazzaccaro
et al. (2011)90
Up to 30 days post operation 6/488 (1.2)
> 30 days post operation 77/391 (19.7)
144 months 32.80 ( ± 4.4)
Parlani et al.
(2002)83
Perioperative 4/336 (1.2) 1/336 (0.4) All-cause mortality (including AAA-related mortality):
congestive heart failure in a patient with severe
respiratory and cardiac disease (n= 1), pulmonary
oedema (n= 1), massive haemorrhage from
intraprocedural aortic rupture requiring immediate
conversion to open repair (n= 1), and sepsis in a
patient affected by chronic leukaemia and tender AAA
(n= 1)
Late mortality 21/336 (6.3) Not related to the endovascular procedure
Schunn et al.
(2000)84
Up to 30 days post operation 1/190 (0.5) Succumbed to retroperitoneal haemorrhage
attributable to an unrecognised iliac artery puncture
Soler et al.
(2015)85
Mean 54.8 months
( ± 35.9 months)
83/197 (42) Group 1 (diameter reduction of ≥ 10mm during
follow-up): 34/102
Group 2 (diameters were increased, stable, or reduced
by < 10 mm during follow-up): 49/95 (p= 0.0144)
5 years post operation Group 1: 71%
Group 2: 58.7%
p< 0.0001
Stella et al.
(2009)86
Mean: 23.3 months 6/100 (6) Data given for 1–24 months; rates given for clinical
success
24 months follow-up 87.90%
Wolf et al.
(2002)87
< 30 days post operation 2/154 (1.3) Both died of myocardial infarction
> 30 days 25/154 (16.2) 0/154 (0) None of the deaths were aneurysm related; post-mortem
examinations were performed in six cases
ID, identification; NR, not reported.
a Data combined for both groups.
b Number of deaths for each cause not reported.
c Number of deaths for each cause not reported.
d In-hospital deaths.
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Appendix 14 State-transition diagram for the
surveillance after endovascular abdominal aortic
aneurysm repair Markov model
The whole cohort starts at the ‘Normal (no residual EVAR complications)’ Markov state. The arrowsin the model show possible transitions from each state. Arrows from and to the same Markov state
have not been drawn for simplicity. Individuals can remain in any of the Markov states for more than
one cycle. The exception to this is the ‘TP – surgery (elective)’ state, as this is a one-cycle tunnel state.
Arrows to the ‘Death’ Markov states have also been omitted for simplicity. Age-adjusted general
population mortality has been accounted for, and individuals can move from any Markov state to the
‘Death (general population mortality)’ state. In addition, individuals with EVAR-related abnormalities can
die as a result of EVAR-related complications, moving to the ‘Death (EVAR related)’ Markov state.
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Abnormal II
(no immediate
intervention)
Abnormal Ia (immediate
intervention needed:
no endoleak)
Normal (no residual
EVAR complications)
FP – normal
TP – abnormal II (close
follow-up; no immediate
intervention needed)
TP – surgery
(elective)
Death 
(EVAR related)
Death
(general population
mortality)
Abnormal Ib (immediate
intervention needed:
endoleak)
FIGURE 13 State-transition diagram for the surveillance after EVAR Markov model. FP, false positive; TP, true positive.
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Appendix 15 Economic evaluation sensitivity
analyses results
TABLE 38 One-way sensitivity analysis: cost of a further assessment visit
Value (£) Strategy Cost (£)
Incremental
costs (£) QALYs
Incremental
QALYs ICER (£)
50 CDU 3484 6.5532
CTA 3680 197 6.5517 –0.0015 Dominated
CEU 4333 849 6.5594 0.0062 136,513
CDU and CTA, then CDU 4448 115 6.5543 –0.0051 Dominated
CEU and CTA, then CEU 5290 957 6.5598 0.0003 2,981,660
100 CDU 3654 6.5532
CTA 3762 108 6.5517 –0.0015 Dominated
CEU 4542 888 6.5594 0.0062 142,673
CDU and CTA, then CDU 4605 64 6.5543 –0.0051 Dominated
CEU and CTA, then CEU 5486 945 6.5598 0.0003 2,943,149
150 CDU 3824 6.5532
CTA 3844 20 6.5517 –0.0015 Dominated
CEU 4750 926 6.5594 0.0062 148,832
CDU and CTA, then CDU 4762 12 6.5543 –0.0051 Dominated
CEU and CTA, then CEU 5682 932 6.5598 0.0003 2,904,637
200 CTA 3925 6.5517
CDU 3994 69 6.5532 0.0015 45,791
CDU and CTA, then CDU 4920 925 6.5543 0.0011 827,921
CEU 4959 39 6.5594 0.0051 7666
CEU and CTA, then CEU 5878 920 6.5598 0.0003 2,866,125
250 CTA 4007 6.5517
CDU 4165 157 6.5532 0.0015 104,639
CDU and CTA, then CDU 5077 912 6.5543 0.0011 816,205
CEU 5167 91 6.5594 0.0051 17,739
CEU and CTA, then CEU 6075 907 6.5598 0.0003 2,827,613
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TABLE 39 One-way sensitivity analysis: cost of a CTA test
Value (£) Strategy Cost (£)
Incremental
costs (£) QALYs
Incremental
QALYs ICER (£)
80 CTA 3438 6.5517
CDU 3660 221 6.5532 0.0015 147,221
CEU 4549 264 6.5594 0.0051 51,682
CDU and CTA, then CDU 4285 625 6.5543 0.0011 559,439
CEU and CTA, then CEU 5169 620 6.5598 0.0003 1,932,376
90 CTA 3539 6.5517
CDU 3694 154 6.5532 0.0015 102,632
CEU 4590 190 6.5594 0.0051 37,132
CDU and CTA, then CDU 4401 707 6.5543 0.0011 632,756
CEU and CTA, then CEU 5292 702 6.5598 0.0003 2,186,672
100 CTA 3640 6.5517
CDU 3728 87 6.5532 0.0015 58,044
CEU 4632 115 6.5594 0.0051 22,582
CDU and CTA, then CDU 4517 789 6.5543 0.0011 706,074
CEU and CTA, then CEU 5415 783 6.5598 0.0003 2,440,968
110 CTA 3741 6.5517
CDU 3762 20 6.5532 0.0015 13,455
CEU 4674 41 6.5594 0.0051 8032
CDU and CTA, then CDU 4633 871 6.5543 0.0011 779,392
CEU and CTA, then CEU 5539 865 6.5598 0.0003 2,695,263
120 CDU 3796 6.5532
CTA 3843 47 6.5517 –0.0015 Dominated
CEU 4715 920 6.5594 0.0062 147,807
CDU and CTA, then CDU 4749 33 6.5543 –0.0051 Dominated
CEU and CTA, then CEU 5662 947 6.5598 0.0003 2,949,559
130 CDU 3830 6.5532
CTA 3944 114 6.5517 –0.0015 Dominated
CEU 4757 927 6.5594 0.0062 149,039
CDU and CTA, then CDU 4865 108 6.5543 –0.0051 Dominated
CEU and CTA, then CEU 5785 1028 6.5598 0.0003 3,203,854
140 CDU 3864 6.5532
CTA 4045 181 6.5517 –0.0015 Dominated
CEU 4799 935 6.5594 0.0062 150,271
CDU and CTA, then CDU 4981 182 6.5543 –0.0051 Dominated
CEU and CTA, then CEU 5909 1110 6.5598 0.0003 3,458,150
150 CDU 3898 6.5532
CTA 4146 248 6.5517 –0.0015 Dominated
CEU 4841 943 6.5594 0.0062 151,503
CDU and CTA, then CDU 5097 256 6.5543 –0.0051 Dominated
CEU and CTA, then CEU 6032 1191 6.5598 0.0003 3,712,445
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TABLE 40 One-way sensitivity analysis: cost of an EVAR procedure
Value (£) Strategy Cost (£)
Incremental
costs (£) QALYs
Incremental
QALYs ICER (£)
6000 CDU 3163 6.5532
CTA 3217 54 6.5517 –0.0015 Dominated
CEU 3997 834 6.5594 0.0062 134,071
CDU and CTA, then CDU 4097 100 6.5543 –0.0051 Dominated
CEU and CTA, then CEU 4930 932 6.5598 0.0003 2,905,650
8000 CDU 3375 6.5532
CTA 3423 48 6.5517 –0.0015 Dominated
CEU 4238 863 6.5594 0.0062 138,646
CDU and CTA, then CDU 4311 74 6.5543 –0.0051 Dominated
CEU and CTA, then CEU 5171 933 6.5598 0.0003 2,907,853
10,000 CDU 3587 6.5532
CTA 3629 43 6.5517 –0.0015 Dominated
CEU 4478 891 6.5594 0.0062 143,222
CDU and CTA, then CDU 4526 48 6.5543 –0.0051 Dominated
CEU and CTA, then CEU 5412 934 6.5598 0.0003 2,910,056
12,000 CDU 3799 6.5532
CTA 3835 37 6.5517 –0.0015 Dominated
CEU 4718 920 6.5594 0.0062 147,798
CDU and CTA, then CDU 4740 21 6.5543 –0.0051 Dominated
CEU and CTA, then CEU 5653 935 6.5598 0.0003 2,912,260
14,000 CDU 4011 6.5532
CTA 4041 31 6.5517 –0.0015 Dominated
CEU 4959 5 6.5594 0.0051 960
CDU and CTA, then CDU 4954 943 6.5543 0.0011 843,974
CEU and CTA, then CEU 5894 935 6.5598 0.0003 2,914,463
16,000 CDU 4222 6.5532
CTA 4247 25 6.5517 –0.0015 Dominated
CEU 5199 31 6.5594 0.0051 6106
CDU and CTA, then CDU 5168 945 6.5543 0.0011 845,943
CEU and CTA, then CEU 6135 936 6.5598 0.0003 2,916,666
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TABLE 41 One-way sensitivity analysis: cost of other surgical procedures
Value (£) Strategy Cost (£)
Incremental
costs (£) QALYs
Incremental
QALYs ICER (£)
2000 CDU 2950 6.5532
CTA 2988 38 6.5517 –0.0015 Dominated
CEU 3864 914 6.5594 0.0062 146,834
CDU and CTA, then CDU 3891 27 6.5543 –0.0051 Dominated
CEU and CTA, then CEU 4798 934 6.5598 0.0003 2,911,629
6000 CDU 3264 6.5532
CTA 3302 38 6.5517 –0.0015 Dominated
CEU 4180 915 6.5594 0.0062 147,130
CDU and CTA, then CDU 4205 25 6.5543 –0.0051 Dominated
CEU and CTA, then CEU 5114 934 6.5598 0.0003 2,911,834
10,000 CDU 3578 6.5532
CTA 3615 37 6.5517 –0.0015 Dominated
CEU 4495 917 6.5594 0.0062 147,426
CDU and CTA, then CDU 4519 23 6.5543 –0.0051 Dominated
CEU and CTA, then CEU 5430 935 6.5598 0.0003 2,912,039
14,000 CDU 3892 6.5532
CTA 3929 37 6.5517 –0.0015 Dominated
CEU 4811 919 6.5594 0.0062 147,722
CDU and CTA, then CDU 4833 22 6.5543 –0.0051 Dominated
CEU and CTA, then CEU 5746 935 6.5598 0.0003 2,912,243
18,000 CDU 4206 6.5532
CTA 4243 36 6.5517 –0.0015 Dominated
CEU 5127 921 6.5594 0.0062 148,018
CDU and CTA, then CDU 5147 20 6.5543 –0.0051 Dominated
CEU and CTA, then CEU 6062 935 6.5598 0.0003 2,912,448
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TABLE 42 One-way sensitivity analysis: utility weight for the normal health state
Value (%) Strategy Cost (£)
Incremental
costs (£) QALYs
Incremental
QALYs ICER (£)
0.5 CDU 3791 4.4668
CTA 3828 37 4.4657 –0.0011 Dominated
CEU 4709 919 4.4712 0.0044 208,846
CDU and CTA, then CDU 4732 22 4.4676 –0.0036 Dominated
CEU and CTA, then CEU 5644 935 4.4714 0.0002 4,212,790
0.6 CDU 3791 5.3602
CTA 3828 37 5.3589 –0.0013 Dominated
CEU 4709 919 5.3654 0.0053 174,038
CDU and CTA, then CDU 4732 22 5.3611 –0.0043 Dominated
CEU and CTA, then CEU 5644 935 5.3657 0.0003 3,510,658
0.7 CDU 3791 6.2535
CTA 3828 37 6.2520 –0.0015 Dominated
CEU 4709 919 6.2597 0.0062 149,176
CDU and CTA, then CDU 4732 22 6.2546 –0.0051 Dominated
CEU and CTA, then CEU 5644 935 6.2600 0.0003 3,009,136
0.8 CDU 3791 7.1469
CTA 3828 37 7.1452 –0.0017 Dominated
CEU 4709 919 7.1539 0.0070 130,529
CDU and CTA, then CDU 4732 22 7.1481 –0.0058 Dominated
CEU and CTA, then CEU 5644 935 7.1543 0.0004 2,632,994
0.9 CDU 3791 8.0402
CTA 3828 37 8.0383 –0.0019 Dominated
CEU 4709 919 8.0482 0.0079 116,026
CDU and CTA, then CDU 4732 22 8.0416 –0.0065 Dominated
CEU and CTA, then CEU 5644 935 8.0486 0.0004 2,340,439
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TABLE 43 One-way sensitivity analysis: utility weight reduction for EVAR surgery
Value (%) Strategy Cost (£)
Incremental
costs (£) QALYs
Incremental
QALYs ICER (£)
0.0 CDU 3791 6.5541
CTA 3828 37 6.5526 –0.0015 Dominated
CEU 4709 919 6.5604 0.0063 145,617
CDU and CTA, then CDU 4732 22 6.5552 –0.0052 Dominated
CEU and CTA, then CEU 5644 935 6.5607 0.0003 2,893,195
0.5 CDU 3791 6.5539
CTA 3828 37 6.5524 –0.0015 Dominated
CEU 4709 919 6.5602 0.0063 146,064
CDU and CTA, then CDU 4732 22 6.5550 –0.0052 Dominated
CEU and CTA, then CEU 5644 935 6.5605 0.0003 2,897,445
1.0 CDU 3791 6.5537
CTA 3828 37 6.5522 –0.0015 Dominated
CEU 4709 919 6.5600 0.0063 146,514
CDU and CTA, then CDU 4732 22 6.5548 –0.0051 Dominated
CEU and CTA, then CEU 5644 935 6.5603 0.0003 2,901,707
2.0 CDU 3791 6.5533
CTA 3828 37 6.5518 –0.0015 Dominated
CEU 4709 919 6.5595 0.0062 147,423
CDU and CTA, then CDU 4732 22 6.5544 –0.0051 Dominated
CEU and CTA, then CEU 5644 935 6.5599 0.0003 2,910,269
4.0 CDU 3791 6.5525
CTA 3828 37 6.5510 –0.0015 Dominated
CEU 4709 919 6.5587 0.0062 149,274
CDU and CTA, then CDU 4732 22 6.5536 –0.0050 Dominated
CEU and CTA, then CEU 5644 935 6.5590 0.0003 2,927,545
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TABLE 44 One-way sensitivity analysis: utility weight decrement from other surgical procedures
Value (%) Strategy Cost (£)
Incremental
costs (£) QALYs
Incremental
QALYs ICER (£)
0 CDU 3791 6.5539
CTA 3828 37 6.5524 –0.0015 Dominated
CEU 4709 919 6.5601 0.0062 147,541
CDU and CTA, then CDU 4732 22 6.5550 –0.0051 Dominated
CEU and CTA, then CEU 5644 935 6.5604 0.0003 2,910,951
1 CDU 3791 6.5536
CTA 3828 37 6.5521 –0.0015 Dominated
CEU 4709 919 6.5598 0.0062 147,579
CDU and CTA, then CDU 4732 22 6.5547 –0.0051 Dominated
CEU and CTA, then CEU 5644 935 6.5601 0.0003 2,911,503
2 CDU 3791 6.5533
CTA 3828 37 6.5518 –0.0015 Dominated
CEU 4709 919 6.5595 0.0062 147,618
CDU and CTA, then CDU 4732 22 6.5544 –0.0051 Dominated
CEU and CTA, then CEU 5644 935 6.5598 0.0003 2,912,055
3 CDU 3791 6.5530
CTA 3828 37 6.5515 –0.0015 Dominated
CEU 4709 919 6.5592 0.0062 147,656
CDU and CTA, then CDU 4732 22 6.5541 –0.0051 Dominated
CEU and CTA, then CEU 5644 935 6.5595 0.0003 2,912,607
4 CDU 3791 6.5527
CTA 3828 37 6.5512 –0.0015 Dominated
CEU 4709 919 6.5589 0.0062 147,695
CDU and CTA, then CDU 4732 22 6.5538 –0.0051 Dominated
CEU and CTA, then CEU 5644 935 6.5592 0.0003 2,913,159
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TABLE 45 One-way sensitivity analysis: mortality risk from an emergency event (e.g. rupture)
Value (%) Strategy Cost (£)
Incremental
costs (£) QALYs
Incremental
QALYs ICER (£)
20 CDU 3781 6.5515
CTA 3817 36 6.5499 –0.0016 Dominated
CEU 4702 921 6.5582 0.0067 137,783
CDU and CTA, then CDU 4722 20 6.5527 –0.0055 Dominated
CEU and CTA, then CEU 5637 935 6.5585 0.0003 2,718,603
40 CDU 3733 6.5430
CTA 3766 33 6.5409 –0.0022 Dominated
CEU 4668 935 6.5520 0.0090 103,821
CDU and CTA, then CDU 4675 7 6.5446 –0.0074 Dominated
CEU and CTA, then CEU 5602 934 6.5525 0.0005 2,040,700
60 CDU 3685 6.5345
CTA 3715 30 6.5318 –0.0027 Dominated
CEU 4633 6 6.5458 0.0093 603
CDU and CTA, then CDU 4628 942 6.5365 0.0020 477,727
CEU and CTA, then CEU 5567 934 6.5464 0.0006 1,633,664
80 CDU 3637 6.5260
CTA 3664 26 6.5228 –0.0032 Dominated
CEU 4599 18 6.5396 0.0113 1624
CDU and CTA, then CDU 4580 943 6.5284 0.0024 399,585
CEU and CTA, then CEU 5532 934 6.5403 0.0007 1,362,184
100 CDU 3590 6.5176
CTA 3613 23 6.5138 –0.0038 Dominated
CEU 4564 31 6.5335 0.0132 2346
CDU and CTA, then CDU 4533 944 6.5203 0.0027 343,576
CEU and CTA, then CEU 5497 933 6.5343 0.0008 1,168,209
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TABLE 46 One-way sensitivity analysis: mortality risk from an emergency procedure
Value (%) Strategy Cost (£)
Incremental
costs (£) QALYs
Incremental
QALYs ICER (£)
10 CDU 3856 6.5648
CTA 3898 42 6.5640 –0.0008 Dominated
CEU 4756 900 6.5679 0.0031 293,910
CDU and CTA, then CDU 4796 40 6.5654 –0.0025 Dominated
CEU and CTA, then CEU 5691 935 6.5680 0.0002 5,644,541
20 CDU 3826 6.5595
CTA 3866 39 6.5584 –0.0011 Dominated
CEU 4735 909 6.5640 0.0045 201,888
CDU and CTA, then CDU 4767 32 6.5604 –0.0037 Dominated
CEU and CTA, then CEU 5670 935 6.5643 0.0002 3,956,617
30 CDU 3797 6.5543
CTA 3834 37 6.5528 –0.0014 Dominated
CEU 4714 917 6.5602 0.0059 154,478
CDU and CTA, then CDU 4737 24 6.5553 –0.0049 Dominated
CEU and CTA, then CEU 5648 935 6.5605 0.0003 3,046,161
40 CDU 3767 6.5490
CTA 3802 35 6.5472 –0.0018 Dominated
CEU 4692 925 6.5564 0.0074 125,567
CDU and CTA, then CDU 4708 16 6.5503 –0.0061 Dominated
CEU and CTA, then CEU 5627 934 6.5568 0.0004 2,476,565
50 CDU 3737 6.5438
CTA 3771 33 6.5416 –0.0021 Dominated
CEU 4671 933 6.5526 0.0088 106,096
CDU and CTA, then CDU 4679 8 6.5453 –0.0072 Dominated
CEU and CTA, then CEU 5605 934 6.5530 0.0004 2,086,592
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TABLE 47 One-way sensitivity analysis: adherence to surveillance
Value (%) Strategy Cost (£)
Incremental
costs (£) QALYs
Incremental
QALYs ICER (£)
40 CDU 2554 6.5240
CTA 2568 14 6.5224 –0.0016 Dominated
CEU 2976 11 6.5319 0.0070 1587
CDU and CTA, then CDU 2965 410 6.5249 0.0009 449,694
CEU and CTA, then CEU 3385 409 6.5323 0.0003 1,263,460
50 CDU 2817 6.5316
CTA 2835 18 6.5299 –0.0017 Dominated
CEU 3337 9 6.5399 0.0073 1205
CDU and CTA, then CDU 3329 512 6.5326 0.0010 503,094
CEU and CTA, then CEU 3847 510 6.5402 0.0003 1,458,998
60 CDU 3061 6.5381
CTA 3083 22 6.5363 –0.0017 Dominated
CEU 3678 4 6.5463 0.0072 617
CDU and CTA, then CDU 3674 613 6.5392 0.0011 564,002
CEU and CTA, then CEU 4288 610 6.5467 0.0004 1,692,335
70 CDU 3293 6.5436
CTA 3319 26 6.5419 –0.0017 Dominated
CEU 4004 711 6.5515 0.0079 90,203
CDU and CTA, then CDU 4006 2 6.5447 –0.0068 Dominated
CEU and CTA, then CEU 4713 709 6.5519 0.0004 1,974,710
80 CDU 3515 6.5483
CTA 3545 31 6.5466 –0.0017 Dominated
CEU 4317 803 6.5556 0.0073 110,298
CDU and CTA, then CDU 4327 10 6.5494 –0.0061 Dominated
CEU and CTA, then CEU 5125 808 6.5559 0.0003 2,322,223
90 CDU 3728 6.5522
CTA 3764 35 6.5506 –0.0015 Dominated
CEU 4620 892 6.5587 0.0065 137,508
CDU and CTA, then CDU 4639 19 6.5533 –0.0054 Dominated
CEU and CTA, then CEU 5526 905 6.5590 0.0003 2,758,785
100 CDU 3935 6.5554
CTA 3975 40 6.5540 –0.0014 Dominated
CEU 4914 979 6.5609 0.0056 176,167
CDU and CTA, then CDU 4944 30 6.5565 –0.0045 Dominated
CEU and CTA, then CEU 5916 1002 6.5612 0.0003 3,321,498
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TABLE 48 One-way sensitivity analysis: sensitivity of the CDU test
Value (%) Strategy Cost (£)
Incremental
costs (£) QALYs
Incremental
QALYs ICER (£)
0.5 CDU 3552 6.5421
CTA 3828 276 6.5517 0.0096 28,822
CEU 4709 882 6.5594 0.0077 114,115
CDU and CTA, then CDU 4506 678 6.5447 –0.0070 Dominated
CEU and CTA, then CEU 5644 935 6.5598 0.0003 2,912,177
0.6 CDU 3654 6.5474
CTA 3828 173 6.5517 0.0043 40,032
CEU 4709 882 6.5594 0.0077 114,115
CDU and CTA, then CDU 4603 775 6.5492 –0.0025 Dominated
CEU and CTA, then CEU 5644 935 6.5598 0.0003 2,912,177
0.7 CDU 3753 6.5517
CTA 3828 75 6.5517 0.0000 Dominated
CEU 4709 14 6.5594 0.0064 2121
CDU and CTA, then CDU 4696 943 6.5530 0.0013 720,056
CEU and CTA, then CEU 5644 935 6.5598 0.0003 2,912,177
0.75 CDU 3800 6.5536
CTA 3828 28 6.5517 –0.0019 Dominated
CEU 4709 909 6.5594 0.0059 154,976
CDU and CTA, then CDU 4741 31 6.5546 –0.0048 Dominated
CEU and CTA, then CEU 5644 935 6.5598 0.0003 2,912,177
0.8 CTA 3828 6.5517
CDU 3847 19 6.5552 0.0035 5367
CEU 4709 863 6.5594 0.0042 205,467
CDU and CTA, then CDU 4784 75 6.5561 –0.0033 Dominated
CEU and CTA, then CEU 5644 935 6.5598 0.0003 2,912,177
0.85 CTA 3828 6.5517
CDU 3892 64 6.5567 0.0050 12,831
CEU 4709 817 6.5594 0.0027 301,755
CDU and CTA, then CDU 4827 118 6.5574 –0.0020 Dominated
CEU and CTA, then CEU 5644 935 6.5598 0.0003 2,912,177
0.9 CTA 3828 6.5517
CDU 3937 109 6.5581 0.0063 17,162
CEU 4709 773 6.5594 0.0014 558,213
CDU and CTA, then CDU 4869 160 6.5586 –0.0009 Dominated
CEU and CTA, then CEU 5644 935 6.5598 0.0003 2,912,177
1.0 CTA 3828 6.5517
CDU 4023 195 6.5602 0.0085 22,844
CEU 4709 687 6.5594 –0.0008 Dominated
CDU and CTA, then CDU 4950 928 6.5605 0.0002 4,263,080
CEU and CTA, then CEU 5644 693 6.5598 –0.0007 Dominated
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TABLE 49 One-way sensitivity analysis: specificity of the CDU test
Value (%) Strategy Cost (£)
Incremental
costs (£) QALYs
Incremental
QALYs ICER (£)
0.8 CTA 3828 6.5517
CDU 3967 140 6.5532 0.0015 92,448
CEU 4709 742 6.5594 0.0062 119,382
CDU and CTA, then CDU 4916 207 6.5543 –0.0051 Dominated
CEU and CTA, then CEU 5644 935 6.5598 0.0003 2,912,177
0.85 CTA 3828 6.5517
CDU 3904 77 6.5532 0.0015 50,833
CEU 4709 805 6.5594 0.0062 129,466
CDU and CTA, then CDU 4850 141 6.5543 –0.0051 Dominated
CEU and CTA, then CEU 5644 935 6.5598 0.0003 2,912,177
0.9 CTA 3828 6.5517
CDU 3841 14 6.5532 0.0015 9018
CEU 4709 868 6.5594 0.0062 139,553
CDU and CTA, then CDU 4784 75 6.5543 –0.0051 Dominated
CEU and CTA, then CEU 5644 935 6.5598 0.0003 2,912,177
0.95 CDU 3778 6.5532
CTA 3828 50 6.5517 –0.0015 Dominated
CEU 4709 931 6.5594 0.0062 149,645
CDU and CTA, then CDU 4718 9 6.5543 –0.0051 Dominated
CEU and CTA, then CEU 5644 935 6.5598 0.0003 2,912,177
1.0 CDU 3715 6.5532
CTA 3828 113 6.5517 –0.0015 Dominated
CEU 4709 57 6.5594 0.0051 11,152
CDU and CTA, then CDU 4652 937 6.5543 0.0011 838,696
CEU and CTA, then CEU 5644 935 6.5598 0.0003 2,912,177
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TABLE 50 One-way sensitivity analysis: proportion of CDU indeterminate results
Value (%) Strategy Cost (£)
Incremental
costs (£) QALYs
Incremental
QALYs ICER (£)
0 CDU 3419 6.5535
CTA 3828 408 6.5517 –0.0018 Dominated
CEU 4709 270 6.5594 0.0048 55,755
CDU and CTA, then CDU 4439 1020 6.5546 0.0011 960,112
CEU and CTA, then CEU 5644 935 6.5598 0.0003 2,912,177
5 CDU 3523 6.5534
CTA 3828 305 6.5517 –0.0017 Dominated
CEU 4709 189 6.5594 0.0049 38,426
CDU and CTA, then CDU 4520 998 6.5545 0.0011 926,163
CEU and CTA, then CEU 5644 935 6.5598 0.0003 2,912,177
10 CDU 3626 6.5534
CTA 3828 202 6.5517 –0.0016 Dominated
CEU 4709 108 6.5594 0.0050 21,587
CDU and CTA, then CDU 4602 976 6.5544 0.0011 893,091
CEU and CTA, then CEU 5644 935 6.5598 0.0003 2,912,177
15 CDU 3729 6.5533
CTA 3828 99 6.5517 –0.0016 Dominated
CEU 4709 26 6.5594 0.0051 5220
CDU and CTA, then CDU 4683 954 6.5544 0.0011 860,869
CEU and CTA, then CEU 5644 935 6.5598 0.0003 2,912,177
20 CTA 3828 6.5517
CDU 3832 4 6.5532 0.0015 2939
CEU 4709 877 6.5594 0.0063 140,201
CDU and CTA, then CDU 4764 55 6.5543 –0.0051 Dominated
CEU and CTA, then CEU 5644 935 6.5598 0.0003 2,912,177
25 CTA 3828 6.5517
CDU 3935 107 6.5531 0.0014 77,897
CEU 4709 774 6.5594 0.0063 121,991
CDU and CTA, then CDU 4845 136 6.5542 –0.0052 Dominated
CEU and CTA, then CEU 5644 935 6.5598 0.0003 2,912,177
30 CTA 3828 6.5517
CDU 4038 211 6.5530 0.0013 163,168
CEU 4709 671 6.5594 0.0064 104,271
CDU and CTA, then CDU 4927 217 6.5542 –0.0053 Dominated
CEU and CTA, then CEU 5644 935 6.5598 0.0003 2,912,177
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TABLE 51 One-way sensitivity analysis: sensitivity of the CEU test
Value (%) Strategy Cost (£)
Incremental
costs (£) QALYs
Incremental
QALYs ICER (£)
0.8 CDU 3791 6.5532
CTA 3828 37 6.5517 –0.0015 Dominated
CEU 4569 778 6.5552 0.0020 384,006
CDU and CTA, then CDU 4732 162 6.5543 –0.0009 Dominated
CEU and CTA, then CEU 5512 942 6.5561 0.0009 1,097,985
0.85 CDU 3791 6.5532
CTA 3828 37 6.5517 –0.0015 Dominated
CEU 4614 823 6.5567 0.0035 234,124
CDU and CTA, then CDU 4732 118 6.5543 –0.0024 Dominated
CEU and CTA, then CEU 5554 940 6.5574 0.0007 1,407,843
0.9 CDU 3791 6.5532
CTA 3828 37 6.5517 –0.0015 Dominated
CEU 4658 867 6.5581 0.0048 179,185
CDU and CTA, then CDU 4732 74 6.5543 –0.0037 Dominated
CEU and CTA, then CEU 5595 937 6.5586 0.0005 1,881,847
0.95 CDU 3791 6.5532
CTA 3828 37 6.5517 –0.0015 Dominated
CEU 4701 910 6.5592 0.0060 151,514
CDU and CTA, then CDU 4732 31 6.5543 –0.0049 Dominated
CEU and CTA, then CEU 5636 935 6.5596 0.0003 2,682,568
1.0 CDU 3791 6.5532
CTA 3828 37 6.5517 –0.0015 Dominated
CEU 4743 11 6.5602 0.0059 1879
CDU and CTA, then CDU 4732 941 6.5543 0.0011 841,931
CEU and CTA, then CEU 5675 933 6.5605 0.0002 4,286,486
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TABLE 52 One-way sensitivity analysis: specificity CEU test
Value (%) Strategy Cost (£)
Incremental
costs (£) QALYs
Incremental
QALYs ICER (£)
0.75 CDU 3791 6.5532
CTA 3828 37 6.5517 –0.0015 Dominated
CEU 4835 104 6.5594 0.0051 20,296
CDU and CTA, then CDU 4732 941 6.5543 0.0011 841,931
CEU and CTA, then CEU 5775 940 6.5598 0.0003 2,930,454
0.8 CDU 3791 6.5532
CTA 3828 37 6.5517 –0.0015 Dominated
CDU and CTA, then CDU 4732 941 6.5543 0.0011 841,931
CEU 4772 41 6.5594 0.0051 7968
CEU and CTA, then CEU 5710 937 6.5598 0.0003 2,921,324
0.85 CDU 3791 6.5532
CTA 3828 37 6.5517 –0.0015 Dominated
CEU 4709 919 6.5594 0.0062 147,626
CDU and CTA, then CDU 4732 22 6.5543 –0.0051 Dominated
CEU and CTA, then CEU 5644 935 6.5598 0.0003 2,912,177
0.9 CDU 3791 6.5532
CTA 3828 37 6.5517 –0.0015 Dominated
CEU 4646 855 6.5594 0.0062 137,498
CDU and CTA, then CDU 4732 85 6.5543 –0.0051 Dominated
CEU and CTA, then CEU 5578 932 6.5598 0.0003 2,903,015
0.95 CDU 3791 6.5532
CTA 3828 37 6.5517 –0.0015 Dominated
CEU 4583 792 6.5594 0.0062 127,355
CDU and CTA, then CDU 4732 149 6.5543 –0.0051 Dominated
CEU and CTA, then CEU 5512 929 6.5598 0.0003 2,893,836
1.0 CDU 3791 6.5532
CTA 3828 37 6.5517 –0.0015 Dominated
CEU 4520 729 6.5594 0.0062 117,196
CDU and CTA, then CDU 4732 212 6.5543 –0.0051 Dominated
CEU and CTA, then CEU 5446 926 6.5598 0.0003 2,884,641
DOI: 10.3310/hta22720 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 72
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Brazzelli et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
215
TABLE 53 One-way sensitivity analysis: proportion of CEU indeterminate results
Value (%) Strategy Cost (£)
Incremental
costs (£) QALYs
Incremental
QALYs ICER (£)
0 CDU 3791 6.5532
CTA 3828 37 6.5517 –0.0015 Dominated
CEU 4405 614 6.5606 0.0073 83,663
CDU and CTA, then CDU 4732 327 6.5543 –0.0062 Dominated
CEU and CTA, then CEU 5409 1003 6.5607 0.0001 9,142,747
5 CDU 3791 6.5532
CTA 3828 37 6.5517 –0.0015 Dominated
CEU 4490 699 6.5603 0.0071 99,125
CDU and CTA, then CDU 4732 242 6.5543 –0.0059 Dominated
CEU and CTA, then CEU 5474 984 6.5604 0.0002 5,970,958
10 CDU 3791 6.5532
CTA 3828 37 6.5517 –0.0015 Dominated
CEU 4574 783 6.5600 0.0067 116,170
CDU and CTA, then CDU 4732 158 6.5543 –0.0056 Dominated
CEU and CTA, then CEU 5539 965 6.5602 0.0002 4,334,894
15 CDU 3791 6.5532
CTA 3828 37 6.5517 –0.0015 Dominated
CEU 4659 868 6.5596 0.0064 135,141
CDU and CTA, then CDU 4732 73 6.5543 –0.0053 Dominated
CEU and CTA, then CEU 5605 946 6.5599 0.0003 3,340,291
20 CDU 3791 6.5532
CTA 3828 37 6.5517 –0.0015 Dominated
CEU 4743 11 6.5593 0.0050 2305
CDU and CTA, then CDU 4732 941 6.5543 0.0011 841,931
CEU and CTA, then CEU 5670 927 6.5596 0.0003 2,674,165
25 CDU 3791 6.5532
CTA 3828 37 6.5517 –0.0015 Dominated
CEU 4828 96 6.5590 0.0046 20,782
CDU and CTA, then CDU 4732 941 6.5543 0.0011 841,931
CEU and CTA, then CEU 5735 908 6.5594 0.0004 2,198,543
30 CDU 3791 6.5532
CTA 3828 37 6.5517 –0.0015 Dominated
CEU 4912 181 6.5586 0.0043 42,443
CDU and CTA, then CDU 4732 941 6.5543 0.0011 841,931
CEU and CTA, then CEU 5801 889 6.5591 0.0005 1,843,151
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TABLE 54 One-way sensitivity analysis: sensitivity of the CTA test
Value (%) Strategy Cost (£)
Incremental
costs (£) QALYs
Incremental
QALYs ICER (£)
0.5 CTA 3581 6.5395
CDU 3749 168 6.5516 0.0121 13,922
CEU 4672 923 6.5584 0.0069 134,033
CDU and CTA, then CDU 4690 18 6.5526 –0.0058 Dominated
CEU and CTA, then CEU 5609 937 6.5589 0.0005 1,986,663
0.6 CTA 3708 6.5463
CDU 3770 62 6.5524 0.0061 10,196
CEU 4691 921 6.5590 0.0065 140,583
CDU and CTA, then CDU 4711 20 6.5535 –0.0054 Dominated
CEU and CTA, then CEU 5626 936 6.5594 0.0004 2,374,667
0.7 CDU 3791 6.5532
CTA 3828 37 6.5517 –0.0015 Dominated
CEU 4709 919 6.5594 0.0062 147,626
CDU and CTA, then CDU 4732 22 6.5543 –0.0051 Dominated
CEU and CTA, then CEU 5644 935 6.5598 0.0003 2,912,177
0.8 CDU 3811 6.5540
CTA 3941 130 6.5559 0.0019 67,435
CEU 4728 786 6.5599 0.0040 197,736
CDU and CTA, then CDU 4752 24 6.5551 –0.0048 Dominated
CEU and CTA, then CEU 5661 933 6.5601 0.0003 3,702,825
0.9 CDU 3832 6.5547
CTA 4049 217 6.5591 0.0044 49,742
CEU 4746 697 6.5603 0.0012 566,664
CDU and CTA, then CDU 4772 26 6.5559 –0.0045 Dominated
CEU and CTA, then CEU 5678 932 6.5605 0.0002 4,974,254
1.0 CDU 3852 6.5554
CTA 4151 299 6.5614 0.0060 50,171
CEU 4764 613 6.5607 –0.0007 Dominated
CDU and CTA, then CDU 4792 641 6.5566 –0.0048 Dominated
CEU and CTA, then CEU 5695 1545 6.5608 –0.0005 Dominated
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TABLE 55 One-way sensitivity analysis: specificity of the CTA test
Value (%) Strategy Cost (£)
Incremental
costs (£) QALYs
Incremental
QALYs ICER (£)
0.5 CDU 4023 6.5536
CTA 4753 730 6.5531 –0.0005 Dominated
CEU 4931 908 6.5596 0.0060 151,652
CDU and CTA, then CDU 5089 157 6.5550 –0.0046 Dominated
CEU and CTA, then CEU 5923 991 6.5600 0.0004 2,582,245
0.6 CDU 3962 6.5534
CTA 4548 586 6.5526 –0.0009 Dominated
CEU 4878 916 6.5595 0.0061 150,596
CDU and CTA, then CDU 5007 129 6.5547 –0.0048 Dominated
CEU and CTA, then CEU 5867 989 6.5599 0.0004 2,761,378
0.7 CDU 3907 6.5533
CTA 4340 433 6.5522 –0.0012 Dominated
CEU 4827 919 6.5595 0.0061 149,598
CDU and CTA, then CDU 4927 100 6.5545 –0.0049 Dominated
CEU and CTA, then CEU 5807 980 6.5598 0.0003 2,886,831
0.8 CDU 3860 6.5533
CTA 4141 281 6.5519 –0.0014 Dominated
CEU 4780 920 6.5595 0.0062 148,725
CDU and CTA, then CDU 4852 72 6.5544 –0.0050 Dominated
CEU and CTA, then CEU 5747 966 6.5598 0.0003 2,948,485
0.9 CDU 3819 6.5532
CTA 3959 140 6.5518 –0.0015 Dominated
CEU 4739 920 6.5594 0.0062 148,029
CDU and CTA, then CDU 4783 44 6.5544 –0.0051 Dominated
CEU and CTA, then CEU 5688 950 6.5598 0.0003 2,948,570
0.95 CDU 3801 6.5532
CTA 3875 74 6.5517 –0.0015 Dominated
CEU 4720 919 6.5594 0.0062 147,760
CDU and CTA, then CDU 4750 30 6.5543 –0.0051 Dominated
CEU and CTA, then CEU 5660 940 6.5598 0.0003 2,929,045
1.0 CDU 3784 6.5532
CTA 3797 13 6.5517 –0.0015 Dominated
CEU 4702 918 6.5594 0.0062 147,549
CDU and CTA, then CDU 4719 17 6.5543 –0.0051 Dominated
CEU and CTA, then CEU 5633 931 6.5598 0.0003 2,899,056
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TABLE 56 One-way sensitivity analysis: proportion of CTA indeterminate results
Value (%) Strategy Cost (£)
Incremental
costs (£) QALYs
Incremental
QALYs ICER (£)
0 CDU 3791 6.5532
CTA 3828 37 6.5517 –0.0015 Dominated
CEU 4709 919 6.5594 0.0062 147,626
CDU and CTA, then CDU 4732 22 6.5543 –0.0051 Dominated
CEU and CTA, then CEU 5644 935 6.5598 0.0003 2,912,177
10 CDU 3791 6.5532
CTA 4045 254 6.5517 –0.0015 Dominated
CEU 4709 919 6.5594 0.0062 147,626
CDU and CTA, then CDU 4739 30 6.5543 –0.0051 Dominated
CEU and CTA, then CEU 5651 941 6.5597 0.0003 3,152,095
20 CDU 3791 6.5532
CTA 4262 472 6.5517 –0.0015 Dominated
CEU 4709 919 6.5594 0.0062 147,626
CDU and CTA, then CDU 4747 38 6.5543 –0.0052 Dominated
CEU and CTA, then CEU 5658 948 6.5597 0.0003 3,430,618
30 CDU 3791 6.5532
CTA 4480 689 6.5517 –0.0015 Dominated
CEU 4709 919 6.5594 0.0062 147,626
CDU and CTA, then CDU 4754 45 6.5543 –0.0052 Dominated
CEU and CTA, then CEU 5665 955 6.5597 0.0003 3,757,877
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FIGURE 14 Two-way sensitivity analysis: CEU sensitivity and specificity (based on net benefit, willingness-to-pay
threshold of £30,000).
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FIGURE 15 Two-way sensitivity analysis: CTA sensitivity and specificity (based on net benefit, willingness-to-pay
threshold of £30,000).
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